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Introduction 
Chapter 1 
Role of surfactant in the pathophysiology of the acute respiratory 
distress syndrome: consequences for treatment strategies 
A. Hartog, D. Gommers, B. Lachmann 
Department of Anesthesiology, Erasmus University Rotterdam, The Netherlands. 
AdaptedJrolll: MOl/aldi Arch Chest Dis 1995: 50; 372-377 
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Chapter 1 
One of the most important clinical syndromes, in which failure of oxygen uptake in the lung 
leads to severe hypoxia, is the so-called acute respiratory distress syndrome (ARDS). ARDS is 
a complex of clinical signs and symptoms which occur following diverse pulmonary or systemic 
insults, including sepsis. shock, pneumonia. trauma, liquid aspiration. hematological disorders, 
smoke inhalation, and many others [I, 2], In ARDS, the treatments available are still inadequate 
and morbidity, mortality, and costs remain unacceptably high [3]. The failure of the lung as a gas 
exchange organ results in peripheral tissue hypoxia, which appears to be related to the 
development of multiple organ failure (MOF). Since MOF is the predominant cause of death in 
ARDS, therapeutic efforts are aimed at improving oxygen delivery to the tissues. 
Available treatments include mechanical ventilation with positive end-expiratory pressure 
(PEEP) and high inspiratory oxygen concentration. However, despite extensive research on new 
ventilation modes, mortality has 110t changed much and remains 30-70% [4], as high as when 
first rcported by Ashbaugh et al. in 1967 [5]. It should be realized that mechanical ventilation 
is only a supportive strategy and that some ventilatory strategies even contribute to lung injury. 
That is why ARDS may, in part. be a product of our therapy - rather than the progression of the 
underlying disease [6]. 
Several strategies for ARDS, such as exogenous surfactant therapy [7], ventilation 
according to the "Open Lung Concept" [6, 8] and partial liquid ventilation [9] are currently under 
evaluation. In this chapter, we describe the central role of pulmonary surfactant in the 
pathophysiology of ARDS, and discuss the impact of these new strategies on surfactant function. 
Acute respiratory distress syndrome 
ARDS has become a well-recognized condition that is characterized by a heterogenous 
deterioration of both alveolar ventilation and pulmonary perfusion. ARDS is associated with an 
increase in alveolar permeability leading to pulmonary edema, hemorrhage and atelectasis. The 
pathophysiological changes in ARDS include hypoxemia, decrease in functional residual 
capacity (PRC), decreased total lung capacity (TLC), and decreased lung compliance [10]. 
As early as 1929, Von Neergaard [11] reported that much larger pressures were required 
to expand an air-lllled lung than a lung filled with tluid (Fig. I); this impmiant linding suggested 
that the surface tension at the air-liquid interface of the alveoli influences lung elasticity. The 
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problem with this discovery was that his work was published in Gennan, and that for 25 years 
no scientists in the evolving field took serious note of this publication. In 1957, Clements 
measured surface tension by using a modified surface balance, and demonstrated that lung 
extracts decreased surface tension [12]. They pointed out that the presence of a material with a 
very low surface tension prevents atelectasis in the lung. 
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Fil-!lII'l' l. Pressure-volume (P/V) diagram of a healthy air-filled lung, a fluid-filled lung and an ARDS 
lung. VOIl Nccrgaard fill showed, in 1929, that much larger pressures were required to expand an air-
filleu lung. than a lung filled with fluid. In ARDS, there arc even higher pressures required to expand the 
lung due to the high surface tension at the air-liquid interface in the alveoli, which is caused by surfactant 
inactivity. ARDS: acute respiratory distress syndrome. 
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Asbaugh et aI., in 1967, demonstrated that the sUlface tension ofbroncho-alveolar lavage 
(BAL) tluid from two adult patients was increased [5]. The clinical and pathological features 
were very similar to those seen in neonates with respiratory distress syndrome. who have a 
primary surfactant deticiency that is caused by the immaturity of the lungs. Therefore, they 
introduced the name adult respiratory distress syndrome (ARDS), and assumed that in the adult 
patient the pulmonary surfactant became inactivated and was responsible for atelectasis. 
Nowadays, it is more appropriate to speak about the acute, rather than adult. respiratory distress 
syndrome, since ARDS is not limited to adults [3], 
Since 1967. several studies have analyzed lung surfactant recovered from BAL of 
patients with ARDS and demonstrated compositional changes in surfactant and/or decreased 
surfactant content of the lungs [10]. Furthermore, Gregory and colleagues [13] showed that 
minimal surface tension was increased, and that total phospholipids and sUlfactant proteins (SP-
A and SP-B) were decreased in the BAL fluid obtained from patients at risk to develop ARDS, 
suggesting that these abnormalities of surfactant occur early in the disease process. 
The central role of surfactant deficiency can further be illustrated by studies in animal 
models of ARDS which demonstrated that exogenous surfactant instillation dramatically 
improved blood gases and lung mechanics (for reviews see [14-16]). The models of surfactant 
deficiency in which these improvements could be demonstrated include: acute respiratory failure 
due to in vivo whole-lung lavage [17-19], neurogenic ARDS [20], respiratory failure as a result 
of oxygen toxicity [21, 22] or oxidant producing enzymes [23], acute respiratory failure after 
instillation of hydrochloric acid [24-26J, plasma instillation [27] and intoxication with N-nitroso-
N-methylurethane (NNNMU) [28] or paraquat [29], and respiratory failure due to pneumonia 
[30-32]. 
Thus, there is clinical and experimental evidence of a deficiency of active pulmonary 
surfactant in patients with ARDS, which would be the rationale for a surfactant replacement 
therapy. 
Pulmonary Surfactant 
Pulmonary surfactant is a complex of phospholipids (80-90%), neutral lipids (5-10%) and at least 
four specific surfactant-proteins (5-10%) (SP-A, SP-B, SP-C and SP-D), synthesized and secreted 
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from the alveolar type II cells, lying as a monolayer at the air-liquid interface to reduce the 
surface tension in the lung [331. Smi'actant is essential for normal breathing at physiological 
transpulmonary pressures and prevents end-expiratory collapse of the alveoli and small airways; 
an intact surfactant system is also essential to maintain the fluid balance in the lung [34]. The 
functional integrity of surfactant depends on the specific proteins [35]. The exact mechanisms 
involved are not yet clear, but there are indications that SP-A regulates surfactant secretion and 
re-uptake of surfactant by the type II cells, whilst SP-B and SP-C are thought essential for rapid 
adsorption of the phospholipid molecules into the monolayer. It has been demonstrated that 
surfactant, in particular SP-A and D, plays a role in the lung's defence against infection [36]. 
Pulmonary surfactant and ARDS 
Despite diverse etiologies in ARDS, the final pathway results in damage of the alveolar 
epithelium and endothelium, which leads to high-permeability pulmonary edema. The exact 
mechanisms responsible for injury to the alveolar-capillary membrane are complex and are still 
under discussion [37]. The formation of edema leads to wash-out or dilution of the stllfactant 
[38] and/or inactivation of the surfactant by plasma components, such as fibrin(ogen), albumin, 
globulin and transferin, hemoglobin and cell membrane lipids; these components are known to 
inhibit pulmonary surfactant in a dose-dependent way [391. Furthennore, surfactant may also be 
disturbed by the following mechanisms: breakdown of surfactant by lipases and proteases; 
phospholipid peroxidation by free radicals; loss of surfactant from the airways due to mechanical 
ventilation with large tidal volumes; disturbed synthesis, storage, or release of surfactant 
secondary to direct injury of type II cells [39-41]. 
Diminished surfactant has far-reaching consequences for lung function. Independent of 
the cause, decreased surfactant function will directly or indirectly lead to [34J: 
decreased pulmonary compliance 
decreased FRC 
atelectasis and enlargement of the functional right-to-Ieft shunt 
decreased gas exchange and respiratory acidosis 
hypoxemia with anaerobic metabolism and metabolic acidosis 
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pulmonary edema with further inactivation of surfactant by plasma 
constituents. 
Th is phase of acute respiratory distress can persist for days to weeks, but recovery without 
persistent impairment of lung function is possible. However, when this condition persists for a 
longer period of time, it is likely that new inflammatory events occur, which can trigger 
fibroblast proliferation that results in progressive lung fibrosis. In this phase of ARDS lung 
damage becomes irreversible, and this condition is associated with a very poor prognosis [42]. 
The pulmonary surfactant system and mechanical yentilation 
The deterioration of gas exchange in ARDS that resuits from the collapse of surfactant-deticient 
alveoli necessitates the implementation of mechanical ventilation. However, it has been shown 
that mechanical ventilation itself, in particular when large tidal volumes and high peak 
inspiratory pressures are used in combination with low end*expiratory pressures, affect the 
pulmonary surfactant system [43]. The exact mechanisms involved are not yet entirely clear, but 
it has been shown that the surfactant in the alveolar lining is actively removed from the alveolus 
towards the larger airways; this can lead to a shortage of surfactant at the alveolar level causing 
changes in surface tension characteristics in the lung, as seen during or after prolonged periods 
of mechanical ventilation [43). 
During end-expiration the surfactant molecules covering the alveolar epithelium are 
compressed on the small alveolar areas leading to low surface tension thus preventing the alveoli 
from collapse. If the surface of the alveolus is smaller than the snrface occupied by the slilt-actant 
molecules, the molecules are squeezed out of the surface of the alveolus and forced toward the 
airways. These surfactant molecules are then 'lost' for the alveoli and are eventually cleared from 
the lungs. During the following inflation of the alveoli, the surface is replenished with sUlfactant 
molecules coming from the underlying hypophase where surfactant molecules are 'stored' for 
later use. During the n~xt expiration, the mechanism repeats itself and again surfactant molecules 
are forced out of the alveolus and subsequently replenished from the hypophase; this is a 
continuing cycle (Fig. 2) [43). 
The amount of surfactant that must be produced and subsequently secreted by the alveolar 
type II cells is proportional to the loss of surface active molecules during the breathing cycle. 
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Figure 2. (A) Balance between synthesis, release and consumption of surfactant in the healthy lung. 111e 
pressure values given represent the intra-pulmonary pressure needed to open up this alveolus. At the 
surface and in the hypophase (micelles), there are sufficient molecules of surfactant. 111ese micelles deliver 
the surfactant necessary to rcplace the molecules squeezed out during expiration (Exp.). (D) Imbalance 
between synthesis, release and consumption of surfactant due to mechanical ventilation. At the beginning 
of inspiration (Insp.), there exists an apparent deficiency of surfactant molecules but there is, in principle, 
enough surfactant on the surface. (C) With the next expiration, surface active molecules are squeezed out 
and no surface active molecules are left in the hypophase for respreading. creating the situation where a 
serious surfactant deficiency follows (from reference [40]). 
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\Vhcn production and secretion of new surfactant molecules keep pace with consumption, no 
surfactant deficiency will occur, as in a normal healthy lung. 
Function of surfactant present in the alveoli can be compromised during mechanical 
ventilation in several different ways. First, due to the pulmonary interdependence of the alveoli 
the forces acting on the fragile lung tissue in non-uniformly expanded lungs are not only the 
applied trans pulmonary pressures, but also the shear forces that are present in the interstitium 
between opened and closed alveoli [44]. These shear forces may well be the major reason for 
epithelial disruption and the loss of ban'ief function of the alveolar epithelium, which results in 
an influx into the alveolar space of plasma proteins, which inhibit surfactant function in a dose-
dependent way [45]. 
Second, the surfactant system consists of surface active large aggregates (LA) and nOI1-
surface active small aggregates (SA). In order to preserve an adequate surt'actant function, it is 
necessary that the balance between small and large aggregates is maintained [46]. Studies have 
shown that the conversion of LA into SA con-elates with changes in alveolar surface area. An 
increase in tidal volume, which increases the magnitude of alveolar surface area changes, has 
been shown to increase the conversion of LA into SA [47, 48]. The same studies demonstrated 
that changing the respiratory rate [47] or level of PEEP [48] did not affect the rate of aggregate 
conversion. 
Tl'eatment stl'ategies fol' ARDS 
Exogellolls surfactant therapy 
Considering its success in neonatal RDS, exogenous surfactant therapy seems very promising 
in the treatment of ARDS patients. Although these two syndromes are very similar, there is an 
important difference: neonatal RDS is characterized by a primary surt~1ctant deficiency due to 
immaturity of the lungs, whereas in ARDS surfactant inactivity is a complication of lung injury. 
Although it seems rational to administer exogenous surfactant to ARDS patients, this not 
yet a clinical reality. At this moment, only a few case reports and results of limited clinical 
studies are available in which adult patients with ARDS are treated with exogenous surfactant. 
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Although these reports showed that some patients did not respond, or had an only transient 
improvement after a single dose of surfactant, better results were seen with higher or multiple 
surfactant doses. The reason for lack of response, or only transient improvement after exogenous 
surfactant application, is attributed to the inhibition of the instilled snrfactant by plasma 
components filling the alveolar space. This means that if after surfactant instillation there is no, 
or only transient, improvement of blood gases in these patients (fibrotic lungs excluded) this does 
not mean that surfactant treatment does not work, it only means that the concentration of the 
exogenous surfactant used is too low in relation to the amount of surfactant inhibitors in the lung 
[45}. Therefore, for treatment of ARDS, a high concentration of smfactant is required to 
overcome the inhibitory effect of plasma components. This was first postulated by Lachmann 
[34] after treating the first "adult" patient, and is now confirmed by the results of Gregory and 
colleagues [49] in a mnlticenter, randomized pilot study in 59 patients with ARDS of different 
etiologies. In this latter stndy, three different dosing strategies were tested and the results showed 
that maximum improvement of oxygenation, minimum ventilatory requirements, and lowest 
mortality rate were obtained following treatment with 400 mg surt:,ctant per kg body weight. The 
surfactant used in Gregory's study was a natural surfactant, as already used in neonates, and was 
given as a bolus. This study is, to our knowledge, the first controlled trial in which the mortality 
of ARDS could be decreased (from 43.8% to 18.8%) by a single therapeutic intervention. 
Wahnrath et al. administered a natural sUlfactant (300 mg/kg) with a bronchoscope to patients 
with severe ARDS and sepsis, which resulted in an increase in arterial oxygenation [50}. In half 
of their patients, an additional dose of 200 mglkg was required to maintain this improvement of 
gas exchange. In contrast to these results, Anzueto et al. found no effect on mortality and lung 
function after administration of aerosolized artificial suli'actant in a multicenter trial in patients 
with sepsis-induced ARDS [51]. However, in their study a much lower dose of surfactant was 
delivered to the lungs «25 mg/kg) than in the study by Gregory and colleagues, which is 
speculated to be an insufficient dose to overcome the inhibition by plasma components in the 
alveolar space. 
The exact amount of exogenous surfactant required in ARDS to restore lung surfactant 
function is not known, but different case reports and pilot studies suggest that a dose between 
50 and 400 mg/kg body weight may be appropriate. Because the quantity of inhibitors differs 
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from patient to patient, an excess of surfactant should always be given or repeatedly be 
substituted ("titrated") until blood gases improve [45]. Experience in neonates has also leamed 
that exogenous suli'actant is more effective when administration takes place in the early stages 
ofRDS with a smaller amonnt of surfactant inhibitors [52]. Early treatment of ARDS may thus 
require smaller amounts of surfactant and the outcome results will probably be better. 
The optimal method to deliver surfactant to patients with ARDS is unknown and 
currently under evaluation. The currently used technique of delivering exogenous surfactant is 
the liquid bolus instillation through the endotracheal tube. This method has been used in most 
animal studies as well as in neonates with RDS [52]. The advantage of this method of instillation 
is that it is rapid and able to deliver the large quantities of surfactant. As already mentioned, a 
large amount of surfactant has to be instilled in ARDS patients to overcome the inhibitory effects 
of the serum components present in the alveoli. This means that a relatively large amount of fluid 
has to be instilled into the injured lungs, which may be potentially harmful. Therefore, Lewis et 
al. [53] investigated surfactant administration as an aerosol. The rationale was that by this 
method of instillation less volume of liquid will be instilled in the lungs at one time and that the 
distribution will he more homogenous. Their study demonstrated that the distribution pattem was 
more homogenolls after aerosolized surfactant administration, but it also showed that bolus 
instillation was superior to aerosolized surfactant in improving blood gases. They suggested that: 
"the low quantities of aerosolized surfactant deposited in the lungs limited the physiological 
responses". The same group of investigators also showed, in another study [54], that it was 
impossible to improve gas exchange after aerosolized surfactant in a non-unifonn pattern of lung 
injury. They found that the less injured areas of the lung received relatively more surfactant than 
the severely injured areas. They conclude that: "one should be cautious in administering 
aerosolized surfactant to patients with ARDS who have non-uniform infiltrates on chest 
radiograph"; this would imply, however, that aerosolized surfactant can not be used in ARDS, 
since the lungs of an ARDS patient are always injured in a non-uniform way [55]. 
To improve the response to exogenous surfactant, it could be useful to lavage the lungs 
of an ARDS patient with a bronchoscope in a lobe-wise fashion, in order to lower the protein 
content of the alveoli, prior to surfactant administration [56]. However, lung lavages with, for 
example, saline also remove endogenous surfactant, which leads to a further deterioration of lung 
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function [57J. To avoid a deterioration of lung function by decreasing the amount of active 
surfactant, broncho-alveolar lavage can be performed using diluted surfactant, as was 
successfully shown in an animal model of ARDS [58]. 
Various surfactant preparations are commercially available, and have been used 
successfully in worldwide clinical trials in neonates with RDS [52]. The natural surfactants 
(derived from animal lungs) contain surfactant proteins Band C while the artificial surfactant 
preparations are protein free. Several animal and clinical studies have shown that the protein-
containing surfactants are more effective in improving lung function [59,60}. Also, various 
studies have demonstrated that surfactant proteins reduce the surfactant inactivation that may be 
caused by plasma constituents, which is of special importance in ARDS [61,62]. 
Application of exogenous surfactant in adult patients obviously requires a larger amount 
of surfactant than in neonates. If the same dose is used, 7-10 g sUifactant would be required to 
treat one adult patient. At ClilTent prices, the cost of this treatment would be 30,000·50,000 euro 
per patient. Thus, the price of surfactant has to be lowered before exogenous surfactant therapy 
for adult patients can be applied on a larger scale. 
The open lung concept 
The open lung concept (OLC) is a ventilation strategy that aims to maintain lung aeration during 
the entire respiratory cycle while preventing ventilation-induced injury to the surfactant system. 
The physiologic rationale for the open lung concept is found in the LaPlace law (p~2y/r, 
P:::;pressure to stabilize an alveolus; Y=surface tension at the air-liquid interface in the alveolus; 
r=radius of the alveolus). From this law it follows that the pressure needed for alveolar expansion 
increases in conditions associated with a decreased surfactant function as, for example, in ARDS. 
Experimental studies on surfactant dysfunction show the behaviour of the alveoli to be quantal; 
that is, they are either open or closed [63J. A critial opening pressure has to be reached until 
previously collapsed alveoli can be opened (Fig. 3). Once they are opened, they remain open until 
the pressure drops below a critical level, then immediate collapse follows. Reopening requires 
the high opening pressure again. Any state between open and closed is unstable and impossible 
to maintain. 
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The pressure needed to induce volume changes in an alveolus depends on the initial 
radius. In other words, to get a certain volume change in larger alveoli, the change in pressure 
required is much smaller than in alveoli which are collapsed or have a lower volume. It can 
further be derived from the law of LaPlace that the pressure necessary to keep the alveoli 
expanded is smaller at a high PRe, since the PRe directly correlates to the amount of open lung 
units and to their size. Therefore, the PEEP necessary to stabilize the end-expiratory volume can 
be minimized if the lungs are once totally opened to the PRe of a healthy lung. 
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Figure 3. Schematic drawing of a prcssurc·volume (PlY) curve showing the proposed mechanism of 
alveolar recruitment and collapse. With the increase of pressure during inspiration the corresponding 
change in volume is given by the P-V curve (solid line). At A the alveolus is still collapsed. It is not before 
point B that the critical opening pressure, Po, is reached, the increase in alveolar volume is immediate 
(dashed line) and reaches D. TIle alveolus is recruited (note that the intra-alveolar pressure is the same at 
B and D). When the pressure is reduced to the closing pressure (Pc) at point C the change in volume 
follows the solid line when the alveolus collapses again. 
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In a clinical study Kesecioglu et al. investigated the effects of pressure-controlled 
ventilation at different inspiratory/expiratory (I:E) ratios in ARDS patients [8]. They applied an 
initial peak inspiratory pressure (PIP) of 50 cmH20 for 10 minutes to reaerate atelectatic luug 
regions (that is, to open up the lung), and prevented them from end-expiratory collapse by 
applying a high enough PEEP (that is, they kept the lung open). With this open lung strategy, 
significant increases in Pa02 were obtained with increased I:E ratios. In addition, they showed 
that when the ventilation mode was changed from volume to pressure controlled with an I:E ratio 
of 4:1, PIP and intrapulmonary pressure amplitude were markedly decreased. Effects on patient 
outcome were not investigated in this study. 
The increase in oxygenation obtained with application of an open lung strategy in patients 
with severe lung injury was confirmed in a study by Amato et al. [64]. In that study, a ventilation 
strategy was used that combined permissive hypercapnia, PEEP levels above the lower intlection 
point of the static pressure-volume curve, and a low tidal volume, together with limited peak 
inspiratory pressures. Furthermore, the application of this approach resulted in a higher rate of 
weaning. a faster normalisation of lung function and a trend towards a higher survival. This 
randomized study was the first one to demonstrate the beneficial effect and the feasibility of 
opening up previously collapsed alveoli and keeping them open during the whole period of 
artificial ventilation. In their study, Amato et al. found the effect on oxygenation of the change 
in ventilation mode to be inunediate though not optimal; the improvement in pulmonary 
compliance was slow and occurred during the days following the change in ventilation strategy. 
Recently, Amato and colleagues showed that the use of an open lung strategy in ARDS patients 
results in an improved survival and a lower rate of barotrauma [65]. 
Parrilli liquid ventilation 
Another rational treatment to compensate for the high retractive forces in an ARDS lung. in 
which the increased surface tension at the air-liquid interface in the alveoli leads to alveolar 
collapse, is based on the elimination of the air-liquid interlace by tilling of the alveoli with fluid. 
Filling of the lung with fluid thereby results in a marked reduction in the pressure that is required 
to expand the lungs, as discussed earlier (see Fig. I). A group of liquids suitable to maintain gas 
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exchange when they are instilled into the lungs are perfluorocarbons (PFCs). Once the lungs are 
filled up to the level of FRC, gas ventilation is superimposed on these fluid-filled lungs; this 
ventilation strategy is called partial liquid ventilation (PLV). 
Pertluorocarbons are a group of odorless, colorless, clear liquids that are insoluble in 
aqueous media. PFCs have a high solubility of both oxygen and carbon dioxide, and a low but 
constant surface tension. These compounds are very stable and biologically inert, and do not 
seem to be metabolized by biological systems. When PFCs are administered to the lungs, 
systemic absorption and distribution of small amounts of PFCs to other tissues has been 
demonstrated; however, the main elimination ofPFCs is through evaporation via the lungs. This 
elimiuation is dependeut on the vapour pressure of the specific PFC used [66]. 
A 
Upper lung 
2616 
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Il'igure 4. Panel A shows an atelectatic surfactant deficient alveoli at cnd-inspiration (dashed line) and end-
expiration (solid line). Panel B shows what happens after administration of PFC into the lung. Due to its 
evaporation, a thin film of PFC is fom1ed at the air-liquid interface and due to its low surface tension, 
pulmonary compliance is improved. This occurs at a low dose of PFC and does not improve at higher 
doses of PFC. Some dependent alveoli are prevented from end-expiratory collapse by the nOI1-
compressabJc PFC, which improves oxygenation. Panel C shows what happens if more PFC is instilled 
into the lungs: more alveoli arc rccmted at end-expiration. Therefore, there is a dose-dependent 
improvement in oxygenation with PFC during partial liquid ventilation. 
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The hypothetical mechanism of PLY is explained in Fig. 4. Panel A shows the atelectatic 
ARDS lung. After administration of a small dose ofPFC (3 mllkg) a thin tilm ofPFC with a low 
surface tension is fonned at the air-liquid intelface. Due to evaporation ofPFC, tlus film reaches 
the whole lung, including the alveoli that do not have direct contact with the instilled PFC (panel 
B). Due to this PFC tilm the increased surface tension at the air-liquid intert;1ce of the surfactant-
deficient lung is decreased. This leads to a reduction in innation pressures needed to expand the 
lung, and this pressure cannot be decreased further by administering IIlore PFC. The dose-
dependent improvement in oxygenation is attributed to the opening and filling of collapsed 
alveoli in the dependent lung parts with the non-compressable PPC, thereby preventing them 
from end-expiratory collapse and thus allowing gas exchange to continue during the entire 
respiratory cycle (panel C). Administration of more PFC leads to filling of mOfe alveoli, thereby 
reducing intrapulmonary shunt. This mechanism is supported by results from Qnintel et ai., who 
showed that during PLY, PFC is distributed predominantly to the lower lung regions, whereas 
gas exchange takes place in the upper lung regions [67]. In the normal lung, without PFCs, 
surfactant is capable of reducing the surface tension at the alveolar air-liquid interface in relation 
to changes in alveolar radius, thus providing alveolar stability at any alveolar volume, even at 
very low lung volumes. PFCs do not display this characteristic, since they have a constant surface 
tension. \Vhen surfactant-deficient alveoli are only covered with a PFC film at the air-liquid 
interface (e.g. in the nondependent area of the lung), end-expiratory collapse can occur in these 
alveoli during exhalation if the applied PEEP is not high enough to counterbalance the increased 
retractive forces. 
Besides preventing non-fluid-filled alveoli from end-expiratory collapse, a certain level 
of PEEP is also necessary to prevent bulk movement of the fluid into the airways before 
instituting the next inspiration [68]. This f1uid movement would result in high peak pressures 
inside the airways during PLY, at volume-constant ventilation. PEEP prevents this movement 
by pushing the tluid distally, keeping it within the alveoli and thus preventing it from filling the 
airways during each subsequent expiratory phase. 
Partial liquid ventilation is currently being investigated in clinical trials in neonates and 
adults with RDS. Leach et al. repofted a pilot safety and efficacy study in thirteen premature 
newborns with RDS who failed to respond to conventional therapy and exogenous sUifactant 
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treatment [69]. Instillation of PFC resulted in an increase in PaO, and dynamic compliance. 
There were no serious adverse side effects associated with PLY. Ten infants completed the study, 
eight of them survived. 
HirschI et al. reported a study in 19 adults, children, and neonates in respiratory failure 
who were treated with PLY [70]. For safety reasons, gas exchange was supported by extra 
corporeal life support (EeLS). The primary outcome measure was the alveolar-arterial oxygen 
difference [(A-a)Do,] during 10-minute periods of discounection of ECLS before and during 
PLY. The (A-a)Do, decreased during disconnection ofECLS, and static pulmonary compliance 
increased over the initial three days ofPLV. All patients tolerated PFC administration without 
hemodynamic compromise. During PLY, six patients had reaccumulation of previous ipsilateral 
pneumothoraces and new pneumothoraces occurred in three patients. Of the 19 patients, 14 were 
successfully weaned from EeLS and 11 survivors were well and without evidence of pulmonary 
or adverse systemic effects from the administration of PFC after 2-12 months of follow-up. 
Comparable results were described in other reports from similar studies [71-75]. 
Repeated bronchoscopy of the PFC-filled lungs did not show any visible evidence of adverse 
effects of PFC in the airways. In some patients, extravasation of PFC into the pleural space 
occurred, but radiographs showed that the PFCs slowly resolved without evident injurious 
effects. A disadvantage of partial liquid ventilation is that PFC may interfere with interpretation 
of chest radiographs, because the radio-opaque liquid can obscure the position of intravascular 
catheters and EeLS cannulas in the fluid-filled regions, as well as making routine interpretation 
of chest radiographs dimcult, especially in patients with lung infections [73, 74]. It was also 
shown that it is necessary to remove pulmonary secretions and exudate, which are immiscible 
and, therefore, tloat on the surface of the PFC. They can be removed with suction to avoid 
blocking the airways. The clinically relevant complications that could be related to PL V 
described in all studies were pneumothoraces. To date, partial liquid ventilation has not 
improved survival in these patients; however, these studies were not designed to detect 
differences in mortality. 
Summary 
In this chapter a description is given of the central role of surfactant in the pathophysiology of 
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ARDS. The physiologic rationale for exogenous smfactant therapy, mechanical ventilation 
according to the open lung concept, and pat1ialliquid ventilation, are presented. These treatment 
strategies all showed encouraging results in animal studies, and are now undergoing clinical 
evaluation. 
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Summary 
Objective: To evaluate whether mechanical ventilation using the "open lung concept" during 
surfactant depletion can attenuate the deterioration in pulmonary function. 
Design: Experimental, comparative study. 
Setting: Research laboratory of a large university. 
SlIbjects: Eighteen adult male Sprague-Dawley rats, weighing 280-340 g. 
Interventions: Twelve rats were anesthetized, mechanically ventilated with 100% oxygen, and 
raudomly divided into two groups (11=6 each). The open lung group underwent six saline lavages 
at different ventilator settings that prevented alveolar collapse. The settings (expressed as 
frequency/peak inspiratory pressure/positive end-expiratory pressure/inspiratory:expiratory ratio) 
were 30/26/6/l:2 during the first lavage, 100/27/10/1:1 during the next two lavages and 
100/33/15/1:1 during the last three lavages and during the remaining ventilation period. The 
ventilated control group underwent six saline lavages with settings at 30/26/6/1 :2. After the 
lavages, peak inspiratory pressure and positive end-expiratory pressure were increased in this 
group by 2 cm H20 each for the remaining study period. An additional group of six animals were 
killed immediately after induction of anesthesia and served as healthy controls. Blood gases were 
measured before lavage, immediately after the last lavage and thereafter hourly. At the end of 
the 4-hr study period, we constructed pressure-volume curves from which we determined total 
lung capacity at a distending pressure of 35 cm H20 (1LC,,). Subsequently, total lung volume 
at a distending pressure of 5 cm H20 (V5) was detemlined, followed by broncho-alveolar lavage. 
Results: In the ventilated control group, PaO" V5 and TLC" were significantly decreased, 
and protein concentration of broncho-alveolar lavage was significantly increased compared with 
the healthy control group. In the open lung group, Pa02 did not decrease after the lavage 
procedure, and V 5. 1LC35 and protein concentration of brancho-alveolar lavage were comparable 
with the healthy controls. 
COIle/usion: \Ve conclude that application of the open lung concept during surfactant 
depletion attenuates deterioration in pulmonary function. 
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Introduction 
In acute respiratory distress syndrome (ARDS), dysfunction of the pulmonary surfactant system 
leads to hypoxemia, decreased functional residual capacity (PRe) and decreased compliance [1]. 
Despite extensive research the mortality rate of ARDS remains> 50% [2J. New strategies that 
are currently under clinical investigation include 'open lung' ventilation strategies. which aim 
to reopen collapsed but recruitable lung units and to keep them open by applying a sufficiently 
high positive end-expiratory pressure [3-6]. Recent studies show that such strategy improves 
oxygenation in ARDS patients, and is associated with a decrease in morbidity and mortality [7-
9J. 
Ventilation strategies that prevent repeated alveolar collapse are thought to prevent 
further damage to the pulmonary surfactant system and progression of lung damage [1O-13J. 
Because surfactant abnormalities are known to be present in patients who are at-risk for ARDS, 
prophylactic use of such a ventilation strategy might prevent or attenuate the decrease in 
pulmonary function by protecting the surfactant system [14J. A previons study, in which an open 
lung concept utilizing an inspiration time of 80% was applied in an animal model during 
repeated lung lavage, showed that this strategy resulted in better gas exchange, hemodynamics. 
and oxygen transport and less lung injury [5]; however, lung mechanics. composition, and 
fUllctioll of the surfactant system were not assessed. 
We hypothesize that when the lungs are kept open in an early stage of lung injury, 
surfactant function is better preserved resulting in less deterioration of pulmonary function. 
Therefore, in this study, we applied a ventilation strategy with a high positive end-expiratory 
pressure and a high frequency during repeated lung lavages, to evaluate whether severity of 
respiratory distress can be influenced by maintaining a better residual surfactant fUllction, 
compared with conventionalmechallical ventilation. 
Materials and methods 
The study protocol was approved by the University's Animal Experimental Committee, and the 
principles of laboratory animal care (National Institutes of Health publication 86-23, revised 
1985) were followed. 
The study was pelformed in 18 adult male Sprague-Dawley rats (body weight 280-340 
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g). After induction of anesthesia with 2% enflurane and 65% nitrous oxide in oxygen, we 
inserted a polyethylene catheter into a carotid artery to draw arterial blood samples. Before 
tracheostomy, the animals received 60 mglkg (i.p.), of pentobarbital sodium (Nembutal, Algin 
BV, Maassluis, the Netherlands). After tracheostomy, muscle relaxation was induced by Imglkg 
(i.m.) pancuronium bromide 1 mgikg (pavulon, Organon Teknika, Boxtel, the Netherlands) 
inunediately followed by connection to a ventilator. The animals were mechanically ventilated 
with a Servo Ventilator 300 (Siemens-Elerna. Soiua, Sweden) in a pressure constant time-cycled 
mode, at an Fia2 of 1.0, frequency of 30 breaths/minute, peak inspiratory pressure set at 12 em 
H,O, positive end-expiratory pressure set at 2 cm H,O, and inspiratory/expiratory ratio of 1:2. 
Anesthesia was maintained with 40 mg/kg/h (i.p) pentobarbital sodium; muscle relaxation was 
maintained with 1 mglkglh (i.m.) pancuroniuIll bromide. Body temperature was kept within the 
normal range with a heating pad. Immediately after induction of anesthesia, six animals were 
killed and served as healthy. non-ventilated controls. The remaining animals subsequently 
underwent six whole lung lavages with warm saline (37°C), according to Lachmann et a!. [15]. 
During lavage. different ventilator settings were used in both groups, which are shown in Table 
1. After lavage, peak inspiratory pressure and positive end-expiratory pressure were increased 
in the ventilated control group to prevent critical hypoxia and remained unchanged in the open 
lung group, after which both groups were ventilated for 4 hrs (Table 1). The recovered volume 
of lavage fluid was recorded, and a phosphorus analysis was performed on the lavage fluid to 
quantify the amount of surfactant phospholipids washed out during lavage. 
Arterial blood gas samples were taken before lavage, after lavage, and hourly for 4 Ius. 
The samples were analysed for Pa02 and PaCO, on a blood gas analyser (ABL 505, Radiometer, 
Copenhagen, Denmark). 
After the animals were killed with an overdose of pentobarbital, we recorded static pressure-
volume curves by using the syringe technique. After the thorax and diaphragm were opened, the 
tracheostomy catheter was connected to a pressure transducer with a syringe attached to it 
(model DP 45-32, Validyne Engineering, Northridge, CA, USA), and pressures were recorded 
on a polygraph (model 7B, Orass Instrument, Quincy, MA., USA). First, the lungs were inflated 
quickly with 100% nitrogen (N,) from the syringe to an airway pressure of35 cmH,O, which was 
maintained for 5 sees, followed by deflation to an airway pressure of 0 cmH,O. Then, the lungs 
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Table 1. Ventilator settings in the two ventilated groups. 
Ventilated control group 
LAV I LAV2-3 LAV4-6 >LAV6 
PIP (cmH,O) 26 
PEEP (cmH,O) 6 
Frequency 30 
lIE 112 
26 
6 
30 
112 
26 
6 
30 
1!2 
28 
8 
30 
112 
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Open lung group 
LAV I LAV2-3 LAV 4-6 >LAV6 
26 
6 
30 
1!2 
27 
10 
100 
III 
33 
15 
100 
III 
33 
15 
100 
III 
LA V, lung lavage; PIP, positive inspiratory pressure; PEEP, positive end-expiratory pressure; UB, 
inspiratory/expiratory ratio. 
were fe-inflated with N2 from the syringe in steps of 0.5 ml until an airway pressure of 35 
cmH20 was reached. For each step, the bolus of N2 was administered quickly, and was followed 
by a 5-sec pause to allow pressure equilibration. After this, the lungs were deflated likewise, 
until an ainvay pressure of 0 cmH20 was reached. The volume of N2 left in the syringe was 
recorded. From the pressure-volume curves we determined total lung capacity (TLC35), which 
was defined as the lung volume above the collapsed volume at a distending pressure of 35 
cmH20. and maximal compliance (Cma:o;), which was calculated from the steepest part of the 
deflation limb. 
After construction of the pressure-volume curves, the lungs were removed ell bloc and 
weighted, and lung volume at an airway pressure of 5 cmH20 (V,) was determined by fluid 
displacement. We chose a positive pressure of 5 cmH20 to compensate for the loss of 
trans pulmonary pressure in the open chest [16). TIle total lung volume at this distending pressure 
was considered close to FRC. 
After we assessed lung mechanics, the lungs were lavaged with 1.5 IIunollL saline-CaeI2. 
The active surfactant component in the bronchoalveolar lavage fluid was separated froIll the 
nonactive surfactant component by differential centrifugation followed by subsequent 
phosphorus analysis. and the ratio between nonactive and active components (small aggregate 
to large aggregate ratio or SNLA ratio) was calculated, as previously described by Veldhuizen 
and colleagues [17). We determined the protein concentration of the bronchoalveolar lavage 
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tluid using the Bradford method (Bio-Rad protein assay, Munich, Germany) [18]. 
We performed statistical analysis by using the Instat statistical package (GraphPad 
software, San Diego, CA, USA). For blood gases, we analyzed intergroup comparisons by using 
the alternate (Welch) Student's I-test, and analyzed intragroup comparisons by using repeated-
measures analysis of variance (ANOY A). All other data were analysed with ANOYA. If 
ANOYA resulted in a I' < 0.05, a Tukey-Kramer posttest was performed. All data are reported 
as mean ± SD and p < 0.05 was considered statistically significant. 
Results 
In the lavage fluid from the six lavages used to induce lung injury, there were no significant 
differences in tluid volume recovered (83% ± 0.7% vs. 83% ± 3%) and total amount of 
phosphorus between the ventilated control group and open lung group (5.58 ± 0.8 !lmol vs. 5.28 
± 1.38 ~'mol), respectively. 
Blood gas values before lavage were comparable for both ventilated groups (Table 2). 
After six lavages, PaO, decreased to 102 ± 118 torr [13.6 ± 15.8 kPa] in the ventilated control 
group, whereas in the open lung group PaO, remained >500 torr [67 kPa] (1'<0.001)( Table 2). 
In both ventilated groups, PaO, did not change during the remaining study period. PaCO, 
increased to >60 torr [8 kPa] (P<O.OOI) in the ventilated control group, whereas it remained in 
the normal range (35-45 torr [4.7-6 kPa]) in the open lung group (Table 2). During the 4-hr 
ventilation period, none of the animals died. 
The pressure-volume curves are shown in Figure 1. TLC35 was decreased in the 
ventilated conlrol group compared with the healthy controls (1'<0.0 I), but in the open lung group 
1LC35 was preserved. Cnm was decreased in the ventilated control group compared with the open 
lung group (5.4 ± 1.0 mUcm H,O/kg vs. 8.6 ± 2.8 mUcm H,O/kg; 1'<0.05), but in both 
ventilated groups Cmax was decreased compared with the healthy control group (13.4 ± 1.1 
mUcm H,O/kg, 1'< 0.001 vs. ventilated control, 1'<0.05 vs open lung group). There was no 
difference between both ventilated groups in total lung volume at a distending pressure of 5 
cmH,O (Y,); however, only in the ventilated control group Y, was lower than in the healthy 
control group (p< 0.001) (Table. 3). 
36 
Profylactic llse of tile open lung concept 
Table 2. Pa02 and PaC02 in the two ventilated groups 
Pa02 PaCO, 
Ventilated control Open lung Ventilated control Open lung 
Before lavage 585.4 ± 36.2 597.4 ± 38.0 43.6 ± 6.7 42.1 ± 5.1 
After lavage 102.3 ± 118.2" 621.3 ± 31.7 64.8 ± 16.4" 33.2 ± 8.0' 
1 hr 109.4 ± 120.5" 599.3 ± 36.7 62.7 ± 19.2" 40.0 ± 8.9 
2 hrs 104.8 ± 125.5" 602.9 ± 30.7 65.5 ± 20.7" 43.9 ± Il.l 
3 hrs 100.5 ± 112.0" 598.2 ± 37.3 66.9 ± 22.0" 44.1 ± 11.6 
4 hrs 100.8 ± 114.7" 600.5 ± 41.6 68.8 ± 24.6" 44.0 ± 9.8 
Values arc mean ± SD, expressed in torr. To convert torr to kPa, multiply the value by 0.1333 
§ p< 0.05 vs. open lung group; 'I p< 0.05 vs. before lavage. 
Table 3. V.5 and lung weight. 
Healthy control group 
V, (mUkg) 
Lung weight (g) 
17.0 ± 3.7 
1.9± 0.2 
Ventilated control group 
7.4 ± 3.5* 
4.5 ± 0.3* 
Open lung group 
12.1 ± 3.4 
4.5 ± 0.3* 
Values are mean ± SD. V j, total lung volume at a distending pressure of 5 cmH10. * p<O.05 vs. healthy control 
group. 
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Figure 1. Pressurc¥volwne curves, mean ± SD. Volwne (mUkg) is lung volume above functional residual 
capacity.*p< 0.01 vs. healthy control group. Maximal compliance emu was decreased in the ventilated 
control group compared with the open lung group (5.4 ± 1.0 VS. 8.6 ± 2.8 mUcm H20lkg; p< 0.05). but 
in both ventilated groups Cm"-l was significantly decreased compared to the healthy control group (13.4 
± 1.1 mIJcm H20/kg. p<O.OOI YS ventilated control, p<O.OS vs open lung group). Filled squares, 
ventilated control group; filled triangles, open lung group; open circles, healthy controls. 
The concentration of protein in the bronchoalveolar lavage tluid was increased in the 
ventilated control group (p< 0.001), whereas it was not increased in the open lung group (Fig. 
2). The total amount of phosphorus in the bronchoalveolar lavage fluid, which we measured to 
quantify the phospholipid-containing surfactant system, was obviously decreased in both lavaged 
groups, but there were no differences between these groups (Table 4). The ratio between 
nonactive and active surfactant components (SNLA ratio) was significantly increased in both 
ventilated groups compared with the healthy control group (p< 0.001) (Table 4). 
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Figure 2. Protein concentration (mean ± SD) (mglmL) of the bronchoalveolar lavage fluid of the three 
study groups. * p< .05 vs. healthy control group. 
Table 4. Pulmonary surfactant data: Total phosphorus, and small aggregate to large aggregate ratio 
(SAILA ratio) in the three study groups. 
Total phosphorus 
(flmol/mL) 
SA/LA mlio 
Healthy control group 
0.14 ± 0.06 
0.3 ± 0.1 
Ventilated control group 
om ± 0.03' 
1.6 ± 0.6' 
Values arc mean ± SD. ~p<O.05 vs. Healthy control group 
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0.06 ± 0.01' 
1.5 ± 0.5 • 
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Discussion 
In this study, we defined the lungs to be open when PaO,lFiO, was above 500 torr [67 kPa], 
indicating that there is no intrapulmonary shunting. \Ve previously showed that sUlfactant-
deficient lungs can be opened and kept open when the open lung concept that applies a high 
positive end-expiratory pressure and high frequency is used [5, 6, 19]. 111erefore, we used these 
same settings in the present study to preserve oxygenation during surfactant depletion. 
In the open lung group. gas exchange and total lung capacity were preserved, and protein 
leakage into the alveoli was prevented, compared with the healthy control group. In the 
ventilated control group, however, all these variables deteriorated. Compared with healthy 
controls, lung volume at a distending pressure of 5 em H20 (V 5), which we took to be FRC, was 
significantly decreased only in the ventilated control group, although we found no significant 
differences in V 5 between the open lung and ventilated control groups. 
An important determinant of protein transport across the alveolar-capillairy membrane 
is integrity of the alveolar epithelium. Repeated alveolar collapse has been shown to compromise 
the integrity of the alveolar epithelium because of the occurreuce of shear forces [20,21]. 
Application of the open lung concept in an animal model after lung lavage previously was 
demonstrated to decrease protein leakage [19; for review, see Ref. 21]. In addition, application 
of positive end-expiratory pressure has been shown to favor the shift of fluid from the alveoli 
to the interstitium by decreasing the pressure gradient across the alveolar-capillary membrane 
[22]. This may explain the decrease in protein leakage that was found in the open lung group, 
in which end-expiratory alveolar collapse was prevented by application of a positive end-
expiratory pressure of 15 cmH,O. 
We found no differences in surfactant quantity and quality (SAILA ratio) between the 
open lung group and the ventilated control group (Table 4). It has been demonstrated that the 
alveolar area cycling, which depends on the pressure difference between inspiration and 
expiration, is responsible for converting active LA into nonactive SA [17]. The difference in 
pressure amplitude was comparable between both ventilated groups, which may explain the 
absence of any difference in SNLA ratio between both ventilated groups. However, we found 
significant differences between both ventilated groups in lung mechanics (TLC35 and maximal 
compliance). We attribute this discrepacy between lung mechanics and surfactant parameters to 
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the difference in protein leakage, because it has been established that plasma proteins inhibit 
surfactant function in a dose-dependent way [23]. Therefore, we conclude that prevention of 
protein leakage during and after surfactant depletion is important to protect the remaining 
smfactant function. 
Recl11itment of collapsed alveoli requires inspiratory airway pressures that overcome the 
critical opening pressure of these alveoli, which implies brief application of a high inspiratory 
airway pressure. However, ainvay pressures can be decreased once the lungs have been opened, 
as has been pointed out previously, with reference to the law of LaPlace [3J. From this law 
(P:::;2y/r, where P::::alveolar pressure; y:::;smface tension at the alveolar air-liquid interface; and 
r:::;alveolar radius) it follows that the pressure necessary to keep alveoli open and the pressure 
difference to induce volume chauges iu the alveoli are smaller at a high FRe level (Le. larger 
alveolar radius). Therefore, when the lungs are opened, gas exchange can be maintained with a 
lower positive end-expiratory pressure and smaller pressure difference, and hence, a lower peak 
inspiratory pressure, than before alveolar recruitment. If positive end-expiratory pressure is kept 
above the critical closing pressure, alveolar collapse will not occur and reperated application of 
higher peak inspiratory pressure will not be necessary. 
Although direct translation to the clinical situation is difficult, our results are in contrast 
to those of a clinical study by Pepe et al. [24J, who found that early application of positive end· 
expiratory pressure in high-risk patients did not affect the incidence of ARDS. However, those 
authors used a positive end-expiratory pressure of 8 cmH20, and removed the positive end-
expiratory pressure for 8 mins wheu takiug blood samples, thus allowing alveolar collapse. In 
a more recent study, Steward et al. [25J evaluated the use of a pressure- and volume limited 
ventilation strategy in patients at high risk for ARDS. Steward et al. [25J, who reported no 
reduction in mortality and possibly an increase in morbidity, also used an average positive end-
expiratory pressure of <10 cmH,O. We hypothesize that the positive end-expiratory pressure 
levels used in these latter studies were not high enough to prevent alveolar collapse, which may 
have increased protein leakage. This hypothesis is supported by results from Gattinoni et al. [26J, 
who in a computed tomography study of ventilated ARDS patients, showed that reinflated lung 
tissue could only be kept open at end-expiration at positive end-expiratory pressure levels of 15 
cmH,O and higher. This might explain the results by Kirby et al. [27J and Douglas and Downs 
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[28], who showed an improvement in pulmonary function in patients with acute respiratory 
failure after application of a PEEP in excess of25 cmH,O, and more recently by Amato et al. [9], 
who demonstrated that application of an open lung approach in ARDS patients resulted in 
improved survival and reduction of barotrauma. 
We conclude that the application of the open lung concept during surfactant depletion 
prevents a decrease in gas exchange. attenuates the deterioration in lung mechanics, and prevents 
an increase in protein leakage. The prevention of protein leakage is of special importance in 
surfactant-deficient lungs, because the low amount of remaining surfactant makes it more 
vulnerable to inhibition of its function. \Ve speculate that the prevention of end-expiratory 
collapse during mechanical ventilation in the early phase of acute respiratory failure may 
decrease morbidity and mortality in patients. 
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SUlllmary 
\Ve have compared three treatment strategies. that aim to prevent repetitive alveolar collapse, 
for their effect on gas exchange, lung mechanics, lung injury, protein transfer into the alveoli and 
surfactant system, in a model of acute lung injury. In adult rats, the lungs were ventilated 
mechanically with 100% oxygen and a PEEP of 6 em H20, and acute lung injury was induced 
by repeated lung lavage to obtain a Pa02 <13 kPa. Animals were then allocated randomly (1/~12 
in each group) to receive exogenous smfactant therapy, or ventilation with high PEEP (18 
cmH20), partial liquid ventilation, or ventilation with low PEEP (8 cmH20) (ventilated 
controls). Blood-gas values were measured hourly. At the end of the 4 h study, in six animals 
per group pressure-volume curves were constructed and broncho-alveolar lavage (BAL) was 
performed, whereas in the remaining animals lung injury was assessed. In the ventilated control 
group. arterial oxygenation did not improve and protein concentration of BAL and conversion 
of active into non-active surfactant components increased significantly. In the 3 treatment 
groups, Pa02 increased rapidly to >50 kPa and remained stable over the next 4 h. The protein 
concentration of the BAL l1uid increased significantly only in the partial liquid ventilation 
group. Conversion of active to non-active surfactant components increased significantly in the 
partial liquid ventilation group and in the group ventilated with high PEEP. In the surfactant 
group and partial liquid ventilation group, less lung injury was found compared with the 
ventilated control group and the group ventilated with high PEEP. We conclude that although 
all three strategies improved Pa02 to >50 kPa, their impact on alveolar protein transfer into the 
alveoli, sUifactant system, and Inng injury differs markedly. 
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Introduction 
Acute lung injury (ALI) is a condition of acute respiratory failure, in which lack of active 
surfactant leads to alveolar collapse, resulting in severe hypoxia [1]. Available treatments 
include mechanical ventilation with high inspiratory oxygen concentration and high peak 
alveolar pressures with large distending tidal volumes, but these are known to induce lung 
damage [2]. Ventilation strategies that prevent repeated alveolar collapse are thought to prevent 
further progression of lung damage [3], Therefore, new treatment strategies that aim to prevent 
repetitive alveolar collapse during ALI are under investigation. 
These new strategies include: I) pressure-controlled ventilation that recruits collapsed 
lung areas by applying an inspiratory pressure that overcomes the opening pressure of collapsed 
but recruitable lung units. After recruitment, ventilation pressures are reduced and PEEP is set 
just above the critical closing pressure of these lung units to prevent end-expiratory collapse [4, 
5].2) Partial liquid ventilation, in which ventilation is superimposed on lungs that are filled with 
pertluorocarbons thus preventing expiratory collapse [6, 7]. 3) Exogenous surfactant therapy, 
in which the lost active surfactant is replaced [8,9]. 
Studies have shown that these strategies improve oxygenation while diminishing the 
effects on lung injury in animal models of ALI [4, 8,10]. All three strategies are currently under 
investigation for clinical use, and although some of the results are promising, they have l1at been 
compared directly [11-15]. In this study, we have compared these three techniques for their 
efficacy on improving arterial oxygenation and lung mechanics in rats who underwent 
bronchoalveolar lavage. and assessed their impact on transfer of protein into the alveoli, the 
surfactant system and on lung injury. 
Methods 
The study was approved by the University's Animal Experimeutal Committee, and the care and 
handling of the animals conformed with European Community guidelines (86/6091EC). The 
study was pertormed in 60 adult male Sprague-Dawley rats (body weight 270-330 g). After 
induction of anaesthesia with 2% enflurane and 65 % nitrous oxide in oxygen, a polyethylene 
catheter was inserted into a carotid artery for drawing arterial blood samples. Before 
tracheostomy, the animals received pentobarbital (pentobarbitone) 60 mg/kg (i.p.) (Nembutal, 
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Algin BY, Maassluis, the Netherlands). After tracheostomy, neuromuscular block was produced 
with pancnronium I mg!kg (i.m.) (pavulon, Organon Teknika, Boxte!, the Netherlands) followed 
immediately by connection to a ventilator. The animals underwent mechanically ventilated with 
a Servo Ventilator 300 (Siemens-Elema, Solna, Sweden) in a pressure constant time-cycled 
mode, at an inspired oxygen concentration (Fi02) of 1.0, frequency of 30 bpm, peak inspiratory 
pressure (pIP) of 12 cm H20, positive end-expiratory pressure (PEEP) of 2 cm H20, and 
inspiratory/expiratory (liE) ratio of I :2. Anaesthesia was maintained with pentobarbital 40 
mglkg/h (i.p.) and neuromuscular block was maintained with pancuronium 1 mglkg/h (i.m.) 
Body temperature was maintained within normal range using heating pad. Immediately after 
induction of anaesthesia 12 animals were killed and served as healthy controls. 
Acute lung injury was induced by repeated broncho-alveolar lavage (BAL) (32 mllkg) 
with warm saline (37"C), according to Lachmann and colleagues [16]. BAL was repeated as 
often as necessary to produce a Pa02< 13 kPa at a PIP and PEEP of 26 and 6 cm H20, 
respectively. Within 10 min of the last lavage, the animals were allocated randomly to one of 
the following groups (11=12 each). In the first group, the lungs were opened by increasing PIP 
to 40 cm H20 and PEEP to 20 cm H20, and the lIE ratio was set at 1: I. After 2 to 3 min, PIP was 
decreased to 35 cm H,G and PEEP to 18 cm H20, and arterial blood-gas values were obtained. 
Ventilator setting remained unchanged for the rest of the study. The second group received an 
intra-tracheal bolus dose ofperfluorocarbon 15 mllkg (APF-I75A; Perfluoro-dimethyldecalin, 
Fluoro-Seal Inc, Round Rock, USA) after disconnection from the ventilator. APF-175A is a 
perfluorocarbon with a density of 1.98 glmI, a vapour pressure of 0.09 kPa, a surface tension of 
20.5 dynes/cm and an oxygen solubility of 35 ml O2 per 100 ml perfluorocarbon per atmosphere 
of oxygen pressure (all values at 25"C). During the stndy, evaporational losses of 
perfluorocarbon were compensated for by administering substitution doses. The substitution 
doses were based on our previous experience with this model, and aimed at maintaining Pa02 
constant during the rest of the study. The third group received exogenous surfactant at a dose 
of 120 mglkg. The surfactant used was isolated from minced pig lungs, prepared as described 
previously [17}. The freeze-dried material was suspended in warm saline to a concentration of 
40 mg/ml. and administered intra-tracheally, after disconnection from the ventilator. The 
slufactaut suspension was administered as a bolus followed by a bolns of air (12 ml/kg), directly 
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into the endotracheal tube via a syringe, and was followed immediately by fe-connection to the 
ventilator. In the fourth group, ventilator pressures were increased by 2 cmH,O (PIP/PEEP of 
28/8 em H,a) to prevent critical hypoxia and remained unchanged throughout study. This group 
served as ventilated controls. 
Arterial blood-gas samples were obtained before lavage, after lavage, and hourly for 4 
h. Samples were analysed for arterial oxygen tension (Pa02) and arterial carbon dioxide tension 
(paCO,) using an electrochemical blood-gas analyser (ABL 505, Radiometer, Copenhagen, 
Denmark). 
At the end of the experiment, the animals were killed by an overdose of pentobarbital. 
Six animals from each group were selected randomly for histopathologic examination. The lungs 
of these animals were fixated, sectioned and stained as described previously [18]. A semi-
quantitative morphometric analysis of lung injury was performed under blinded conditions by 
a pathologist (R.S.), who scored atelectasis, oedema, vascular wall thickening and leucocyte 
intiItration as none, light, moderate or severe (score D, 1,2 or 3, respectively). Lung injury score 
was defined as the average from all parameters for each group. 
The remaining animals from each group were used to assess lung mechanics. Static 
pressure-volume curves were recorded using conventional techniques [16]. Total lung capacity 
(TLC3S) was defined as lung volume at intlation with a distending pressure of 35 cmH,O. After 
pressure-volume recordings, BAL was performed five times with saline-eaCh 1.5 nunoUlitre. 
The active surfactant component in the BAL fluid was separated from the non-active surfactant 
component by differential centrifugation followed by subsequent phosphorus analysis, and the 
ratio between non-active and active components (small aggregate to large aggregate ratio 
(SAfLA) ratio) was calculated, as described previously [19]. Protein concentration ofBAL tluid 
was determined using the Bradford method (Bio-Rad protein-assay, Munich, Germany) [20]. 
Statistical analysis was performed using the Instat statistical package. Inter-group 
comparisons were analysed with ANaVA and intra-group comparisons were analysed with 
repeated measures ANOV A. If ANOV A resulted in a p < 0.05 a Tukey-Kramer post-test was 
performed. All data are reported as mean ± SD and p < 0.05 was considered statistically 
significant. 
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Results 
Blood gas values before and immediately after lavage were comparable for all groups (Fig. 1 , 
Table I). None of the animals died during the 4 h observation period. In the ventilated control 
group Pa02 did not improve whereas it increased to pre-lavage values and remained stable 
during the 4 h observation period in the surfactant treated group and the group ventilated with 
high PEEP (Fig. I). In the partial liquid ventilation group, instillation of a bolus dose of 
perfluorocarbon 15 mUkg resulted in a significant improvement ofPa02 but pre-lavage values 
were not reached (Fig. I). Pertluorocarbon needed to be substituted periodically to compensate 
for the evaporationalloss and the substitution dose of perfluOfocarbon was 1.1 ± 0.4 mIIkglh. 
PaCO, data are give in Table I. PaCO, decreased significantly in both the surfactant 
treated group and the partial liquid ventilation group, and was signitlcantly lower in the 
surfactant treated group compared to the other groups (Table I). 
Figure 2 shows the deflation limbs of the pressure-volume curves. At deflation less than 
15 em H20, lung volume in the healthy controls exceeded lung volume in all other groups, other 
than the group treated with surfactant. 1LC35 was significantly decreased in the ventilated 
control group. but not in the three treatment groups, compared with the healthy controls. 
The protein concentration of BAL fluid was significantly increased in both the partial 
liquid ventilated group and the ventilated control group compared with healthy control animals 
(Fig. 3). SAILA ratio, the ratio between non-active and active sUlfactant components, was 
significantly increased in the ventilated control group, the group ventilated with high PEEP, and 
the partial liquid ventilation group, but not in the surfactant treated group (Fig. 4). Compared 
with healthy control animals, the total amount of phosphorus in BAL fluid, measured to quantify 
the phospholipid-containing surfactant system, was significantly lower in the ventilated control 
group, the group ventilated with high PEEP, and the partial liquid ventilation group (Table 2). 
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Table 1. PaC02 (mean (SD), kPa) for all treatment groups. Before lavage (Healthy), immediately after lavage (Lav) and 1,2,3 and 4 hours after 
lavage. § p<O.05 compared with SURF group. * P<O,Q5 compared with CONTR group. Intra-group compansson: 1p<O.05 compared to Lav. 
CONTR "'" ventilated controls with low PEEP; H-PEEP = high PEEP; PLY = partial liquid ventilation; SURF = exogenous surfactant therapy. 
Healthy Lav Ih 2h 3h 4h ~ 
'" " 
CONIR 5.8 (0.9) 9.0 (1.4) 7.5 (1.7)" 7.7 (1.7)" 7.8 (1.8)" 8.0 (2.1)' ~ H-PEEP 5.2 (0.6) 8.6 (1.3) 7.7 (1.2)' 6.9 (1.5)" 6.4 (1.7)" 6.8 (1.8)' , " :,-5.5 (1.1) 6.8 (1.6)" 6.6 (1.7)" 6.2 (1.8)" 6.1 (1.9)* , -. PLY 9.9 (1.5) :,-SURF 5.2 (1.2) 8.5 (1.5) 4.7 (0.6)' 4.4 (0.5)' 4.3 (0.6)' 4.5 (0.7)' ;;; 
til 
" ~ 
" 
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c::=J Ventilated control 
E3 Surfactant 
IIilil8iJll PLV 
~H-PEEP 
* 
TIme (h) 
Figure 1. Pa02 values (mean ± SD, kPa) in the ventilated control, surfactant-treated, partial liquid 
ventilation (PLV) and high (H) PEEP groups. * p < 0.05 vs. PLY group. 
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Figure 2. Deflation limbs from the pressure-volume curves, (mean ± SO) in healthy control, ventilated 
control, surfactant-treated, partial liquid venliiatioll (PLV) and high (H) PEEP groups. Volume is lung 
volume above PRe. At deflations less than 15 cmH20,Iung volume in the healthy controls exceeded lung 
volume in all other groups, except the surfactant-treated group. TLCJS was decreased only in the ventilated 
control group compared with the healthy control group. 
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* 
Healthy Venlilaled Surfaclant H·PEEP 
control control 
Figure 3. Protein concentration (mean ± SD, mg/ml) of BAL fluid in healthy control, ventilated control, 
surfactanHrcated, partial liquid ventilation (PLY) and high (H) PEEP groups. >;:: p < 0.05 vs. healthy 
control group. 
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Figure 4. Ratio between non-active and active surfactant components (mean ± SD) in healthy control, 
ventilated control, surfactant-treated, partial liquid ventilation (PLY) and high (H) PEEP groups. 
(SA/LA, small to large aggregates). * p < 0.05 vs. healthy control group. 
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Semi-quantitative lung injury analysis showed that in both the surfactant and the partial liquid 
ventilation groups, lung injury was significantly lower than in the two groups that were 
ventilated only (high and low PEEP, Figure 5). However, only in the surfactant group, lung 
injury was not signitlcantIy increased compared with the healthy controls. 
Table 2. Total phosphorus recovered from bronchoalveolar lavage fluid (mean ± SD, ~lffiol!m1). § p<O.05 
vs. healthy controls (Healthy); '1p<O.05 vs. all other groups. Control:;;: ventilated controls with low PEEP; 
H-PEEP::: high PEEP; PLY:;;; partial liquid ventilation; surfactant = exogenous surfactant therapy. 
Healthy 
Control 
H-PEEP 
PLY 
Surfactant 
i':' 
o 
() 
<Il 
C 
::> 
:S-
rn 
c 
::> 
--' 
3 
Total phosphorus OUlloIlml) 
0.14 ± 0.06 
0.05 ± 0.01! 
0.05 ±0.0l' 
0.05 ± O.Ol § 
0.45 ± 0.05' 
0--'----
Healthy Ventilated Surfaclanl H-PEEP PLV 
conlrol control 
Figure 5. Lung injury score (mean ± SD) in healthy control, ventilated control, surfactanHreated, partial 
liquid ventilation (PLY) and high (H) PEEP groups. * p < 0.05 vs. healthy control group; tp < 0.05 VS. 
surfactant group; {: p < 0.05 vs. partial liquid ventilation group. 
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Discussion 
We have shown that although exogenous surfactant therapy, ventilation with high PEEP and 
partial liquid ventilation increased PaD2 to greater than 50 kPa, the impact on transfer of proteins 
into the alveoli, lung injury, and on the surfactant system differed markedly. Ventilation with 
high PEEP and exogenous surfactant therapy prevented transfer of proteins into the alveoli, 
whereas partial liquid ventilation did not. Conversion of active to non-active surfactant 
aggregates was increased in both the partial liquid ventilation group and the group ventilated 
with high PEEP, but not in the surfactant treated group. Lung injury score was reduced in both 
the partial liquid ventilation and the surfactant groups compared with the groups that were 
ventilated only. 
The sustained improvement in PaG2 to pre-lavage values in the group ventilated with 
high PEEP indicates that the applied PIP and PEEP were sumcient to open the lungs and to keep 
them open (Fig. I), That alveolar recruitment and stabilization in this group was a result of 
mechanically counterbalancing the increased retractive forces and not recovery of the 
endogenous surfactant system, was evident by the lack of improvement in surfactant variables 
of BAL tluid determined at the end of the study (Table 2). However, protein concentration of 
BAL tluid was not increased during the 4-h ventilation period with high PEEP. This is important 
as plasma proteins are known to inhibit surfactant function in a dose-dependent manner [21]. 
Therefore, protein leakage may mediate the destructive chain of events that lead to further 
progression of lung injury. The clinical significance of the findings in this high PEEP group 
remains to be determined, but studies by Kesecioglu, Tibboel and Lachmann [II], and recently 
by Amato and colleagues [12], have shown an improvement in Pa02 in patients when using an 
'open lung' strategy, and provided the first results indicating that the technique is associated 
with a decrease in morbidity and mortality [22]. 
In sUlfactant-deficient lungs, partial liquid ventilation with pertluorocarbons has been 
shown to provide adequate gas exchange, which was confirmed in our study (Fig. I) [10, 23]. 
However, despite the high Pa02 values which indicate that the lungs were kept open, we found 
that transfer of proteins into the alveoli was increased after partialliql1id ventilation tor 4 hours 
(Fig. 2). The mechanism responsible for this is not known. It is hypothesized that the 
improvement of gas exchange with partial liquid ventilation results from filling the collapsed 
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atelectatic alveoli in the dependent part of the lung with the non-compressible, high-density 
perfluorocarbons thus preventing them from end-expiratory collapse. In the non-dependent pmt 
of the lung, a thill film of perfluorocarbons is formed at the air-liquid interface because of 
evaporation of perfluorocarbons from the lower lung regions [23], \Ve speculate that as a result 
of the low constant sUlface tension of perfluorocarbon, the retractive forces in the non-dependent 
part of the lung are reduced, resulting in large volume changes at small increments in pressure, 
making the lungs prone to epithelial overstreching, which has been shown to damage the 
alveolar-capillary membrane leading to increased transfer of proteins into the alveoli [24] (for 
review see Dreyfuss and Saumon [25]). This mechanism is supported by a study of Cox aud 
colleagues [26] who showed that during partial liquid ventilation perfluorocarbon is distributed 
predominantly to the lower lung regions, whereas gas ventilation takes place in the upper lung 
regions. Furthermore, several pathology studies have demonstrated a significant variance in lung 
injury between the non-dependent and dependent lobes after partial liquid ventilation, with 
greater non-dependent lobe damage [27, 28]. 
In our study, the partial liquid ventilation and the surfactant groups underwent 
ventilation with the same PIP and PEEP pressures, but the protein concentration of the BAL 
tluid from the surfactant group was not increased (Fig. 2). Pulmonary surfactant has the unique 
property of reducing surface tension in parallel with a decrease in alveolar radius, thus keeping 
the ratio of surface tension/radius of the alveolus constant and thus preventing epithelial 
overstretching. Furthermore, as seen in the surfactant-treated group, a lower lung injury score 
was found in the partial liquid ventilation group despite the increased transfer of protein into the 
alveoli. This probably reflects a direct effect of perfluorocarbon on inflammation processes, as 
ill l'itro evidence suggests a decrease in alveolar macrophage and neutrophil adherence, 
chemotaxis, phagocytosis and superoxide release [29, 30]. 
Total lung capacity on a distending pressure of 35 cm H20 (TLC35) was decreased only 
in the ventilated control group (Fig. 3). As substances with surface tension lowering properties 
were administered into the lungs of the pmtialliquid ventilation group and the surfactant treated 
group, it is not surprising that TLC35 was preserved in these groups. However, preservation of 
TLC35 in the group ventilated with high PEEP, but decreased TLCJ5 in the ventilated control 
group is striking as there were no differences in recovery of pulmonary surfactant between these 
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groups (Fig. 4, Table 2). We speculate that the difference in lie" is explained by the difference 
in transfer of protein into the alveoli between these two groups, because of inhibition of the 
already compromised surfactant function by plasma proteins, as mentioned above. 
In our study we used the lung lavage model which has been studied extensively and is 
considered a reliable model of acute lung injury [16]. Repeated whole-lung lavage produced an 
acute quantitative surfactant deficiency and, together with conventional mechanical ventilation 
leading to severe lung injury with impaired gas exchange, decreased lung compliance and FRC, 
increased pClmeability changes of the alveolo-capillairy membrane with oedema, and sustained 
pulmonary hypertension [16, 17, 31]. Despite the fact that the lung injury in this study is not 
representative of the pathology in humans with ALI, this model is ideal for testing interventions 
which may prove therapeutic for acute lung injury [4, 6, 17]. 
In sununary, we have shown that although exogenous surfactant therapy, mechanical 
ventilation with high PEEP and partial liquid ventilation opened up the lungs and kept them 
open, as indicated by the high PaO, values, the impact on pulmonary function differed markedly. 
Only with exogenous surfactant therapy there was improvement in all variables. Some studies 
have reported physiological and pathological benefits of partial liquid ventilation or ventilation 
with high PEEP in combination with exogenous surfactant, but whether either one of such 
hybrid techniques has advantages over the use of exogenous surfactant alone remains yet to be 
confirmed. 
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Summary 
Application of a ventilation strategy which aims to recruit collapsed alveoli and to prevent them 
from repeated collapse by applying a high PEEP, has shown to decrease alveolar protein influx 
in experimental acute lung injury (ALI). This could be important for the pulmonary response 
to exogenous surfactant, since plasma proteins are known to inhibit surfactant fUIlction. This 
study was performed to evaluate the effect of exogenous surfactant on lung mechanics aftcr 4 
hours of mechanical ventilation with either high or low PEEP. Twenty-two adult male Sprague-
Dawley rats were anaesthetized, tracheotomized and submitted to pressure controlled 
mechanical ventilation with 100% oxygen. One group served as healthy controls (n=6). In the 
remaining animals acute lung injury was induced by repeated lung lavages to obtain a PaO,<13 
kPa at a peak inspiratory pressure (PIP) of 26 cmH,O and a PEEP of 6 cmH,O. After steady 
state, animals were randomly divided to receive either ventilation with high PEEP (n=8; 100 
breaths/min., I:E=I:I, PIP of 35 cmH,O, PEEP of 18 cmH,O), or to receive conventional 
mechanical ventilation (pIP of28 cmH,O, PEEP of 8 cmH,O; n=8; control group). After four 
hours of ventilation, all animals received exogenous surfactant (120 mglkg) and ventilation was 
continued for 15 minutes. At the end of the study pressure-volume curves were constructed from 
which total lung capacity at 35 cmH,O (TLC,,) and maximal compliance (Cmu> were calculated, 
and thereafter brancho-alveolar lavage was performed to assess alveolar protein influx. After 
lavage, PaO, remained around 13 kPa in the ventilated control group and improved to >66 kPa 
in the high PEEP group. After surfactant, PaO, was >53 kPa in both groups. In the ventilated 
control group alveolar protein influx was higher, and TLC35 and emu were lower than in the 
high PEEP group. We conclude that the pulmonary response to exogenous surfactant after 
mechanical ventilation in experimental ALI is improved when a ventilation strategy with high 
PEEP is used. 
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Introduction 
Mechanical ventilation strategies that prevent repeated alveolar collapse are thought to prevent 
further progression of lung injury during ventilation of snrfactant detlcient lungs [1, 2]. 
Application of a high PEEP was previously shown to decrease accumulation of lung water, 
protein leakage and prevent intra-alveolar edema in experimental acute lung injury (ALI) [3-5]. 
A decrease in protein transfer into the alveoli has important consequences for pulmonary 
function, since proteins are known to inhibit sUlfactant function in a dose dependent way [6]. In 
previous studies in an animal model of ALI, we showed that ventilation with a high PEEP 
attenuated the decrease in lung mechanics, which was attributed to a decrease in protein transfer 
into the alveoli [3, 7]. 
Exogenous surfactant is successfully administered in the respiratory distress syndrome 
(RDS) of the premature newborn, resulting in improvement of gas exchange, lung mechanics, 
and outcome [8]. Since hypoxia and deterioration in lung mechanics in ALI are also caused by 
a lack of active surfactant, the emcacy of surfactant replacement in ALI is currently evaluated 
in both experimental and clinical studies [9-11]. An important problem with surfactant therapy 
in adults is the high costs and non-availability of the large amounts of sUlfactant that are needed. 
A decrease in ventilation-induced protein influx in ALI patients who may benefit from 
exogenous surfactant might reduce the surfactant dose required to improve pulmonary function, 
which could make surfactant replacement in ALI more feasible. 
We hypothesize that the improvement in lung function that is obtained by surfactant 
replacement in experimental ALI after 4 h of mechanical ventilation, is better when during 
ventilation a high PEEP is used to decrease alveolar protein influx. We therefore ventilated 
surfactant-depleted rats with either a high or a low PEEP, followed by surfactant replacement, 
and evaluated gas exchange and lung mechanics. 
Methods 
The study protocol was approved by the University's Animal Experimental Committee, and the 
care and handling of the animals conformed with European Community guidelines (861609/EC). 
The study was performed in twenty-two adnlt male Sprague-Dawley rats (body weight 270-330 
g). After induction of anaesthesia with 2% enflurane and 65% nitrous oxide in oxygen, a 
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polyethylene catheter was inserted into a carotid artery for drawing arterial blood samples. 
Before tracheostomy, the animals received 60 mg/kg pentobarbital sodium, i.p. (Nembutal, Algin 
BV, Maassluis, the Netherlands). After tracheostomy, muscle relaxation was induced by 
pancuronium bromide 1 mg/kg, i.m. (Pavulon, Organon Teknika, Boxtel, the Netherlands) 
immediately followed by connection to a ventilator. The animals were mechanically ventilated 
with a Servo Ventilator 300 (Siemens-Elema, SalIm, Sweden) in a pressure constant time-cycled 
mode, at an inspired oxygen concentration (FiO,) of 1.0, frequency of 30 breaths per minute 
(bpm), peak inspiratory pressure (pll') of 12 cm H,O, positive end-expiratory pressure (PEEP) 
of 2 cmH,O, and inspiratory/expiratory (VE) ratio of 1 :2. Anaesthesia was maintained with 
pentobarbital sodium 40 mglkg/h, i.p.; muscle relaxation was maintained with pancuronium 
bromide I mg/kg/h, i.Ill. Body temperature was kept within nonnal range by means of a heating 
pad. Six animals were killed immediately after induction of anaesthesia and served as healthy 
controls. 
In the remaining animals acute lung injury was induced by repeated brancho-alveolar 
lavage (BAL) (32 ml/kg) with warm saline (37 0 C), according to Lachmann and colleagues [12J. 
BAL was repeated as often as necessary to produce a PaO,<l3 kPa at a Pll' and PEEP of 26 and 
6 cmH20, respectively. Within 10 min after the last lavage, the animals were randomised to one 
of two study groups (each group 11=8). In the lirst group, mechanical ventilation according to the 
open lung concept was applied. We have previously shown that this strategy, in which collapsed 
alveoli are recruited by applying a high Pll' and kept open with a high PEEP, PaO, can be kept 
>65 kPa in surfactant-<leficient rats [3]. In the present study, we used identical ventilator settings. 
First, the lungs were opened by increasing Pll' to 40 cmH,O and PEEP to 20 cmH,O, and the 
VE ratio was set at 1: I. After 2 to 3 min, Pll' was decreased to 35 cmH,O and PEEP to 18 
cmH,O, and arterial blood gas samples were taken. Ventilator setting were kept unchanged for 
the remainder of the study period. In the second group, that served as ventilated controls, 
ventilator pressures were increased by 2 cmH,O (PlF/PEEP of 2818 cmH,O). These ventilator 
settings were chosen based on the results from a previous study using this model, where it was 
found that at these settings PaO, remained stable at a low value of about 13 kPa for 4 h at an 
FiO, of 1.0, indicating that large parts of the lungs remain atelectatic [3]. Protein transfer into 
the alveoli was found to be increased with these settings. In the present study, both ventilated 
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groups were treated with exogenous surfactant at a dose of 120 mglkg after 4 hours of 
ventilation. The surfactant used was isolated from minced pig lungs, that were processed as 
previously described [13]. The freeze-dried material was suspended in warm saline to a 
concentration of 40 mglml, and administered intratracheally, for which the animals were 
disconnected from the ventilator. The surfactant suspension was administered as a bolus 
followed by a bolus of air (12 mlIkg), directly into the endotracheal tube via a syringe, and was 
immediately followed by re-connection to the ventilator. After surfactant administration, 
ventilation was continued for 15 min, while ventilator settings were unchanged in both groups. 
This short interval was chosen since maximal improvement of lung function by exogenous 
surfactant occurs 2-5 min after administration, and because surfactant inactivation by proteins 
is an event that occurs instantaneously. 
Arterial blood gas samples were taken prior to lavage, after lavage, hourly for 4 h after 
lavage, immediately and 15 min after surfactant administration. The samples were analysed for 
arterial oxygen tension (Pa02) and ru1erial carbon dioxide tension (paC02) on an electrochemical 
blood gas analyser (ABL 505, Radiometer, Copenhagen, Denmark). 
At the end of the experiment, the animals were killed by an overdose of pentobarbital. 
Static pressure-volume curves were recorded using conventional techniques. Total lung capacity 
(TLC35) was defined as lung volume at inflation with a distending pressure of 35 cmH,O. 
Maximal compliance (C=,) was detined as the steepest part of the deflation limb of the pressure-
volume curve. After the pressure-volume recordings, BAL was performed five times with saline-
CaCI,I.5 mmoVlitre. The active surfactant component in the BAL fluid was separated from the 
non-active surfactant component by differential centrifugation followed by subsequent 
phosphorus analysis, and the ratio between non-active and active components (small aggregate 
to large aggregate ratio = SAILA ratio) was calculated, as previously described by Veldhuizen 
and colleagues [14]. The protein concentration of the BAL fluid was determined using the 
Bradford method (Bio-Rad protein-assay, Munich, Germany) [15]. 
Statistical analysis was performed using the Instat 2.0 biostatistics package (GraphPad 
software, San Diego, CA, USA). For blood gases inter-group comparisons were analysed using 
the alternate (Welch) t-test, while intra-group comparisons were analysed using repeated 
measures ANOV A. All other data were analysed with ANOV A. If ANOV A resulted in a p < 0.05 
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a Tukey-Kramer post-test was performed. All data are reported as mean ± SD and p < 0.05 lVas 
considered statistically significant. 
Results 
Blood gases before and immediately after lavage were comparable for both ventilated groups 
(Fig.1 and Table I). None of the animals died during the 4 hand 15 min observation period. In 
the group ventilated with high PEEP. PaO, increased to pre-lavage values and remained stable 
during the 4 h ventilation period. but decreased to 61.8 ± 5 kPa after surfactant administration. 
In the control group, PaOz did not improve until surfactant was administered, after which Pa02 
increased to 54.0 ± 17 kPa. 
PaCO, data are given in Table I. In both ventilated groups PaCO, increased after lavage. 
and remained unchanged during the entire study period (Table I). 
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Figure 1. PaD1 values (mean ± SD, kPa) of the ventilated groups. Striped bars:::high PEEP group; open 
bars=ventilated control group with low PEEP; Before Lav:;:::before lavage; After Lav=after lavage; 
surf=aftcr surfactant administration; S+ 15=15 minutes after surfactant administration. »;: p<O.05 VS. 240 
minutes. 
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Table 1. PaCOz values (mean ± SD), kPa) for the ventilated groups, before lavage (Healthy), immediately 
after lavage (Lav). 60. 120. 180 and 240 minutes after lavage, immediately after surfactant administration 
(Surt), and IS minutes after surfactant (Surf+IS'). *p<O.OS vs. Healthy. H-PEEP=high PEEP; 
Control=ventilated controls with low PEEP. 
H-PEEP Control 
Healthy 4.9 ± 1.0 S.O± O.S 
Lav 6.7 ± 0.9* 7.2 ± 1.3* 
60' 7.6 ± 1.8* 6.7±1.6* 
120' 7.1±I.S* 7.0 ± I.S* 
ISO' 7.S ± 1.6* 7.3 ± 1.9* 
240' 7.6 ± 2.0* 7.6 ± 1.6* 
Surf 7.1 ± 2.4* 7.7± 1.8* 
Surf+IS' 7.8 ± 2.6* 7.8±2.1* 
The protein concentration of BAL fluid was significantly increased in both ventilated 
groups compared to healthy control animals (Fig. 2). However, in the ventilated control group 
protein concentration was significantly higher than in the high PEEP group. 
There were no differences in SAILA ratio between the three groups (Table 2). In 
comparison with healthy control animals, the total amount of phosphorus in the BAL fluid (that 
was measured to quantify the phospholipid-containing surfactant system) was significantly 
higher in both groups that received exogenous surfactant (Table 2). 
Table 2. Data on maximal compliance (Crna", mllcm H20Ikg). total phosphorus (~lmol!ml) recovered from 
the BAL fluid, ~lmol!ml, and SAILA ratio. aU values mean ± SD). * p <0.05 vs. healthy controls 
(Healthy), ' p <O.OS vs. high PEEP. 
Cmu 
(ml/cm H,Olkg) 
Healthy 13.4 ± l.l 
High PEEP 10.0 ± 2.6 
Control 6.8 ± 1.2*' 
Total phosphonts 
(I'mol/ml) 
0.14 ± 0.06 
0.32 ± 0.08* 
0.29 ± 0.06* 
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SAILA ratio 
0.31 ±0.12 
0.36 ± 0.17 
0.47 ± 0.19 
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Figure 2. Mean protein concentration ± SD. rug/mi. of the BAL fluid of the different groups. * p < 0.05 
I'S healthy controls (Hcalthy); t p < 0.05 I'S high PEEP group. 
Figure 3 shows the pressure-volume curves. On deflation to 15 cmH20, lung volume is 
decreased only in the ventilated control group. Below 15 cmH,O, lung volume in both ventilated 
groups is decreased compared to the healthy controls. Maximal compliance (Cmll) was decreased 
in the ventilated control group compared to the high PEEP group, and to the healthy controls 
(Table2). 
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Figure 3. Deflation limbs from the pressure-volume curves, mean ± SO. Volume is lung yolume above 
FRC. On deflation to 15 cml-hO, lung yoltune is decreased only in the ventilated control group. Below 15 
cml-hO, lung volume in both ventilated groups is decreased compared to the healthy controls. * p <0.05 
vs healthy controls (Healthy). 
Discussion 
This study shows that the efficacy of exogenous surfactant therapy, administered after 4 h of 
mechanical ventilation, to improve total lung capacity at a distending pressure of 35 cmH20 and 
maximal compliance is less attenuated after ventilation with a high PEEP compared to 
ventilation with a low PEEP. Protein concentration in the BAL t1uid of the high PEEP group was 
lower compared to the ventilated controls with low PEEP. 
In the venti~ated control group, 1LC3S and Cma..-..: were decreased compared to the healthy 
controls, but not in the high PEEP group (Table 2 and Fig. 3). This indicates that function of the 
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exogenous surfactant was better in the high PEEP group compared to the ventilated controls. 
Surfactant has the unique property of reducing surface tension at the air-liquid interface in the 
alveoli in parallel with the decrease in alveolar radius, thus improving lung distensibility and 
alveolar stability. It was previously shown that plasma proteins decrease the capability of 
surfactant to decrease surface tension [6]. We therefore speculate that the decreased 
improvement Dflung mechanics in the low PEEP group after surfactant administration is caused 
by the increased protein transfer into the alveoli in this group. These results are consistent with 
previous results obtained in this model, where mechanical ventilation with high PEEP resulted 
in a decrease in protein transfer into the alveoli, and better lung mechanics [3, 7]. 
Preservation of the integrity of the alveolar epithelium by prevention of the occurrence 
of shear forces that are caused by repeated alveolar collapse is considered an important factor 
in decreasing protein int1ux [4]. Application of PEEP has also been shown to lead to a shift of 
fluid from the alveoli to the interstitium by decreasing the pressure gradient across the alveolar-
capillary membrane [16]. Furthermore, there is evidence that PEEP prevents the loss of 
surfactant from the alveoli, which prevents an increase in surface tension mediated suctioning 
across the alveolar capillary membrane that increases alveolar protein influx [5]. 
Before surfactant administration, Pa02 was >66 kPa in the high PEEP group, indicating 
that the applied ventilator settings were sufficient to open up the lungs and keep them open, 
which confirms previous experience in this model (Fig. 1) [3, 7]. The decrease in oxygenation 
which is observed after surfactant administration in this group is attributed to the bolus of liquid 
in which the surfactant was suspended, that partly filled up the alveoli causing a decrease in 
diffusion [9]. 
No differences were found between the ventilated groups in non-active and active 
surfactant aggregates (SNLA ratio). This is in accordance with data from Veldhuizen et aI., who 
showed that the conversion of LA into SA is dependent on alveolar area cycling and time [17]. 
Alveolar cycling is determined by tidal volume, which was comparable for both ventilated 
groups. 
An important factor in the successful application of exogenous surfactant in RDS of the 
premature infant is the fact that the surfactant is administered shortly after birth, thus reducing 
the time in which proteins can transfer into the surfactant-deficient alveoli. In the adult ALI 
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patient, where the surfactant deficiency is secondary to lung injury, protein concentration in the 
alveoli is increased [18]. It was previously shown that mixing exogenous surfactant with plasma 
proteins decreases the capability of sUlfactant to improve gas exchange, and that larger amounts 
of surfactant are necessary to overcome the inhibitory effects [6]. The results of the present study 
show that the efficacy of exogenous surfactant can be improved by attenuating the increase in 
protein transfer into the alveoli. It has previously been suggested that a decrease in alveolar 
protein concentration, for example by lobe-wise lung lavage, could improve the effect of 
exogenous surfactant on pulmonary function [19]. Our study implicates that when the lungs are 
kept open by application of a high PEEP during the ventilation period which usually precedes 
exogenous surfactant administration in patients, the efficacy of surfactant replacement can be 
improved. Given the dose-dependent inhibition of surfactant by proteins, a reduction in protein 
influx during mechanical ventilation prior to surfactant administration is important since this 
could lead to a decrease in the exogenous surfactant dose that is necessary to improve pulmonary 
function in ALI patients. Thereby, a reduced protein influx could reduce costs and improve 
outcome in ALI. 
In conclusion, this study shows that the improvement in lung function that is obtained 
by smfactant replacement in experimental ALI after 4 h of mechanical ventilation, is better when 
during ventilation a high PEEP is used to decrease alveolar protein influx. Future clinical studies 
are necessary to evaluate if application of a high PEEP in ALI patients that could benefit from 
exogenous surfactant therapy can improve efficacy of surfactant replacement and improve 
outcome. 
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Summary 
The aim of this study was to compare high-frequency oscillatory ventilation (HFOV) with 
conventional mechanical ventilation (CMV) with and without surfactant in the treatment 
surfactant-deficient rabbits. A previously described saline lung lavage model was used. The 
emcacy of each therapy was assessed by evaluating gas exchange, lung deflation stability and 
lung histopathology. Arterial oxygenation did not improve in the CMV group without surfactant, 
but increased rapidly to prelavage values in the other three study groups. During deflation 
stability, mean PaO, values decreased to post-lavage values in the group that received HFOV 
alone but not in both surfactant treated groups (HFOV and CMV). The HFOV group without 
surfactant showed more cellular infiltration aud epithelial damage compared with both 
surfactant-treated groups (HFOV and CMV). There was no difference in gas exchange, lung 
deflation stability, and lung injury between HFOV and CMV after surfactant therapy. 
It is concluded that the use of surt~'lctant therapy in combination with high-frequency 
oscillatory ventilation is not superior to conventional mechanical ventilation in improving gas 
exchange, lung deflatiou stability and in the prevention of lung injury, if the lungs are kept 
expanded. This indicates that achieving and maintaining alveolar expansion (i.e. open lung) is 
of more importance than the type of ventilator. 
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Introduction 
In the fIrst reported high-frequency oscillatory ventilation (HFOV) trial, a low distending airway 
pressure was used in order to minimize the risk of barotrauma [1]. However, experimental 
studies have shown that alveoli should be actively opened and that relatively high airway 
pressure has to be used to stay above the closing pressure to avoid hypoxemia and lung injury 
[2, 3]. Results of recent pilot studies in neonates with respiratory distress syndrome (RDS) 
applying this high-lung volume strategy are encouraging [4-6]. 
To date, very few studies have been published on the combined use of surfactant and 
HFOV in animals or humans [4, 6-9]. Those studies demonstrated that after surfactant therapy 
HFOV was superior to conventional mechanical ventilation (CMV) in improving pulmonary 
function and reducing lung injury (4, 6~9], However, in those studies, HFOV was used in 
combination with the high-lung volume strategy whereas CMV was not. Recently. Froese and 
colleagues [8] compared HFOV to CMV after snrfactant therapy at low- and high-lung volume 
and contilTI1cd that HFOV at high-lung volume was superior to the aItematives in improving gas 
exchange and lung mechanics in lung-lavaged rabbits. Surprisingly, these authors were not able 
to maintain oxygenation above 46.7 kPa (350 mmHg), despite the high-lung volume strategy, 
after sUlfactant therapy with the use of CMV [8]. This fInding is in contrast to earlier results of 
CMV with surfactant therapy in lung-lavaged rabbits in which oxygenation increased rapidly to 
prelavage values after surfactant instillation and was kept stable for hours [10-12]. The purpose 
of the present study was to compare the use of HFOV to CMV with and without surfactant 
therapy in the management of acute lung injury caused by lung lavage in adult rabbits. 
Materials and methods 
Allimal preparation 
This study was approved by the local Animal Committee of the Erasmus University Rotterdam; 
care and handling of the animals were in accord with the European Community guidelines 
(86/609/EEG) [13]. A total of 27 adult New Zealand White rabbits (IFFA-Credo, Brussels, 
Belgium) with a mean body weight of 2.7 ± 0.3 kg were anaesthetized with pentobarbital sodium 
(50 mglkg body weight) via an auricular vein and then placed in a supine position. An 
endotracheal tube (Ld. 3.5 mIll) was inserted via tracheostomy and mechanical ventilation was 
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initiated with a Servo Ventilator 900C (Siemens-Elema AB, Solna, Sweden) in a pressure-
control mode, indicating time-cycled ventilation with decelerating flow. with the following 
ventilator settings: FiO, of 1.0, positive end-expiratory pressure (PEEP) of 2 cm H20, frequency 
of 30 breathslmin, inspiratorylexpiratory ratio of 1:2 and a peak inspiratory pressure of 10-14 
cm H20 to keep PaCO, within normal range. An infusion of 2.5% glucose was continuously 
administered via the auricular vein as a maintenance fluid (5 mllkg body weight Ih), Anaesthesia 
was maintained by hourly injection of pentobarbital sodium (5 mg/kg body weight Ih, Lv.); 
muscle paralysis was achieved by hourly injection of pancuronium bromide (0.1 mg/kg body 
weight Ih, Lm.). 
A carotid artery was cannulated for continuous blood pressure measurements and for 
intermittent blood sampling. Arterial samples were analysed for blood gases, pH and 
haemoglobin using conventional methods (ABL-505 and Osm-3; Radiometer, Copenhagen, 
Denmark). Core temperature was monitored with an esophageal thennistor (Elektrolaboratoriet, 
Copenhagen, Denmark) and maintained within normal range by a heating pad. 
Induction o/lullg injll1)' 
In all animals, respiratory insufficiency was induced by repeated whole-lung lavage according 
to the technique described by Lachmann et al. [14]. Each lavage was preformed with saline (30 
mllkg body weight) heated to 37°C. Lung lavage was repeated 5-8 times at 2-5 min intervals to 
achieve a Pa02<11.3 kPa « 85 mmHg) at a peak pressure of 26 cm H20 and a PEEP of 6 cm 
H20 (other ventilator settings were not changed). 
Study design 
After reaching steady state, 24 animals were divided randomly into four groups of six animals. 
In the first group, animals received a bolus (100 mg/kg body weight, 25 mg/ml) of a natnral 
surfactant intratracheally (Alveofact"'; Thomae, Biberach, Germany) and immediately followed 
by connection to a high-frequency oscillator (type OHF-I, S.A. Dufour, Villeneuve d' Ascq, 
France). During HFOV, a frequency of 10 Hz was used and mean airway pressure (MAwP) was 
increased until PaO, was above 46.7 kPa (350 mmHg) to guarantee the high-lung volume 
strategy (i.e. open lungs) [4, 5]. When PaO, was above 73.3 kPa (550 nllnHg) during the study 
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period, MAwP was decreased by steps of 1 cm H20. Pressure amplitude was initiated with 30 
cm H20 and was altered as necessary to keep PaC02 within normal range (4.7-6.0 kPa (35-45 
mmHg)). The second group received exogenous surfactant intratracheally (Alveofact"; 100 
mglkg body weight) and conventional mechanical veutilation (CMV) with the Servo Ventilator 
900C was continued (ventilator settings were not changed). For instillation of surfactant, the 
animals were disconnected from the ventilator and received the surfactant suspension (25 
mglml) directly into the endotracheal tube via a syringe followed by immediate reconnection to 
the ventilator. The other two groups served as controls and received HFOV or CMV alone in the 
same way as described above. 
After 4 h of ventilation, MAwP was first decreased to 12 cm H20 for 10 min in those 
animals that received a MAwP of:2: 12 cm H20 and then to 9 and 6 cm H20 during the same 
period of time. Finally, all study groups were restarted on CMV at the same settings as used 
during lung lavage (pIPIPEEP=26!6 Clll H20). Ten minutes later, blood samples were taken for 
blood gases. 
During the observation period (4 hand 40 min), arterial blood samples were collected 
at the following times: before lavage; 5 and 10 min after the last lavage; 5, 15, 30 min after 
surfactant or HFOV application; every 30 min for 4 h; 10 min after the three reduction steps of 
MAwP; and finally 10 min after CMV with the same settings as during the lavage procedure. 
Continuous blood pressure monitoring enabled observation of changes of mean arterial blood 
pressure. Volume expansion (Isodex"; 5 mlIkg body weight, Lv.) was indicated when mean 
arterial pressure was below 6.7 kPa (50 mmHg). 
Pathological evaluations 
At the end of the observation period, lungs were ventilated with air with no changes in the 
ventilatory parameters. The abdomen of the rabbit was opened and the diaphragm was inspected 
for evidence of pneumothorax. The inferior vena cava was cannulated and perfused with a 
solution, consisting of saline saturated with 95% 0, and 5% CO" 2.2 mM CaCl2, 0.5% procaine 
and 1 % heparin. was then infused at a rate of 50 InlImin. The abdominal aorta was cut and the 
infusion was stopped when clear fluid flowed from the aorta. Thereafter, the peak pressure was 
lowered to 1 cm H20, that was maintained while the lungs were fixated by infusing ±100 ml of 
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a fixation solntion, consisting of 3.6% fonnaldehyde and 0.25% glutaraldehyde, via the inferior 
vena cava. After fixation, the trachea was clamped at a pressure of 6 em H20, the thorax was 
opened and the lungs were removed en bloc and stored in the fixation solution. The lungs were 
numbered and histopathologic examinations of the lungs were performed blindly. The lungs of 
the three remaining animals were fixed 10 min after the lavage procedure as described above and 
histopathologic examinations were performed. These animals were used to study the influence 
of the lavage procedure itself on morphological changes. 
The lungs were then embedded in paraffin, sectioned and stained with the haematoxylin 
and eosin (HE) and elastica-van Gieson (EvG) technique. A semi-quantitative morphometric 
analysis of lung injury was performed under blinded conditions by a pathologist who scored 
atelectasis, edema, vascular wall thickening and leucocyte infiltration as none, light, moderate 
or severe (score 0-3). Lung injury score was defined as the average from all parameters for each 
group. For transmission electron microscopic examination, lung tissue was pre-contrasted with 
2% osmium acid, dehydrated, and embedded in epoxy resin (Epon SI2). Semi-thin sections (l.5 
flm) and ultrathin sections (0.5 fun) were produced. Semi-thin sections were stained with 2% 
methylene blue and 3% alkaline fuchsin. Ultrathin sections were counterstained with uranyl 
acetate and lead citrate. The specimens for the scanning electron microscope were dehydrated 
with increasing lines of alcoholic solutions, dried with the critical point method, and sputtered 
with gold. 
Statistical analysis 
All data are expressed as mean ± SD. Analysis of variance (ANOV A) was used to assess whether 
there was an overall difference within or between the two groups. If a difference was found, a 
post hoc test was used (Student-Newman-Keuls' multiple comparison procedure). Lung injury 
data were analysed lIsing the Kurskal-Wallis nonparametric ANOV A test, followed by Dunn's 
multiple comparisons test if a difference was found. Statistical significance was accepted at p-
values <0.05. 
Results 
Blood gases before lavage and directly after lavage were comparable in all animals. In one 
so 
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animal of the HFOV group which developed a pneumothorax at 210 min, measurements were 
discontinued but the lungs were fixated for histologic examinations. 
Mean PaO, values in both HFOV groups (with or without surfactant) were kept above 
46.7 kPa (350 mmHg) in the first 4 h by using appropriate MAwP (Fig. I, Table 2). In the CMV 
group with surfactant, PaO, increased from 8.3 ± 2.1 kPa (62 ± 16 mmHg) to 53.3 ± 10.7 kPa 
(400 ± 80 IllInHg) within 5 min and remained stable dnring the subseqnent 4 h without changing 
the ventilator settings (Fig. I). 
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Figure 1. Change in mean arterial oxygen tension (PaOI) (±SD) of the four study groups before lung 
lavage (H; healthy), after lavage (L; 10 min after the last lavage), and during the subsequent 4 It and 40 
min observation period. I, II and III are the 3 reduction steps ofMAwP to: 1= 12 em H20; II::: 9 em J.hO; 
III = 6 em H20. C, pressure-controlled ventilation with the same settings as during the lavage procedure. 
indicating a MAwP of ±12 elll H20. 0, animals (n=6) that received HFOV without surfactant; 0, animals 
(n=6) that received CMV withollt surfactant; 0, animals (n=6) that received CMV and surfactant (100 
mglkg body weight); fl, animals (n=6) that received HFOV and surfactant (100 mglkg body weight). H, 
healthy. L, 10 min after the last lavage. "', p < 0.05 versus HFOV group. #, p < 0.05 versus PaO,! values 
at 4 h; t: death of one animal. 1 ITImHg=0.133 kPa. 
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Table 1. Data on PaCO, (mmHg) and MAwP (em H20) of the different study groups. Values are given as mean ± SD. 
Group H L 5' 0.5 h Ih 2h 3h 4h I II ill C 
PaC02 
CMV 31±4 44±lO 44±9 47±1l 45±1l Sl±9* 5S±8"'t 68±9'tt 58±ll't 
-tt 
HFOV 27±3 40±4 42±S 41±5 42±6 3S±2 35±3 34±3 34±2 41±5 49±5 44±7 
CMV+ 29±6 4S±5 38±1l 37±6 45±5 35±2 35±5 36±4 38±6 40±9 4S±12 47±14 
Surf. 
HFOV+ 31±5 40±9 40±4 40±4 36±9 32±4 29±2 30±3 29±3 30±3 38±3 35±2 
Surf. 
MAwP N 00 
CMV 6.1±0.7 12.1±0.S 12.3±1.6* 12.8±2.3* 12.3±1.4* 12.9±I.S 13.1±I.S 13.3±2.1 12 9 6 
HFOV 5.3±0.S 11.3±O.S 20 IS.8±I.O 16.5±3.4 16.7±3.4 16.S±3.2 15.4±1.5 12 9 6 13.4±0.9 
CMV+ 5.S±0.S II.S±O.S 11.3±2.6* 11.8±23* 12.3±2.4 12.3±2.3 11.7±1.8'" 12.3±2.3 12 9 6 11.2±12 
Surf. 
HFOV+ 6.3±O.5 11.9±0.3 19.0±2.0# 16.6±2.6 15.2±2.S 12.6±1.9 11.6±2.2 lO.4±2.6* 9.8±2.3 S.4±0.9 6 12.1±0.S 
Surf. 
'.p<O.05 vs. HFOV group. #,p<O.05 vs. group CMV+Surf. HFOV, group that received high-frequency oscillatory ventilation without surfactant. CMV, 
group that received pressure-controlled ventilation without surfactant. CMV+Surf, group that received surfactant with pressure-controlled ventilation. 
j HFOY+Surf, group that received high-frequency oscillatory ventilation with surfactant. H, healthy. L, 10 min after the last lavage. MAwP, mean airway ~ pressure. I, II and ill are the 3 reduction steps ofMAwP to: 1= 12 em H20; II = 9 em H:P; III = 6 em H20. C, pressure-controlled ventilation with the 
6 same settings as during the lavage procedure. t, death of one animal. 
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In the CMV group without surfactant, mean PaO, values gradually decreased over time and all 
animals died after reduction of the MAwP to 9 cm H20 (Fig. I). Mean PaO, values were 
comparable up to a MAwP of 12 cm H,O between the following groups: HFOV without 
surfactant; HFOV with surfactaut; and CMV with surfactant (Fig. I). Mean PaO, values of the 
animals ventilated with HFOV without sUlfactant dropped to post-lavage values after MAwP 
was lowered to 9 and 6 em H20, respectively. Mean Pa02 values did not improve when those 
HFOV animals were switched to CMV at the end of the observation period. However, in both 
surfactant groups (HFOV and CMV) mean PaO, values were significantly higher at a MA wP 
of 9 and 6 cm H,O compared to the group HFOV without surfactant (Fig. I). Furthermore, mean 
PaO, values restored to the PaO, levels at time point 4 h in both surt1ctanHreated groups 
(HFOV and CMV) after CMV for 10 min with the same settings as used during the lavage 
procedure, indicating a MAwP of ±12 cm H,O (Fig. I). 
The Illean carbon dioxide tension in arterial blood (PaC02) values gradually increased 
in the group CMV without surfactant (Table 2). In the other three groups, mean PaCO, values 
were maintained at 4.7-6.0 kPa (35 and 45 nunEg). MAwP data are shown in Table 2. In both 
groups that received HFOV (with or without surfactant), MAwP was initially increased to 18-20 
cm H,O and could be decreased significantly during the subsequent 4 h while PaO, remained 
stable. At time point 4 h, MAwP of the group HFOV with surfactaut was significantly lower 
compared to the HFOV group without surfactant (Table 2). 
All animals showed evidence of pneumonitis Ulat was composed mainly of eosinophils 
with some neutrophils. The three animals that were Javaged only and ventilated with CMV for 
10 min showed also a pneumonitis that was similar in extent and distribution as the animals of 
the 4 study groups. The pneumonitis was similar to that originally described by Lachmann et al. 
[15] and the presence of the pneumonitis even in the lavage control animals suggested that a 
chemical pneumonitis is induced by the lavage process itself (4). 
Figure 2 shows the lung injury score of the different groups. Animals treated with 
surfactant combined with HFOV or CMV had significantly less lung injury than both groups 
without surfactant (HFOV and CMV) at the end of the ventilation period. The extent of lung 
injury of both surfactanHreated groups was comparable with that of the animals that were 
lavaged only. Representative photomicrographs are shown in Figures 3 and 4. More detailed 
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quantitative comparisons between both surfactant treated groups (HFOV and Ci\1V) were not 
made. 
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Figure 2. Semi·quantitative lung injury score for all groups. Lav: animals that were lavaged only; CMV: 
conventional mechanical ventilation; HFOV: high-frequency oscillatory ventilation; CMV+Surf: animals 
that received CMV and surfactant; HFOV+Surf: animals that received HFOV and surfactant. *, pS:O.05 
vs. animals that were lavaged only. Data are presented as mean ±SD. 
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Figure 3. (A) Half of the lung tissue is atelectatic in the group that was lavaged only. No cellular reaction 
exists and the septa are structured regularly. (8) TIle lung tissue is evenly aerated and only focally 
atelectatic (group conventional mechanical ventilation and surfactant). Few granulocytes are situated next 
to the bronchioli and small vessels. (C) Aerated lung tissue with focal atelectasis (group high-frequency 
oscillatory ventilation +Surfactant), Collapse of the alveoli is accompanied by a slight interstitial and 
intra-alveolar infiltrate. Light microscopy, haematoxylin eosin stain, original magnification x 40. 
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A 
B 
Figure 4. Representative alveoli of the group that received (A) conventional mechanical ventilation for 
only to min after the lavage procedure and of the group that received (n) high-frequency oscillatory 
ventilation (HFDY) without surfactant for 4.5 h. The alveolus of the HFOV group contain fibrin, 
leucocytcs, erythrocytes, and macrophages. Scanning electron microscopy, magnification x 750. 
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Discussion 
In the present study we used the lung lavage model that has proved to be a consistent and 
convenient model of acute lung injury [10-12, 14]. Despite the use of adult animals, it has been 
postulated that this model reflects a primary slllfactant deficiency, as seen in neonatal RDS [15]. 
Several investigators have confirmed the direct relationship in this model between arterial 
oxygenation and lung volume [2, 3, II, 16]. It has been demonstrated that arterial oxygenation 
increased with increasing lung volume as alveoli fe-expanded and shunt flow decreased [16]. 
In the present study, we therefore used arterial oxygenation as a reflection of lung volume. 
The results of this study demonstrate that after surfactant therapy there is no difference 
between the use of HFOV and CMV in improving gas exchange, lung deflation stability and 
prevention oflung injury in lung-Iavaged rabbits. These results are in contrast to the results of 
Froese ef al. [10] who demonstrated that the effect of exogenous surfactant on arterial 
oxygenation remained stable with HFOV, whereas it decreased significantly during the 4 h study 
period with CMV at high-lung volume. In their study, the high-lung volume strategy with CMV 
was performed by a gradual increase of PIP and PEEP but without an active volume recruitment 
manoeuvre as used with HFOV [8]. Furthermore, CMV was used with high tidal volumes (20 
mllkg body weight) which is known to increase the conversion from active into non-active 
surfactant subfractions; this leads to a shortage of 'active' sUlfactant at alveolar level [17,18]. 
In the present study, an active volume recruitment manoeuvre was not performed with CMV 
after surfactant therapy, but arterial oxygenation increased to above 46.7 kPa (350 mmHg) 
within 5 min (without change of ventilator settings) and kept stable during the subsequent 4 h. 
In contrast to the study of Froese ef al. [8], this study utilized normal tidal volumes (10 ml/kg 
body weight) and installed the sUlfactant at a higher concentration (100 mg/kg body weight) and 
as one bolus, that is known to improve the surfactant distribution and its efficacy [12). 
Surfactant metabolism and turnover is known to be strongly influenced by ventilation 
and some authors suggested that secretion of sUlfactant is increased with HFOV [19-21]. In the 
present study, it was confirmed that in lung-Iavaged rabbits optimal gas exchange can be 
obtained with HFOV without surfactant, by using the high-lung volume strategy. However, lung 
function does not improve over time, as shown by the results that mean Pa02 values at the end 
of the observation period were comparable with the post-lavage values at the same ventilatory 
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support (Fig. I). This indicates that the reduced end-expiratory stability, due to the repeated lung 
lavages (i.e. surfactant deficiency), was apparently not improved by HFOV. This confirms the 
resuIts by Meredith el al. [22], who showed excellent gas exchange using HFOV with the high-
lung volume strategy in premature baboons, but no beneficial effect on lung volume at zero 
pressure (functional residual capacity) determined at 24 h. This indicates that optimization of 
alveolar expansion with HFOV markedly improves oxygenation but does not influence alveolar 
stability as long as the underlying cause, Le. surfactant deficiency, is not reversed. This will 
occur by gradual synthesis of endogenous surfactant over time, or after exogenous surfactant 
instillation [15]. 
Morphologic changes were more pronounced in the animals that received CMV or 
HFOV alone compared to the animals that were lavaged only (Fig. 2). In surfactant-deficient 
lungs, high shear forces between open and closed alveoli are, to a great extent, held responsible 
for the damage caused by artificial ventilation [7]. Therefore, alveoli should be actively opened 
and kept open during the entire respiratory cycle in order to minimize additional lung damage 
[2, 3]. Studies in lung-Iavaged rabbits demonstrated that HFOV had beneficial effects on 
preventing development of lung injury due to mechanical ventilation when arterial oxygenation 
was kept above 46.7 kPa (350 nnnHg) (indicating alveolar expansion) and not when arterial 
oxygen tensions were maintained at 9.3-13.3 kPa (70-100 mmHg) [2, 3]. This may explain the 
higher degree of lung injury as seen in the present study in the group HFOV witllOut surfactant. 
In that group, mean PaO, values dropped to <13.3 kPa «100 mmHg) for only 30 min, after 
MAwP was decreased to ~9 em H,O at the end of the observation period (Fig. 1). In contrast, 
mean PaO, values remained >46.7 kPa (350 mmHg) almost for the entire observation period, 
despite the reduction of the MAwP, in both surfactant-treated groups (HFOV and CMV). Also, 
histopathology examinations of both groups that received surfactant (HFOV and CMV) showed 
no additional structural lung damage in comparison with the animals that were lavaged only 
(Fig. 2). This result is supported by earlier experimental studies in which surfactant therapy has 
shown to improve uniform alveolar expansion and end-expiratory alveolar stability and thereby 
effectively prevents the progression of ventilator-induced lung injury [7,23]. In the CMV group 
without surfactant, mean PaO, values were d3.3 kPa (dOD mmHg) during the entire study 
period and evidenced the high lung injury score in this study (Fig. 2). In contrast to HFOV, the 
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CMV group did not receive a high-lung volume strategy. In pilot studies, McCulloch et aJ. [3] 
and Kolton et aJ. [24] tried to have a CMV group at high-lung volume but found that this was 
not possible. They concluded that the severity of lung lavage lesion necessitated such high 
ventilator pressures with CMV that fatal barotrauma terminated all such attempts (2). 
In contrast to Jackson ef al. [9], the current study found no difference in the prevention 
of lung damage between HFOV and CMV after surfactant therapy (Fig. 2). Further, it was shown 
that the HFOV group without surfactant showed more cellular infiltration and epithelial damage 
than the HFOV group with surfactant (Fig. 2). This indicates that achieving and maintaining 
alveolar expansion (Le. open lung) is of more importance than the type of mechanical ventilation 
(HFOV vs. CMV). The imp0I1ance of an open lung strategy is supported by the results of Amato 
and colleagues [25] who recently demonstrated in adults with ARDS that CMV with an open-
lung approach had, for the tirst time, a significant impact on survival and barotrauma. Therefore, 
it was concluded that surfactant therapy with CMV is equally effective to prevent ventilator-
induced lung injury as HFOV combined with surfactant, as long as alveoli are opened and kept 
open to avoid high shear stress. This can be achieved by the use of a PEEP level that sufficiently 
counterbalances the retractive forces or by higher and/or repeated doses of exogenous surfactant 
to reduce the retractive forces. 
I! is concluded that after surfactant therapy the use of high-frequency oscillatory 
ventilation was not superior to conventional mechanical ventilation in improving gas exchange, 
lung deflation stability and reducing lung injury, if lungs are kept expanded independently of the 
mode of ventilation. Furthennore, it was confirmed that high-frequency oscillatory ventilation 
with the high-lung volume strategy markedly improves blood gases but without improvement 
of lung function, in particular arterial oxygenation at low mean airway pressure, in surfactant-
depleted rabbits. This indicates that the high mean airway pressure used with high-frequency 
oscillatory ventilation only counterbalances the increased collapse tendency due to surfactant 
deficiency and therefore exogenous surfactant therapy is still required. 
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Summary 
Objective: The inhalation of nitric oxide increases oxygenation by improving ventilation-
perfusion ratios in neonates with respiratory distress syndrome and those ratios in adults with 
acute respiratory distress syndrome. There is evidence that inhaled nitric oxide is ineffective 
when the lung remains atelectatic and poorly inflated. This study aimed to enhance nitric oxide 
delivery by improving lung aeration by means of exogenous surfactant or by increasing positive 
end-expiratory pressure. 
Design: Experimental, comparative study. 
Setting: Research laboratory of a large university. 
Subjects: Twenty-eight adult New Zealand white rabbits (2.7 ± 0.3 kg). 
lllten/elltiolls: Lung injury was induced by repeated whole-lung lavage with saline. The animals 
were mechanically ventilated with a tidal volume of 10 mlIkg, an FiO, of 1.0 and a PEEP of 6 
em H20. Forty-five minutes after the last lavage, animals were randomly assigned to five groups. 
In two groups, lung aeration was first increased either by instillation of a low dose of exogenous 
surfactant (25 mglkg) or by increasing the positive end-expiratory pressure to 10 cm H20, before 
inhalation of nitric oxide was started. In each of these animals, five different nitric oxide 
concentrations (4-20 parts per million) were inhaled for 30 min, followed by a 30 min washout 
period. The other three groups served as controls and received only one treatment protocol: nitric 
oxide (4-20 parts per million), or surfactant (25 mglkg), or positive end-expiratory pressure (10 
cm H20). 
Measurements and Main Results: Before and after lavage, blood gases and lung mechanics were 
measured every 30 min. Both strategies to increase lung aeration improved Pa02 values from 
61 ± 13 mmHg (8.1 ± 1.7 kPa) to 200 to 300 mmHg (26.6 to 39.9 kPa) in 30 min. After 
inhalation of nitric oxide, additional increases of oxygenation were seen only in the animals that 
received a low dose (25 mglkg) of surfactant. The control group that inhaled nitric oxide showed 
no significant change in oxygenation, and four of the six animals did not survive the observation 
period. In the two groups in which positive end-expiratory pressure was increased to 10 cm H20, 
half of the animals developed a pneumothorax during the observation period. 
Conclusions: These data indicate that inhaled nitric oxide is able to improve arterial oxygenation 
after alveolar recruitment by means of a low dose of exogenous surfactant and not by elevation 
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of PEEP Irom 6 to 10 cm H20, in lung-Iavaged rabbits. 
Introduction 
In 1987, nitric oxide, the endothelium-derived relaxing factor synthesized from L-arginine by 
the enzyme nitric oxide synthase, was identified as an important endogenous vasodilator [1]. 
Inhalation of exogenous nitric oxide has been shown to be beneficial with respect to reducing 
pulmonary hypertension and improving arterial oxygenation in neonates with respiratory distress 
syndrome (RDS) and adults with acute respiratory distress syndrome (ARDS) [2-7]. It is 
assumed that inhaled nitric oxide rapidly diffuses across the alveolar barrier to vascular smooth 
muscle causing relaxation of the vascular smooth muscle which, in turn, causes vasodilation of 
the pulmonary vessels [8]. Excess nitric oxide that reaches the bloodstream binds rapidly and 
avidly to hemoglobin; this binding to hemoglobin eliminates the availability of nitric oxide for 
causing systemic vasodilation [8]. 
Recently, Kinsella and colleagues [9] reported that the inhalation of nitric oxide resulted 
in a limited success in improving blood gases, especially in newborns with reduced lung 
compliance. It has been suggested that the reduced lung volume will probably contribute to 
decreased efficacy of inhaled nitric oxide by decreased effective delivery of nitric oxide to the 
pulmonary vasculature [9,10]. Therefore, it could be expected that after reaeratiou of atelectatic 
lung regions by either exogenous surfactant or by increasing the positive end-expiratory pressure, 
the effect of inhaled nitric oxide on oxygenation will be enhanced, as long as a 
ventilation/perfusion mismatch is present. 
To test this hypothesis, a study was designed in which we investigated the effects of 
inhaled nitric oxide combined either with a low dose of exogenous surfactant or increased 
positive eud-expiratory pressure, on blood gases in surfactant-depleted rabbits. 
Materials and methods 
This study was approved by the local Animal COlmnittee of the Erasmus University Rotterdam. 
Care and handling of the animals were in accord with the Europeau Community guidelines 
(86/609IEEG). A total of 28 adult New Zealand white rabbits (lFFA-Credo, Brussels, Belgium) 
with a meau body weight of 2.7 ± 0.3 kg were anesthetized with intravenous pentobarbital 
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sodium (50 mg/kg) via an auricular vein. Tracheostomy was perfonned, and an uncuffed 
endotracheal tube was introduced into the trachea. Mechanical ventilation with an Fi02 of 1.0 
was performed using a ventilator (Servo 300, Siemens-Elema, Solna, Sweden) with volume-
controlled mode, tidal volume of 10 mllkg, positive end-expiratory pressure of 2 cm H20, 
frequency of 30 breaths/min, inspiration time of25% and a pause time of 10%. An infusion of 
2.5% glucose was continuously administered via the auricular vein as a maintenance fluid (5 
mllkg/h). Anesthesia was maintained with intermittent injection of pentobarbital sodium (5 
mg/kg/h, i.v.); muscle paralysis was achieved with pancuronium bromide (0.1 rug/kg/h, i.m.). 
A femoral artery was cannulated with a polyethylene catheter for continuous blood pressure 
measurements and for intermittent blood sampling. Arterial samples were analysed for blood 
gases, hemoglobin and methemoglobin saturation using conventional methods (ABL-505 and 
Osm-3; Radiometer, Copenhagen, Denmark). Core temperature was measured using an 
esophageal thermistor (Elektrolaboratoriet, Copenhagen, Denmark) and maintained at 99 ± I "F 
(37 ± 0.5 "C) by a heating pad. 
In all animals, respiratory insufficiency was induced by repeated whole-lung lavage (30 
mllkg) according to Lachmann ef al. [11]. After the fIrst lavage, positive end-expiratory pressure 
was increased to 6 em H20 (other ventilator settings were not changed) and whole-lung lavage 
was repeated until PaO, was <80 nunHg «10.6 kPa). After the last lavage, all animals were 
ventilated for 45 min, and after blood gases were measured, the animals were randomly divided 
into five groups. The first group (n=6), received a low dose of surfactant (25 mg/kg) 
intratracheally which, 30 min later, was followed by inhalation of nitric oxide. Five different 
concentrations of nitric oxide (4, 8, 10, 16 and 20 parts per million [ppm]) were each inhaled for 
30 min. The sequence of the five nitric oxide concentrations was randomized for each animal. 
After each nitric oxide inhalation for 30 min, blood gases were measured and nitric oxide was 
tumed off for 30 min to get a new baseline blood gas value. In another group (n=6), positive end-
expiratOl)' pressure was increased from 6 to 10 cm H20, and, after 30 min, inhaled nitric oxide 
was given in the same way as described above. The other three groups served as controls and 
received the following treatments: (a) nitric oxide alone in the same way as described above 
(n=6); (b) 25 mg/kg surfactant alone (n=5); or (c) a positive end-expiratory pressure of 10 cm 
H,O alone (n=5). 
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The surfactant used in this study was a freeze-dried natural surfactant isolated from 
minced pig lungs as previously described [12]. For instil1ation of the surfactant, animals were 
disconuected from the ventilator aud received the Sur!:1ctaut suspension (25 mglml) directly iuto 
the endotracheal tube via a syringe. The animals were then immediately reconnected to the 
ventilator (ventilator settings were not changed). 
A new prototype of a ventilator was used (Siemens-Elema, Solna, Swedeu), with a built 
in, computerized, nitric oxide delivery system, consisting of an additional digital-controlled 
nitric oxide valve. An on-line electrochemical sensor was used to continuously measure 
expiratory nitric oxide and nitric dioxide concentrations. This system has been used in adult 
patients with ARDS aud has proven to be reliable [5]. 
Data were collected at the following times: before lavage; 5 and 45 min after the lavage 
procedure; and every 30 min for 5.5 h. In the control group, that received nitric oxide only, data 
were collected for only 5 h because there was no lung aeration improvement procedure. At each 
data collection point, PaO" PaCO" methemoglobin, blood pressures, peak airway pressure, 
positive end-expiratory pressure and mean airway pressures were measured. 
Statistical analysis of the data was performed using the SAS statistical package (SAS 
Users Guide, 1990, SAS Institute Inc., Cary NC). Between-group differences for PaOlo PaCO" 
mean arterial pressure, mean airway pressure and peak pressure were tested with an analysis of 
variance (ANOV A) for repeated time measurements using the general linear models procedure. 
In addition, a paired twtest was performed to test the effect of each nitric oxide concentration on 
PaD2 within one group. When nitric oxide was switched on for 30 min, the mean PaDI value was 
compared with the mean baseline PaD2 value that was defined as the mean PaD2 of both washout 
periods before and after nitric oxide was switched on. Differences were accepted as significant 
at p<0.05. For the nitric oxide effects, no adjustments were made for multiple comparisons. 
Results 
In a preliminary study [unpublished observations], it was found that giving a dose of 25 mg 
surfactant per kg body weight or increasing the positive endwexpiratory pressure level from 6 to 
10 cm H20 after the lavage procedure, led to an improvement of arterial oxygenation to 50% of 
the prelavage PaO, values (paO,lFiO, from 60 to 80 mmHg [8.0 to 10.7 kPal to 200-300 nunHg 
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[26.7 to 40.0 kPa]). 
In the two groups receiving exogenous surfactant (25 mglkg), mean PaD, values 
increased from 58 ± II mmHg (7.7 ± 1.5 kPa) to 283 ± 64 mmHg (37.6 ± 8.5 kPa) in 30 min 
(Figure I). After additional nitric oxide inhalations, PaD, fm1her increased and decreased when 
nitric oxide was switched off. The mean PaOl values of the group receiving the combination of 
surfactant and nitric oxide were significantly higher compared with the group that received 
surfactant only (Figure I). In this last group, PaD, was maximal at 30 min after surfactant 
instillation and decreased over time (Figure I). PaCO, and peak airway pressure decreased 
directly after surfactant instillation but slowly increased during the following observation period 
(Table I). 
In the two groups in which positive end-expiratory pressure was increased from 6 to 10 
em H,O, mean PaD, values increased from 62 ± 15 mmHg (8.2 ± 2.0 kPa) to 239 ± 48 ImnHg 
(31.8 ± 6.4 kPa) in 30 min (Figure I). After nitric oxide was inhaled by one of these groups, no 
significant difference in mean Pa02 values was seen compared with the group that received a 
positive end-expiratory pressure of 10 em H,O only (Figure I). In the group receiving the 
combination of positive end-expiratory pressure of 10 em H20 and inhaled nitric oxide, mean 
PaG2 values improved over time but did not decrease when nitric oxide was switched off. Peak 
airway pressure and mean airway pressure were significantly higher in the two groups that 
received a positive end-expiratory pressure of 10 crn H20 as compared with the two surfactant 
treated groups; half of the animals in both positive end-expiratory pressure groups developed a 
pneumothorax during the observation period (Table I). 
There was no change in mean PaOl values after inhalation of nitric oxide in the group 
that received nitric oxide only (Figure I). In this group, PaCO, and peak airway pressure 
increased over time and 4 of the 6 animals did not survive the observation period (Table I). For 
the three groups that received nitric oxide, the mean changes of Pa02 per nitric oxide 
concentration are given in Figure 2. The Pa02 response was higher in the group receiving the 
combination of surfactant and nitric oxide for each nitric oxide concentration but there was no 
difference in PaD, response to the different nitric oxide concentrations used (Figure 2). Non-
response (defined as an increase of PaD, of < 10% above the baseline PaD, value) was 27% in 
group surfactant and nitric oxide; 93% in group positive end-expiratory pressure and nitric oxide; 
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Figure 1. Mean PaGl values (±SD) of all 5 groups. Diagonal-striped bar: animals (11=6) treated with a 
low dose of exogenous surfactant (25 mglkg) and inhaled nitric oxide; horizolllal-striped bar: animals 
(n=6) treated with a positive end-expiratory pressure of 10 em H20 and inhaled nitric oxide; solid bar: 
animals (n:::6) treated with inhaled nitric oxide alone. The solid lines are two control groups: triangles, 
animals (11:::5) treated with a low dose of exogenous surfactant (25 mglkg) alone; circles, animals (n=5) 
treated with a positive end-expiratory pressure of 10 em H20. [..av, 45 min after the last lavage. To covert 
mmHg to kPa multiply the value by 0.1333. 
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Figure 2. Mean change in Pa02 values (±SD) per nitric oxide concentration for the three different groups 
that inhaled nitric oxide. Diagonal-striped bar: animals (n=6) treated with a low dose of exogenous 
surfactant (25 mglkg) and inhaled nitric oxide; horizOlllal-striped bar: animals (n=6) treated with a 
positive end-expiratory pressure of 10 em H20 and inhaled nitric oxide; solid bar: animals (n=6) treated 
with inhaled nitric oxide alone. * = significant improvement of Pa02 due to inhaled nitric oxide (evaluated 
with a paired Hest by comparing the mean PaD! value when nitric oxide was switched on for 30 min with 
the baseline PaOI value). The baseline blood gas value was defined as the mean PaD2 value of both wash 
out periods before and after nitric oxide was switched on. To COil vert mmHg to kPa, multiply the value 
by 0.1333. 
and 58% in the group that received nitric oxide only. 
Mean arterial pressure did not change after inhaling any nitric oxide in the different 
groups (Table I). Methemoglobin concentration remained low (0.3 ± 0.1 %) and there was no 
increase after any nitric oxide inhalation in any of the groups. The expired nitric dioxide 
concentration was never> 1 ppm during any nitric oxide inhalation in any of the groups The 
expired nitric dioxide concentrations are given in Table 2. 
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Table 1. PaCO, (mmHg), MAP (mmHg), mean aitwaypressure (MAwP) and peak pressure (em H2 0) in the five study groups (mean ± SD). 
PaCO~ 
MAP 
MAwP 
Ppeak 
Prelavag Group Lavage 30' 60' 90' 120' 150' 180' 210' 240' 270' 300' 330' 
36±3 
37±3 
34±5 
32±6 
32±4 
97±9 
108±Il 
99±8 
108±7 
104±11 
5±3 
6±1 
5±O 
5±O 
6±1 
11±1 
I3±2 
13±2 
12±1 
SURF+NO 58±1O 46±6 45±3 48±6 48±7 48±7 48±8 48±9 49±10 50±Il 50±Il 50±10 
PEEP+NO 
NO 
SURF 
PEEP 
57±7 
52±6 
55±6 
46±4 
54±6 57±6 58±4 60±5 SS±5 57±7 55±6 55±4 55±S§H 53±2 51±1 
51::1:10 54::1:12 55±14 57±13 60±14 60±1St 55::1:19" 53±17t 54±2t 54±2 
400 49±6 49±2 48±3 500 50±5 SI±5 51±6 51±6 52± 7 52±6 
45±4 46±7 47±3 48±4 49±6 53±3~ 53±3 55±3§ 54±2 57±1 § 54±4 
SURF+NO 90±10 82±11 
PEEP+NO 101±14 87±9 
NO 88±13 82±17 
SURF 91±9 90±14 
PEEP 94±10 89±5 
SURF+NO 
PEEP+NO 
NO 
SURF 
PEEP 
SURF+NO 
PEEP+NO 
NO 
SURF 
11±1 
12±1 
11±1 
11±1 
12±2 
24±2 
24±2 
25±1 
25±2 
10±1 
17±2 
12±1 
10±1 
16±1 
22±2 
28±1 
26±2 
24±2 
81±7 81±11 81±7 83±7 
86±12 89±13 86±14 82±12 
83±14 85±10 88±10 89±15 
89±13 90±14 S9±12 89±14 
91±Il 89±5 85±5 91±9 
10±1 
17±2 
12±1 
11±1 
16±1 
22±2 
27±1 
26±2 
24±2 
10±1 
17±2 
12±1 
11±1 
16±1 
22±3 
27±1 
28±2 
24±2 
10±1 
17±2 
12±1 
11±1 
16±1 
23±3 
28±1 
28±1 
25±2 
10±1 
17±2 
12±1 
11±1 
16±1 
23±3 
28±1 
29±2 
25±3 
87::1:9 88±6 90±10 89±9 91±10 89±9 
78±10 7S±1l 78±9 77±Sm 76±6 70±15 
74±18 77::1:23T 82±9t 87::1:3t 85±4 
94±13 88±13 91±17 86±15 83±2S 80±19 
90±9* 88±1 85±S§ 84±5 90±4§ 76±16 
10±1 
17±2 
12±1 
11±1 
16±1§ 
23±3 
28±1 
29±2 
25±3 
10±1 
17±2 
12±ft 
1 I±I 
16±1 
23±3 
28±1 
30±1 t 
25±3 
10±1 
17±2 
12±2t 
11±1 
16::1:2* 
23±2 
11±1 
17±2§H 
12±2t 
11±1 
16±2 
23±2 
U±l 
18±2 
12±2 
1l±1 
15±1* 
23±2 
28±2 28±l m 27±1 
30±1t 30±1t 30±1 
25±3 25±3 25±3 
11±1 
18±2 
11±1 
15±1 
24±2 
27±1 
25±3 
12±1 PEEP 26±2 29±2 ~0±2 29±1 29±1 30±1 3l±1§ ~1±1 ~2±1* 32±1 32±1* 3J±1 
SURF+NO, represents the animals treated with surfactant and nitric oxide; PEEP+NO, represents the animals treated with a PEEP of 10 cmHp and nitric oxide; NO, 
represents the animals treated with nitric oxide only; SURF, represents the animals treated with surfactant only; PEEP, represents the animals treated with PEEP of 10 
cmliz0 only; MAP, mean arterial pressure; MAwP, mean airway pressure; ppeak, peak inspiIatory pressure; t, death of one animal; §, pneumothorax of one animal. 
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Table 2. Expiratory nitric oxide (NO) and nitric dioxide (NO,) concentrations measured with 
an oIl-line electrochemical sensor (mean±SD). 
NO (ppm) NO·expired (ppm) NOrexpil'cd (ppm) 
4 3.7±O.6 O.2S±O.04 
8 7.2±O.6 O.34±O.OS 
10 8.8±O.8 O.38±O.O6 
16 14.3±O.7 O.60±O.OS 
20 17.7±O.7 O.78±O.O7 
Discussion 
The application technique limits the pharmacologic effect of nitric oxide to the aerated regions 
of the lungs [8]. Therefore, progressive atelectasis, as seen in severe RDS or ARDS, decreases 
effective delivery of this inhalational agent to its site of action in the terminal lung units [7,9,10). 
This hypothesis was confirmed by the results of the present study, in which inhalation of nitric 
oxide was less efficacious in improving arterial oxygenation in the control group that received 
inhaled nitric oxide only, as compared with the group with prior administration of exogenous 
surfactant (Figure 2). In congenital diaphragmatic hernia lambs, Karamanoukian et al. [13) 
reported that the combination of exogenous surfactant and inhaled nitric oxide is beneficial to 
improving arterial oxygenation. They [13] found that inhalation of 80 ppm of nitric oxide for 10 
min did not improve oxygenation without prior administration of surfactant (50 mglkg) [13]. 
From experimental and clinical studies [12,14) in neonatal RDS, it is known that instillation of 
100 to 200 mglkg of surfactant resulted in recruitment of atelectatic lung regions with maximal 
improvement of arterial oxygenation. In the present study, we administered a dose of only 25 
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mg/kg surfactant, and the results showed that PaO, improved to 50% of the prelavage values 
within 30 min and decreased over time due to diminished surfactant function (Figure I). After 
treatment of late-stage RDS and ARDS with a low dose of surfactant, transient improvement of 
PaG! is attributed to inhibition of the exogenous surfactant by plasma-derived proteins that are 
filling the alveolar space due to leakage of the alveoli-capillary membrane [l4-16J. In addition, 
in the present study, arterial oxygenation was significantly higher during the whole observation 
period in animals that received a combination of surfactant and inhaled nitric oxide. compared 
with the group that received a low dose (25 mglkg) of surfactant only (Figure I). This result may 
imply that inhaled nitric oxide had a therapeutic effect on the lung injury. In patients with acute 
lung injury, Benzing and colleagues [I7J showed that inhalation of 40 ppm nitric oxide 
decreased pUlmonary transvascular albumin flux. The exact mechmlism is not yet known, but the 
authors [I7J suggested that the decreased pulmonary capillary pressure due to inhaled nitric 
oxide reduced transvascular filtration. Therefore, we speculate that in our study, inhaled nitric 
oxide may have decreased the influx of plasma proteins into the alveolar space, and thereby 
decreased the inhibition of the low dose (25 mg/kg) of exogenous surfactant, leading to higher 
PaOl values in lung-lavaged rabbits. 
Other strategies designed to recruit atelectatic lungs, such as increased positive end-
expiratory pressure, may be as beneficial as surfactant therapy in the delivery of inhaled nitric 
oxide to the target cells. In the present study, arterial oxygenation improved after positive end-
expiratory pressure was increased from 6 to 10 em H20 but no additional effect of inhaled nitric 
oxide was seen on PaO, (Figure I). Furthermore, half of the animals of both positive end-
expiratory pressure groups developed a pneumothorax during the observation period indicating 
that the used peak airway pressures were high (Table I). From clinical experience, it is known 
that one of the benefits of sUifactant therapy includes lower peak airway pressures with reduced 
risk of barotrauma [I4,I6J, which is confirmed by the results of this study (Table I). Putensen 
e/ al. [18J demonstrated that in dogs with oleic acid-induced lung injury, adequate recruitment 
of the lung by a positive end-expiratory pressure of 10 em H,O was essential to get an increase 
in oxygenation atter inhaled nitric oxide compared with a control group without positive end-
expiratory pressure. Also, in adult patients with ARDS, Puybasset e/ al. [7J reported that the 
effect of nitric oxide on PaO, was potentiated by the application of !O em H20 positive end-
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expiratory pressure. This potentiation occurred only in patients in whom positive end-expiratory 
pressure had induced a significant alveolar recruitment. Thus, it seems realistic to conclude that 
alveolar recruitment by positive end-expiratory pressure can also improve the efficacy of inhaled 
nitric oxide. However, we speculate that in the present study, the airway pressures used were too 
high, leading to high intrathoracic pressures that made vasodilation of the pulmonary vasculature 
impossible due to inhaled nitric oxide. Therefore, we suggest that alveolar recruitment induced 
by exogenous surfactant is more beneficial than increased positive end-expiratory pressure for 
improving arterial oxygenation due to inhaled nitric oxide because of the use of lower airway 
pressures. 
The results of previous clinical observations are controversial concerning the dose-
dependency of inhaled nitric oxide [5,6,19,20]. In the present study, there was no dose-dependent 
effect of the different used nitric oxide concentrations (4 to 20 ppm) (Figure 2). Most of the 
animals had a different nitric oxide concentration by which the change in arterial oxygenation 
was maximal. It appears that each lung has its own 'optimal' nitric oxide concentration that 
probably depends of the severity of the disease process (Le., atelectasis, edema). In the present 
study, a low doses of nitric oxide «20 ppm) were used because of the demonstrated efficacy of 
low doses in animal experiments and patients, and to minimize toxicity [21]. In the presence of 
oxygen, nitric oxide is rapidly oxidized to nitrite, or nitrates that can induce tissue damage (22]. 
Also, nitric oxide reacts with superoxide anions to produce peroxynitrite [22]. Haddad and 
colleagues [23,24] demonstrated ill vitro that peroxynitrite inhibits pUlmonary surfactant 
function by lipid peroxidation and damaging surfactant proteins. In the present study, there was 
no evidence that the surfactant function was more decreased after inhalation of nitric oxide when 
compared with the control group that only received sUlfactant (Figure 1). Furthermore, severe 
methemoglobinemia due to inhalation of nitric oxide has been reported (25]. However, in the 
present study, no changes in methemoglobin concentration were observed with the used nitric 
oxide concentrations that were used during the 30 min inhalation periods. 
In the present study, we used the lung lavage model which has proved to be a consistent 
and convenient model of acute lung injury [II]. Repeated whole-lung lavage produces an acute 
quantitative surfactant deficiency. This deficiency, together with conventional mechanical 
ventilation, leads to severe lung injury with impaired gas exchange, decreased lung compJiance 
104 
SIlI!actant alld Illhaled NO 
and functional residnal capacity, increased permeability changes of the alveoli-capillary 
membrane with edema, and sustained pulmonary hypertension [11,12,26]. In the present study, 
animals were first ventilated for 45 min after the last lavage before treatment was started to 
induce a IllorC severe lung injury. Although an untreated control group was not used in this 
study, we [27J have previously demonstrated with the same model that following the lavage 
procedure, there is no spontaneous improvement in oxygenation or lung mechanics over a 6 h 
period. Despite the fact that the lung injury in this study is not representative of the pathology 
as seen in humans with ARDS, this model is ideal for testing various therapeutic interventions 
that may prove therapeutic for acute lung injury [12,27-32J. 
\Ve conclude that in lung lavaged rabbits, the effect of nitric oxide on improving 
oxygenation is superior when lung aeration is increased with exogenous surfactant rather than 
with positive end~expiratory pressure. In neonates with RDS and patients with ARDS, it has been 
shown that both exogenous surfactant and nitric oxide increase Pa02 by improving the 
ventilation Iperfusion match [2-6,14,16]. Whereas the inhalation of nitric oxide improves 
perfusion of the ventilated areas of the lung, instillation of exogenous surfactant leads to 
improvement of the ventilation by reaeration of atelectatic regions. Therefore, combined therapy 
of exogenous surfactant and nitric oxide inhalation could be clinically important, especially in 
patients with ARDS. Nevertheless, in terms of our goal of improving oxygenation while 
diminishing lung injury, it remains unclear whether a low dose of surfactant plus inhaled nitric 
oxide is more optimal than a high dose surfactant. 
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Combining partial liquid ventilation with nitric oxide to 
improve gas exchange in acute lung injury 
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SUIllmary 
Objective: To assess the effects of increasing concentrations of inhaled nitric oxide (NO) during 
incremental dosages of partial liquid ventilation (PLY) on gas exchange, hemodynamics and 
oxygen transport in pigs with induced acute lung injury (ALI). 
Design: prospective experimental study. 
Setting: Experimental intensive care unit of a university. 
SlIbjects: 6 pigs with induced ALI. 
Interventions: Animals were surfactant depleted by lung lavage to a partial pressure of oxygen 
in arterial blood (PaO,) < 100 mmHg. They then received four incremental doses of 5 mllkg 
perflubron (LiquiYent). Between each dose the animals received 0, 10,20,30,40 and 0 parts 
per million (ppm) NO. 
Measurements alld Main Reslllts: Blood gases, hemodynamic parameters, and oxygen delivery 
were measured after each dose of perflubron as well as after each NO concentration. Perflnbron 
resulted in a dose-dependent increase in PaO,. At each perflubron dose, additional NO 
inhalation resnlted in a fnrther significant (ANOY A p<0.05) increase in PaO" with a maximum 
effect at 30 ± 10 ppm NO. The 5 mllkg perflubron dose led to a significant decrease in mean 
pulmonary artery pressure which decreased fnrther with higher NO concentrations. 
Conclusions: PLY can be combined with NO administration and results in an cumulative 
etIect on arterial oxygenation and to a decrease in pulmonary artery pressure, without having any 
deleterious effect on measured systemic hemodynamic parameters. 
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Introduction 
The presence of an increased surrace tension at the alveolar air-liquid interrace during acute lung 
injury (ALI) leads to end-expiratory alveolar collapse, atelectasis, right-to-Ieft shunt and a 
decrease in the prulial pressure of oxygen in arterial blood (Pa02), finally resulting in hypoxemia 
[1]. Rational therapies to treat this condition are: first, counterbalancing the increased tendency 
for collapse by applying positive end-expiratory pressure (PEEP) to prevent end-expiratory 
collapse, and/or decreasing alveolar surrace tension by application of exogenous surfactant. 
Another option could be elimination of the air-liquid intert;,ce by filling the lung with a fluid 
that is able to maintain gas exchange. Such a tluid could be pertluorocarbon (pFC), which is 
capable of dissolving large amounts of respiratory gases. Recently, the use of PFC was modilied 
by filling the injured lung up to the functional residual capacity (PRC) level with PFC, and 
ventilating the lung with normal gas ventilation superimposed on the fluid-filled lung. This type 
of ventilation is called partial liquid ventilation (PL V), or perfluorocarbon associated gas 
exchange (PAGE). This technique was used in animals suffering from respiratory failure of 
different etiologies showing an improvement in gas exchange (2-9]. In some of these studies, 
there was a clear dose dependent effect on oxygenation, creating the possibility for titrating the 
amount of PFC to its effect. The results of a clinical pilot study on the use of PAGE have 
recently been published [10]. 
Besides hypoxemia due to atelectatic regions in the lung, other serious problems 
complicating the treatment of ALI are disabled ventilation/pelfusion matching and pulmonary 
hypertension. Administration of inhaled nitric oxide (NO) in adult patients with acute respiratory 
distress syndrome (ARDS) has been shown to cause selective vasodilation of the pulmonary 
vasculature of ventilated lung regions leading to an improved oxygenation due to a decrease in 
pulmonary right-to-Ieft shunt [11-13]. 
Based on these findings we hypothesized that, after increasing the area of gas exchange at end-
expiration by PLY, the administration of NO by inhalation may liniher enhance oxygenation and 
result in decreased pulmonary artery pressures. To test this hypothesis we investigated the 
effects of increasing concentrations of NO during incremental dosages of PFC on gas exchange, 
hemodynamics and oxygen transport in pigs with induced ALI. 
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Materials and methods 
Animal preparation 
The study protocol was approved by the Uuiversity's animal experimental commiUee. Anesthesia 
was induced in 6 female Yorkshire pigs (weight 7 ± 1 kg) with ketamine (10 mglkg) and 
midazolam (0.5 mglkg), and was maintained with a continuous infusion of ketamine (80 
~,glkglmiu) and midazolam (9 ~'glkglmin). All animals were tracheotomized, intubated with a 
6.0 mIll endotracheal tube fitted with a Filtratlux heat-moisture exchanger with bUilt-in bacterial 
filter (ICHOR AB, Bromma, Sweden) and cannulated with a carotid artery catheter, a 5 Fr 
pulmonary artery catheter (SP51055H Viggo-Spectramed, Wiltshire, UK), a continuous blood 
gas mouitoring seusor (Paratrend 7, Pfizer, Biomedical Sensors, High Wycombe, UK) placed 
in the left femoral artery, and a central venous catheter. During animal preparation, volume 
controlled ventilation with a Servo 300 ventilator equipped with a built-in NO administration 
module (Siemens, Solna, Sweden) (set at frequency 20 Imin, inspiratory time 25%, pause time 
10%, inspiratory rise time 5%, PEEP 5 em H20 and 100% oxygen) was used. Muscle relaxation 
was achieved by a continuous infusion of pancuronium bromide (2.5 ~,glkglmin). Minute 
ventilation was set to deliver tidal volumes of 10 mUkg body weight. These ventilator settings 
were maintained during the entire study period. 
All animals were surfactant depleted according to Lachmann et al. [14] by repeated lung 
lavage with warm saline (38'C, 30 mllkg) to reduce Pa02 below 100 mmHg. Subsequently, all 
animals were vent Hated for I hour to obtain stable baseline values. Following this baseline 
period all animals received four intratracheal doses of 5 mllkg pertlubron (LiquiVent; Alliance 
Pharmaceutical Corporation, San Diego, USA); in between these doses a sequence of different 
concentrations of NO (0, 10, 20, 30, 40 and 0 ppm NO) was added to the inspiratory gas. Each 
concentration of NO was administered for period of about 10 min. 
Measurements 
Arterial and mixed veno.us samples were analyzed for blood gases, pH and mixed venous oxygen 
saturation (SvO,) and hemoglobin concentration by conventional methods (ABL-505 OSM-3 
combination, Radiometer, Copenhagen, Denmark). This combination was used to calculate base 
excess (BE), intrapulmonary shunt. arterial oxygen content (Ca01), oxygen delivery and 
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ru1eriovenous oxygen content difference. Additionally blood gases were monitored continuously 
by means of a blood gas monitor. 
Using Statham P23XL transducers (Spectramed, Oxnard, CA, USA), systolic, diastolic 
and mean arterial pressure as well as systolic (SysP AP) diastolic (DiaPAP) and mean pulmonary 
artery pressure eMP AP), pulmonary capillary wedge pressure and central venous pressure were 
recorded in all animals. Cardiac output was measured in triplicate using the thermodilution 
technique with 5 ml saline, using a Sirecust 1280 monitor (Siemens, Danvers, MA, USA) that 
also traced heart rate. This monitor was also llsed to calculate pulmonary vascular resistance and 
systemic vascular resistance. 
All measurements were recorded just prior to a change in PFC andlor NO concentration. 
At the end of the study period all animals were sacrificed with an intracardiac overdose of KCI. 
Statistical analysis 
Statistical analyses were performed nsing the Instat 2.0 biostatistics package (GraphPad 
Software, San Diego, USA). For each PFC dose and subsequent NO concentrations intra-group 
comparisons were made with repeated measures ANOV A. If ANOV A resulted in a p < 0.05 a 
Dunnett post test was performed. This post test used the data measured after each increment of 
perflubron with the first 0 ppm NO setting as control value. A p value of 0.05 was taken as 
significance level. All data are reported as mean values ± standard error of the mean (SEM). 
Results 
Before and after lung lavage in all animals all data for blood gases and hemodynamics were 
comparable (p > 0.05, ANOV A). No improvement in blood gases was observed dnring the 
I-h postlavage period. All animals survived the study period. 
Gas exchange parameters (Table 1) 
Administration of increments of pertlubron of 5 In1Ikg resulted in an increase in Pa02 of 22.0, 
55.3,47.5 and 51.2 mmHg (i.e. 35, 58, 28 and 24% resp.); supplemental NO inhalation at each 
dose of perflubron resulted in an additional significant increase in Pa02 with a maximum effect 
of NO at 20-30 ppm NO (Fig la). The incremental increases in perflubron dose did not result 
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in a statistically significant improvement ofPaC02 and pH values~ however, these PaCO! and 
pH values showed a dose-dependent significant improvement when combined with additional 
NO administration at the 15 and 20 mVkg body weight perflubron dose. There were no 
significant changes in BE during the study period. 
The first dose of 5 mllkg BW perflubron resulted in a signitlcant improvement in SvO, 
from 48.5 ± 5.3% to 54.9 ± 9.6%. Additional NO inhalation at the 15 and 20 mllkg pertlubron 
doses significantly improved SvO, at 10-30 ppm NO. 
Shunt was reduced at each increment of perflubron reaching statistical signiticance at 
10-20 mllkg pertlubron. At each dose of pertlubron additional NO admiuistration further 
reduced shunt, although these changes were not significant. 
Each increment in perflubron resulted in an increase in mean Ca02; at the 5 and 10 
mllkg perflubron doses CaO, was significantly increased by additional NO administration. 
At each dose of peltlubron, DO, was not significantly changed by NO administration. 
Online blood gas recordings showed a time-related effect of NO on blood gases. Figure 
2 shows the dose-dependent improvement in gas exchange in one animal at a dose of 10 mllkg 
pertlubron. Figure 3 shows a rapid « 3 min) decrease in PaO, from 140 to 89 mm Hg, as a result 
of switching from 40 to 0 ppm NO in an other animal at a perflubron dose of 5 ml/kg. 
Hemodynamics (Table 2) 
Administration of 5 InlIkg perflubron to a total dose of 10 mllkg resulted in a significant 
decrease in SysPAP (-14%) and MPAP (-11%). All other decreases in pulmonary artery 
pressures were observed during additional NO administration: SysPAP showed a significant 
decrease with additional 30 ppm NO (15 and 20 mllkg perflubron), DiaP AP showed a significant 
decrease with additional 30-40 ppm NO inhalation (15 mllkg perflubron) and MPAP values (Fig 
lb) showed a significant dose-dependent decrease at the 10, 15 and 20 ml/kg BW pertlubron 
doses. 
Stopping NO administration resulted in a significant rebound hypertension in.MPAP at 
a dose of 5 nIl/kg B\V perflubron, with a simultaneous increase in pulmonary vascular 
resistance. 
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This was reduced significantly at a dose of 10 mllkg BW perflubron with 40 ppm NO and at a 
dose of 15 ml/kg BW perflubron with 20 ppm NO. 
There was a significant decrease in HR at the 10 mllkg pertlubron dose with 
additional 40 ppm NO. There were no significant changes in any other measured or 
calculated hemodynamic parameters. 
Table I Data on gas exchange parameters in pigs (/I = 6) with ALI following a comhinalion of pcrnuhron (UquiVent) and NO.' Villu~5 
are mean ± SEM 
pCO!(mmHg) pH 
Baseline:~ 55.2 ± 3.1 6O.S±7.5 58.6 ± 6.6 56.1 ±6.2 7.27±O.oJ1 7.25 ±o.t~ 7.23 ± 0.059 7.26 ±O.U54 
UquiVent: 5mllkg 10 mUkg ISmJlkg 20 mllkg 5 mllkg IOmllkg 15 mllkg 2Umllkg 
Oppm NO 52.8 ± 2.5 53.2 ± 4.5 6tO±8.0 57.3 ± 6.4 7.26 ± 0.028 7.25±O.O51 7.22±OJ)61 7.25 ± 0.052 
10 ppm NO 50.2 ± 3.2 53.0±S.7 56.7 ± 6.6 52.5 ± 4.6 7.29 ± 0.036 7.26 ±O.U56 7.26! O.05S" 7.27 ± (l.04R 
20 ppm NO 49.2±2.9 53.1 ±6.0 55.5 ± 6.6+ 5L2±4.9> 7.29±0.£l.tO 7.26 ± (1.057 7.27 to.056· 7.28 ± 0.0-16· 
30 ppm NO 49.9±3.5 54.5±5.9 54.5 ± 5.8' 5tH 4.9+ 7.28 ± OJl47 7.25±OmS 7.27 ±0.05S· 7.29 ± O.fI.l4· 
4(lppmNO 50.4±3.7 55.5 ± 6.4 53.4 ± 6.0' 50.7 ± 4.6" 7.28 ± 0.043 7.25 ± 0.0.'17 7.27 ±O.U5S· 7.29 ± O.().jO' 
Oppm NO 60.8±7.5 58.6 ± 6.6 56.1±6.2 52.2 ± 4.5 7.25 ±0.044 7.23 + 0.059 7.26 ±().U54 7.2R ±U.tIJ6 
Shunt (%) Mixed venous 02 saturation (%) 
Baseline: 43.4±7,1 42.3 ± 7.3' 32.4 ± 5.4· 26.5 ± 3.7· 48.5±5Y 54.9±9.6 65.7 ± 4.7 71.2±J.9 
UquiVent: 5mUkg tOmUkg 15 mllkg 20 mllkg 5mllkg 10 ml/kg ISmllkg 2Umllkg 
Oppm NO 37.2±6.2 32.8 ± 6.0 25.6 ± 3.7 19.2± 1.9 60.2 ± 7.5 58.9 ± 7.0 67.5 ± 5.0 73.0 ± J.J 
10 ppm NO 32.7±5.6 25.7 ± 3.9 21.5 ± 2.7 19.511.9 63.5 ± 7.5 6-t6 ± 6.2 73.1 ± 3.6 77.6 ± 4.3-
20 ppm NO 28.7 ± 4.6 25.7 ± 3.5 20.6 ± 2.1 16,4f 1.1 63.9 ± 6.7 64.9 ± 5.2 xu." ± S.6' 7S.1 ±3.2 
30 ppm NO 27.4 ±4.1 24.1 ±3.J 21.4 ± 2.S 16.2 ± J.I 63.4±7.\ 66.1-i± S.t) 76.2 ± 3.3' 76,4 ± 2.t} 
40 ppm NO 28.4 ± 4.2 24.1 ±3.1 22.7 ± 2.5 16.21 1.2 62.9 ± 7.0 70.0 ± 4A 7S.7± 3.8 76.U ± 3.7 
Oppm NO 42.3 ± 7.3 32.4 1 5.4 26.5 ± 3.7 19,4 ± 2.3 54.9 ± 9.6 65.7 + 4.7 71.2 ± 3.9 72.5 ± 3.X 
Arterial oxygen content (mlldl) 
Baseline: 12.1 ±0.9 13.7± 1.1 15.7 ± 1.2 16.1 ± 1.2 
UquiVent: 5 mllkg 10 mllkg ISmllkg 20 m\lkg 
o ppm NO 133±0.9 15.1 ± 1.0 16.5± IJ 17.HI.O 
Wppm NO 15.1 ±0.9· 16.5 ± 1.1 * 16.S± I.J 17.0± I.U 
20 ppm NO 15.4 ±O.S· 16.2± 1.1* 17.1 ± 1.1 17.1 ± 0.9 
30 ppm NO 15.8±0.9' 16.3 ± 0.9' 16.7 ± \.2 17.2 ± 11.9 
40 ppm NO 16.0 ± 0.9· 16.4 ± 0.9· 16.7 ± 1.0 16.9 ± 1.0 
Qppm NO D.7± 1.1 15.7 + 1.2 16.3± 1.2 16.S + \.0 
• p <OJ)5 I> Baseline represents th~ oala prior to <In incr~'as~' in I.iljuiVem 
., Intragroup comparisons ANOVA with Dunnett poslIesl if ANO· uose 
VA p < n.os. using the data after each increment of LiquiVent <IS 
control 
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Figure 1. Artenal oxygen tension (PaOI) (a), and mean pulmonary artery pressure (MPAP) (b) in relation to the 
amount of LiquiVcnt followed by different NO concentrations in parts per million (ppm) in pigs (n=6) with acute 
lung injury. Bars represent increments of per flub ron. Data are means ± sm.'I. Intra-group comparisons ANOVA 
with Dunnet post-lest if ANOVA (p<O.05), using the data after each increment of perflubron with the first setting 
o ppm NO as control 
+=p <0.05. 
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40/5 015 0110 10/10 20/10 30/10 
Nitric Oxide (ppm)/LiquiVent (mVKg) 
Figure 2. Print-out from the online blood gas monitor, showing the effect of different doses of inhaled NO 
(0, 10,20,30 ppm) on pH, PCO, and PO, in one pig ventilated with 10 ml/kg LiquiVent. 
Figure 3. Print-out from the on-line blood gas monitor, showing the effect on pH, PCOI and POI when 
switching from 40 to 0 ppm NO in one pig ventilated with 5 mltkg LiquiVent. 
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Table 2 Data on hemodynamicparametenin pigs(n:; 6) with AU following the combinationor~rf1ubron (LiquiVent) and NO.' Val-
ues arc mean ± SEM 
Mean arterial pressure (rnmHg) Systolic pulmonary pressure (mmHg) 
Basclincb; 96.2 ±5.4 91.0±6.8 95.5±5.1 91.7 ± 3.8 37.8 ± 3.4 39.4 ± 3.6· 37.6±4.8 33.4 ± 4.1 
liquiVcnt: 5 mllkg 10 mIlkg 15 mlfkg ZOmUkg Smllkg JOmUkg IS mllkg 20 mllkg 
Oppm NO 94.0±5.0 97.8±4.7 95.7±6.1 93.5 ± 4.4 32.0± 1.7 33.8±4.2 33.4 ± 3.6 31.8±3.1 
10 ppm NO %.8 ±5.S 98.0±6.6 93.0 ± 6.3 89.3 ± 3.8 27.0±0.8 32.2±3.6 28.0± 2.5 28.4 ±25 
20 ppm NO 95.8 ±6.0 92.5 ±5.0 93.3 ± 5,4 90.7±3.9 28.0± 1.9 31.0 ± 4.0 27.4 ± 2.1 28.2±2.5 
30 ppm NO 91.3 ± 7.7 93.2 ± 7.3 93.8±5.1 87.7 ±5.9 28.2 ± 25 32.2 ± 3.7 26.8 ± 3.0· 27.0±3.4· 
40 ppm NO 93.8 ± 5.2 94.7 ± 6.2 9O.5±3.1 89.0±7.3 30.4 ±2.9 31.4 ± 4.1 30.0 ± 3.0 27.8±2.6 
Oppm NO 91.0 + 6.8 95.5 ± 5.1 91.7±3.8 90.0 ± 6.4 39.4 ± 3.6 37.6 ± 4.8 33.4 ± 4.1 JD.6 ± 3.7 
Diastolic pulmonary pressure (mrnHg) Central \'enous pressure (mmHg) 
Baseline: 24.0± 1.6 24.4 ±3.4 22.8±4.1 17.6±3.0 4.5 ± 1.1 4,S± 1.0 4.H 1.4 5.3 ± 1.2 
UquiVent: 5mllkg IOmUkg 15mifkg 20mUkg 5mllkg 10 m1fkg 15 mUkg. 20mllkg 
OppmNO 20.6 ± 2.0 22.0 ±3.3 20.8 ± 3-2 17.6±3.0 4.2± 1.1 4.3± 1.1 5.0± 1.4 5.2 ± 1.2 
lOppm NO IS.0±1.8 17.0±5.4 17.0±2.5 15.8 ± 1.8 4.0± 1.4 5.8± 1.0 4.7 ± 1.3 3.7 ± 1.0 
20 ppm NO 18.6±2.0 19.4 ± 3.9 16.6 ± 2.7 14.6 ± 1.9 13± ].0 5.H 1.1 5.2 ± 1.3 6.J ±0.9 
30 ppm NO 18.8± 1.8 19.8 ± 3.6 15.2± IY 14.2 ± 2.6 3.5 ± 1.1 4$ ± 1.0 5.5 ± 1.5 4.8±0.6 
40 ppm NO 19.4 ± 2.2 17.8±3.3 15.2 ± 2.5· 14.2 ± 1.6 4.0± 1.2 4.J± LI 4.7± 1.3 6.3 ± 0.5 
Oppm NO 24.4 ± 3.4 22.8±4.1 17.6±3.0 19.4 ± 2.7 4.8± 1.0 4.5 ± 1.4 53 ± 1.2 ".2iOA 
Heart rate (beatymin) CO (lfmin) 
Baseline: 152.5 ± 10.2 156.7 ± 10.0 143.7 ± !!.! 14H.7 ± 8.6 l.t ! (1.1 0.<)10,\ 1.010.2 1.1 iO.l 
UquiVent: 5 mllkg 10 mllkg 15 ml/kg 20mllkg 5mlfkg 10 ml/kg l5ml/kg 20 ml/kg 
OppmNO 152.0 ± lOA 153.7 ± 9.7 144.7 t 10.2 152.X ± 10.4 1.0±0.1 0.9 to.2 1.010.1 1.1 ±IU 
10 ppm NO 150.7 t 85 149.8±9.2 144.1i ± 8.7 152.2 ± 9.8 1.0±0.2 1.0±0.2 1.1 ± 0.1 1.1 ±0.2 
20 ppm NO 155.5±11.3 148.8±8.1 145.7 ± 8.U 149.2 ± 10.0 1.0iO.1 1.1 ±O.2 LI iO.l I.U±O.2 
30 ppm NO 155.8±11.4 144.21 10.3 146.2 ±KI 149.2 ± 9.6 0.9 ± 0.2 1.0±0.2 l.O±O.1 1.1l±0.1 
40 ppm NO \52.3 ± 10.4 139.2 ± 8.4' 149.2±ID \52.8± 11.7 0.9 ± 0.2 1.0±0.\ I.\±O.I 1.1 ±O.] 
o ppm NO 156.7 ± 10.0 143.7±IU 148.7 ± 8.6 140.8 ± 6.7 0.9±0.1 1.0±0.2 1.1 ±O.I J.[ ± 0.2 
Pulmonary wedge pressure (mmUg) PVR (dynes..Y(m') 
Basdin~; 6_2 ±0.5 6.6± U 5A± IJI 5.2 ± U) IS28 ± 249 2452.i41~ 2092!414 lfi03.i315 
liquiVent: 5ml/kg 10 ml/kg ISml/kg 20ml/kg 5mllkg iO mllkg 15mllkg 211 mllkg 
o ppm NO 5.2 ± 0.2 6.0± 1.0 5.6±H.7 '.8 0.9 1743 ± 223 2407 ± 5R6 1R71t4Q<{ 1649± 33'l 
iO ppm NO 4.0 ±0.6 5.6±0.9 5.21 l.l 
" 
1.0 1754 ± 428 1999 ± 505 14m ± 234 14(,[ ± 270 
20 ppm NO 6.0±O.9 5.0 to.S 5,2 ± 1.2 5JI 0.8 15461272 1859 ± 557 JJ53 1 225' 145fli 2'J~ 
30 ppm NO 6,0 ± 0.9 5.U ± 1.0 4.6 ± 1.11 4.(, 1.0 1742 ± 324 1913±435 14141232 13SI1 1 2X4 
40 ppm NO 5.611.0 5.41 1.0 4.4.i 1.1 5A 0.7 1946 ± 433 1732 ± 369" 13RS ± 260 12')9 ± 225 
o ppm NO 6.6±1.J 5All.11 5.2 ± 1.1) 4.6 0.9 2452±418" 2092±414· 160)f JI5 1755 i 3M 
'p<0,05 h Baseline represents the data prior to an innellse in UquiVcnt 
'!ntragroupeomparisonsANOVA with Dunnell post· test if ANO· dose 
VA (j1 < 0.05). using the data aller each increment of !.iq~iVef!l!is 
control 
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Discussion 
The model of induced ALI used in the preseut study leads to decreased arterial oxygenation as 
a result of end-expiratory collapse due to surfactant deficiency, and is comparable to the changes 
found in ARDS [14-16J. 
The results of the present study show that PLY is au effective therapy, leading to a dose-
dependeut improvement iu gas exchange in surfactaut-depleted pigs. These findings confrnn the 
results from previous reports on PLY [5, 8J. The beneficial effect ofPLV on gas exchange is 
mediated through the physical presence of PFC in the alveoli preventing them from expiratory 
collapse. This collapse usually accounts for two-thirds of the time of the respiratory cycle. The 
high dissolved volume of oxygen (perflnbron; 55 mlllOO ml at 37'C and at 1 atmosphere of 
pressure) continues to oxygenate the blood during the expiratory period, resulting in improved 
arterial oxygenation. Furthennore, PFC enhances alveolar recmitmcnt in the surfactant-deficient, 
atelectatic lung [17J. 
Pulmonary hypertension due to pulmonary vasoconstriction andlor widespread vascular 
obstruction is a common finding in severe ALlor ARDS [18]. Due to an increased 
microvascular filtration pressure pUlmonary hypertension, can increase the accumulation of 
extravascular lung water [19]. This extravascular lung water may lead to worsening oxygenation, 
resulting in further increase in hypoxic vasoconstriction. Furthermore, pulmonary hypertension 
can cause right ventricular dysfunction [20J. Because of its selective pulmonary vasodilating 
properties inhaled NO was suggested as a therapy for pulmonary hypertension [13J. NO-therapy 
is feasible because NO is short acting, is easily titrated to its effect and can readily be removed 
from the lungs [2IJ. 
Our study also shows that administration of NO, after pretreatment with PFC, results in 
a further improvement in gas exchange. with a simultaneous decrease in pulmonary artery 
pressures. The successful combination of NO and PFC was first reported in a hypoplastic 
congenital diaphragmatic hernia lamb model [9]. However, this lamb model is a neonatal model 
in which the pathophysiology of respiratory failure is different from that of ALI in adults. 
Figure la shows that the maximal effect of additional NO inhalation resulted in a more 
than 100% increase in PaO, values (48.9 ± 10.6 to 177.1 ± 42.1 mmHg) at the 5 ml/kg 
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perflubron dose. A similar increase in Pa02 was obtained with the next increment of 5 mllkg 
perflubron alone. At the higher doses of pertlubron, additional NO inhalation resulted in a 
smaller increase (30·50%) in Pa02 values, whereas each subsequent increment in pertlubron 
showed an equal increase in Pa02 as obtained with NO administration at the previous perflubron 
dose. These effects indicate that, after an initial improvement in Pa02 by administration of 
peJtlubron a further increase in oxygenation can be obtained by either a low dose of perflubron 
in combination with NO or a higher dose of perflllbron without NO. 
The well-known finding that high NO concentrations decrease PaO, by diffusing to 
nonventilated lung regions, dilating the vessels in these areas, resulting in an increase in right-to-
left shunt [22J, was observed in our experiments only at the 5 mllkg pertlubron dose. This effect, 
however, was not significant. 
The improvement in COl elimination by administration of pertlubron was enhanced by 
additional NO inhalation resulting in an improvement in pH. The findings proved to be 
statistically significant; however, we can not contribute this effect to additional NO inhalation 
alone. Because of the fact that during the study period minute ventHatiou was not changed, 
baseline PaCOz values varied widely. Therefore we question the significance of these findings. 
Perflubron has a high solubility for respiratory gases. To date there is no information 
available on the solubility of NO in PFC, nor were we able to measure the amount of NO 
dissolved. However, online bloodgas monitoring showed that changes in NO concentration 
resulted in rapid changes in PaO,. (Fig 2 aud ). This rapid response to NO was similar to the 
time-response curves reported by Gerlach et al. (1-2 min)[21 J. The rapid response to changes 
in NO concentration in our study shows that there is no clinically important effect of PFC on the 
time-response effect of NO, indicating that the total amount of NO dissolved in perllubron must 
be low. When applying partial liquid ventilation with perllubron higher concentrations of 
inspired oxygen are needed to maintain a high oxygen diffusion gradient. in order to adequately 
oxygenate the blood. Higher inspired concentrations of oxygen are known to react rapidly with 
NO to form toxic redox fonns of NO [23J. In the present study no measurements were made to 
quantify the transformation of NO. However methaemoglobin concentration, as well as mixed 
expired NO, concentration both remained low «5% and <5 ppm respectively). Further 
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discussion of the safety of inhaled NO alone or in combination with PFC is beyond the scope 
of this paper. The toxicity of nitrogen oxides has recently been reviewed [23]. 
In conclusion: This study showed that the combination of perflubron and NO has an 
cumulative effect in increasing gas exchange and lowering pulmonary artery pressures. Due to 
its additive effeet it may even be possible to reduce the amount of PFC's by adding NO to get 
a certain oxygenation which normally results after higher doses ofPFC. However, before this 
combination may be used routinely to treat patients, lllore basic information is required about, 
for example, what is happening with NO in the PFC, is there any accumulation of possible 
radicals in the PFC, or what is the solubility of NO in PFC. 
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Summary 
Partial liquid ventilation (PLV), a hybrid technique that superimposes gas ventilation on lungs 
that are filled with perfluorocarbons (PFCs), has been shown to improve oxygenation in animal 
models of acute lung injury (ALI). Several physico·chemical properties of pertluorocarbons are 
considered important in their capability to improve pulmonary function. This study was 
performed to allow a direct comparison of four perfluorocarbons with different physico-
chemical properties during PLY with respect to gas exchange. lung mechanics, alveolar protein 
influx and surfactant system. Thirty-six adult male Sprague-Dawley rats were anesthetized, 
tracheotomized and submitted to pressure controlled mechanical ventilation at an FiOl of 1.0, 
30 breaths/min, lIE of I :2, a positive inspiratory pressure (PIP) of 26 cmH20, and a PEEP of 6 
cmH20. Acute lung injury was induced by repeated lung lavages to obtain a PaO, < 100 rmnHg. 
After steady state, animals were raudomly divided (each group n=6) to receive either APF-140, 
APF·215, APF·175A or FC 3280 intratracheally, in a dose of 15 ml/kg body weight. One group 
received no PFCs, but was ventilated with a PIP of 28 cmH20 and a PEEP of 8 ClnH20 
(veutilated control group). Gas exchange was determined hourly during a 4 h observation period. 
In the groups that received PFCs, evaporationallosses were compensated for. Instillation of APF 
175A resulted in a significant and sustained improvement in gas exchange, an increase in total 
lung capacity, and prevented an increase in alveolar protein influx. Instillation of APF 140 
caused a transient increase in oxygenation and prevented an increase in alveolar protein influx, 
but did not increase total lung capacity. In the other two pertluorocarbon treated groups, gas 
exchange did not improve and no differences were found compared with the ventilated controls. 
We conclude that the efficacy of pertluorocarbons to improve pulmonary function cannot be 
predicted based on their physico·chemical properties. 
126 
Comparing four diJferellf perjlllorocarbolls 
Introdnction 
In the last few years, several studies have investigated the effect of partial liquid ventilation 
(pLY) in animal models of acute lung injury (ALI). Filling the lungs up to the level of functional 
residual capacity with perfluorocarbons, followed by gas ventilation, has been shown to improve 
gas exchange and lung mecharucs, and to result in less lung injury [1-4]. In clinical studies, some 
of these beneficial effects have been confirmed in patients with acute respiratory distress 
syndrome (ARDS) [5, 6, for review see 7]. 
The exact mechanisms by which pertluorocarbons improve gas exchange and lung 
mechanics, and the way in which these are influenced by the physico-chemical properties of the 
perfluOfocarbons, have not yet been elucidated. Different pertluorocarbons with a wide range 
of physico-chemical properties are available for experimental use, thus allowing evaluation of 
these different profiles and their efficacy. One of these perfluorocarbons, FC 3280 has shown 
to improve gas exchange and lung mechanics, and to attenuate lung injury [8, 9]. Others 
perfluorocarbons have not yet been tested for use in partial liquid ventilation. 
The aim of the present study was to compare four pertluorocarbons with different 
physico-chemical properties on their efficacy in improving pUlmonary function. We performed 
the study in lung lavaged rats, which were submitted to partial liquid ventilation under well 
standardized experimental conditions. We used the rat model of surfactant deficiency which has 
proven to be a convenient and consistent model of ALI. Gas exchange was assessed during 4 
hours of partial liquid ventilation, after which lung mechanics, alveolar protein influx, and 
several parameters characterizing the surfactant system were determined. 
Methods 
The study protocol was approved by the University's animal experimental committee, and the 
care and handling of the animals conformed with European COlllmUluty guidelines (86/609IEC). 
The study was performed in 36 adult male Sprague-Dawley rats (body weight 270-330 g). After 
induction of anaesthesia with 2% enflurane and 65% nitrous oxide in oxygen, a polyethylene 
catheter was inserted into a carotid artery for drawing arterial blood samples. Before 
tracheostomy, the animals received 60 mglkg pentobarbital sodium, i.p. (Nembutal®, Algin BY, 
Maassluis, the Netherlands). After tracheostomy, muscle relaxation lVas induced by 
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pancuronium bromide I mglkg, i.m. (pavulon®, Organon Teknika, Boxtei, the Netherlands) 
immediately followed by connection to a ventilator. The animals were mechanically ventilated 
with a Servo Ventilator 300 (Siemens-Elema. Soina, Sweden) in a pressure constant time-cycled 
mode, at an inspired oxygen concentration (FiO,) of 1.0, frequency of 30 breaths per minute 
(bpm), peak inspiratory pressure (pIP) of 12 cm H,O, positive end-expiratory pressure (PEEP) 
of 2 cmH,O, and inspiratory/expiratory (IIE) ratio of I :2. Anaesthesia was maintained with 
pentobarbital sodium 40 mg/kglh, Lp.; muscle relaxation was maintained with pancuroniulll 
bromide 1 mg/kg/h, i.m. Body temperature was kept within normal range by means of a heating 
pad. Immediately after induction of anaesthesia one group of animals (11=6) was killed to serve 
as healthy controls. 
Acute lung injury was induced in the remaining animals by repeated brancho-alveolar 
lavage (BAL) (32 mllkg) with wrum saline (37°C), according to Lachmann and colleagues [10]. 
BAL was repeated as often as necessary to produce a PaO,<lOO mmHg at a PIP and PEEP of 
26 and 6 cmH20, respectively. \Vithin 10 min after the last lavage, 30 animals were randomised 
to receive an intra-tracheal bolus of 15 mllkg of one of four perfluorocarbons, with different 
physico-chemical properties (Table I), or to serve as ventilated controls (each group 11=6). For 
administration of the bolus of perfluorocarbons, the animals were disconnected from the 
ventilator, immediately followed by fe-connection to the ventilator. To compensate for 
evaporationallosses of perfluorocarbon during the study period, an hourly check was made to 
establish whether a meniscus was visible just above the tracheostomy-cannula at disconnection 
from the ventilator. If this was not the case, perfluorocarbon was administered in boluses of 3 
mllkg until the meniscus was visible. In the ventilated control group, which did not receive 
pertluorocarbons, ventilator pressures were increased by 2 cmH,O (PIPIPEEP of 28/8 cmH,O) 
to maintain Pa02 above 50 mmHg. These ventilator settings were not changed throughout the 
remaining study period; this group served as ventilated controls. 
Arterial blood gas samples were taken prior to lavage, after lavage, and hourly for 4 h. 
The samples were analysed for arterial oxygen tension (Pa02) and arterial carbon dioxide tension 
(paCO,) on an electrochemical blood gas analyser (ABL 50S, Radiometer, Copenhagen, 
Denmark). 
At the end of the experiment, the animals were killed by an overdose of pentobarbital. 
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Table 1. Physico-chemical properties of the tested perfluorocarbons. All values are at 25°C. 
Surface tension 
(dynes/em) 
Vapor pressure 
(mmHg) 
Density 
(glml) 
O2 solubility 
(mIIlOO mJ PFC) 
APF 140 APF 175A 
(Perf1uorodecalin) (Perfluorodimethyl-
decalin) 
19.3 20.5 
6 0.67 
1.93 1.98 
49 35 
APF215 
(Perfluoro-
phenantrane) 
21.6 
0.12 
2.01 
37 
FC 3280 
12 
61 
1.75 
40 
APF-140, APF-17SA and APF-2IS were provided by F1uoro-Seal Inc, Round Rock, USA. FC-3280 was 
provided by 3M Chemical Products, Neuss, Gennany, 
Static pressure-volume curves were recorded using conventional techniques [10]. Total lung 
capacity (TLC,,) was defined as lung volume above collapsed volume at inflation with a 
distending pressure of 35 cmH,O. After the pressure-volume recordings BAL was performed 
five times with saline-CaC\, 1.5 mmol/litre. The active surfactant component in the BAL fluid 
was separated from the non-active surfactant component by differential centrifugation followed 
by subsequent phosphorus analysis, and the ratio between non-active and active components 
(small aggregate to large aggregate ratio = SMA ratio) was calculated, as previously described 
by Veldhuizen and colleagues [II]. The protein concentration of the BAL fluid was determined 
using the Bradford method (Bio-Rad protein-assay, Munich, Germany) [12]. 
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Statistical analysis was performed using the Instat statistical package. Inter-group 
comparisons were analysed with ANOV A and intra-group comparisons were analysed with 
repeated measures ANOV A. If ANOV A resulted in a p < 0.05 a Tukey-Kramer post-test was 
performed. All data are reported as mean ± SD and p < 0.05 was considered statistically 
significant. 
Results 
Blood gas values before and immediately after lavage were comparable for all five ventilated 
groups (Fig. I and Table 2). All animals survived the study period. In the groups treated with the 
perfluorocarbons APF 140 and APF 175a, PaO, increased significantly after lavage, and 
remained stable in the APF 175A group but decreased significantly in the APF 140 treated 
group. In the groups treated with APF 215 and Fe 3280, as well as in the ventilated control 
group, PaO, did not improve after lavage. 
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Figure 1. PaOl values (mmHg, mean ± SD) for all ventilated groups. Conlrol = ventilated control group. 
*, p<O.05 vs ventilated controls. 
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Pertluorocarbon was substituted periodically to compensate for the evaporational loss 
and the substitution doses (mUkglh) were 1.6 ± 0.1 (APF 140), l.l ± 0.4 (APF 175A), and 3.3 
± 0.5 (FC 3280). In the APF 215 treated animals no substitution was necessary. 
PaC02 data are given in Table 2. After lavage, PaC02 increased significantly in all groups. 
Administration of APF 140 and APF 175A resulted in a significant decrease ofPaC02 (Table 
2). 
Table 2. PaC02 values in the ventilated groups (mean ± SD, nunHg) 
Before lavage 
After lavage 
I h 
2h 
3h 
4h 
Ventilated 
Control 
45 ± 5.1 
67 ± 11.4 
59 ± 12.7 
60 ± 14.2 ' 
63 ± 15.1 
63 ± IS.1 
APF 140 APF 175A 
39 ± 4.1 44 ± IO.S 
66 ± 5.9 72 ± 12.9 
44 ± 5.1 ' 53 ± I3.1 ' 
41 ± 4.2 ' 50 ± 13.6 ' 
46 ± 4.3 ' 48 ± 14.2 ' 
47 ± 2.S ' 47 ± 12.4 ' 
APF215 
39 ± 2.3 
67 ± IO.S 
64 ± 12.8 § 
63 ± 10.9 ' 
69 ± 11.5 " 
70 ± 10.3 " 
h, hour. § vs. APF 140; 1 vs. APF 175a; Intra-group comparison: * vs. aftcr lavage 
FC 32S0 
45 ± 4.5 
71 ± 13.7 
49 ± 5.2 
60 ± 7.3 § 
66 ± 3.7 • 
54 ± 12.1 
Figure 2 shows the detlation limbs of the pressure-volume curves. Lung volume in the 
healthy controls exceeded the lung volume in all other groups. TLC" was significantly increased 
in the APF 175A treated animals compared to the ventilated control group, but not in the other 
perfluorocarbon treated groups. At deflation below 10 cmH20. there was no significant 
difference in lung volume between the ventilated control group and any of the perfluorocarbon 
treated animals. 
The protein concentration ofBAL fluid was significantly increased in the APF 215, FC 
3280 and ventilated control groups, but not in gronps APF 140 and APF 175a, compared to the 
healthy controls (Fig. 3). The SNLA ratio, which is the ratio between non-active and active 
surfactant components, was increased in all ventilated groups compared to the healthy controls 
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Figure 2. Deflation limbs from the pressure-volume curves, mean ± SD. Volume is lung volume above 
functional residual capacity. 6=healthy controls; O=vcntilated controls; V:::::.AFF 140; II=APF 175A; 
+=APF 215; e=FC 3280. For all pressures, volume was significantly decreased in all ventilated groups 
compared to the healthy controls. *, p<O.05 vs ventilated controls. 
1 
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Control Control APF 140 APF 175A APf 215 Fe 3280 
Figure 3. Protein concentration (mean ± SD) of the BAL fluid of the different groups. *. p<O.05 VS. 
healthy control group. 
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but there were no differences between the ventilated groups. The total amount of phosphorus 
in the BAL fluid, that was measured to quantify the phospholipid-containing surfactant system, 
was obviously decreased in alliavaged and ventilated groups compared to the healthy controls 
but there were no differences between the ventilated groups (Table 3). 
Table 3. Data on pulmonary surfactant: Total phosphorus, and small aggregate to large aggregate ratio 
(SNLA ratio) in the six study groups (mean ± SD). 
Healthy control 
Ventilated control 
APFI40 
APF 175a 
APF 215 
FC 3280 
• p<O.05 vs. Healthy control 
Discussion 
Total phosphorus 
(flmollml) 
0.14 ± 0.06 
0.05 ± 0.01 
0.05 ± 0.01 
0.05 ± 0.01 
0.09 ± 0.03 
0.05 ± 0.01 
SAILA ratio 
0.3 ±O.I 
1.5 ± 0.4 * 
1.8 ± 1.0 * 
2.5±0.8 * 
1.6 ± l.l * 
2.5 ± 0.7 * 
We could not identify a single factor that predicts efficacy of a perlluorocarbon to improve gas 
exchange and lung mechanics, or to prevent alveolar protein influx, during partial liquid 
ventilation. Instillation of APF 175A results in a significant and sustained improvement in gas 
exchange and total lung capacity, and prevents an increase in alveolar protein influx. Instillation 
of APF 140 caused a transient increase in oxygenation and prevented an increase in alveolar 
protein inllux, but did not increase total lung capacity. In the other perlluorocarbon treated 
groups, no differences were found compared with the ventilated controls. 
The improvement in gas exchange in the APF 140 and APF 175A treated animals is in 
accordance with previous reports on partial liquid ventilation in animal models of ALI [1-4, 8, 
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9]. Recent studies have shown that after intra-tracheal instillation, perfluorocarbons are 
predominantly distributed to the dependent regions of the lung, leading to recruitment of 
collapsed alveoli with an increase of end-expiratory lung volume, thereby reducing 
transpulmonary shunt and thus improving gas exchange [13, 14]. In the present study, in the 
APF 140 treated animals a decrease in oxygenation was seen after an initial improvement. In 
previous studies it was noted that, when perfluorocarbons are lost from the lungs by evaporation, 
alveolar collapse fe-occurs leading to a decrease in PaOz [3]. However, in the present study 
evaporationallosses were compensated for each hour by retilling the lungs with perfluorocarbon 
until a meniscus was visible above the tracheostomy catheter. Therefore, the decrease in PaOz 
over the 4 h ventilation period in group APF 140 cannot be explained by evaporation. 
The lack of improvement in oxygenation in the APF 215 and FC 3280 treated animals 
is striking given their physico-chemical profile. Several mechanisms could hamper an 
improvement in oxygenation, such as insufficient oxygen solubility or an increase in 
ventilation/perfusion mismatch due to compression of pulmonary vessels by the 
perfluorocarbons. However, oxygen solubility was comparable in the tested perfluorocarbons. 
and although APF 215 is the perfluorocarbon with the highest density, it is comparable to the 
density in APF 175A which showed a sustained improvement in PaO, (Fig I). However, in 
previous studies in lung lavaged pigs an improvement in oxygenation was found after instillation 
ofFC 3280 [8, 9]. 
It has been hypothesized that after intra-tracheal instillation of perfluorocarbon, a thin 
film covering the entire alveolar surface of the non-dependent part of the lung is formed as a 
result of evaporation of perfluorocarbon from the lower lung parts [3]. Since perfluorocarbons 
have a low constant surface tension, this results in a reduction of the retractive forces in the 
surfactant deficient lung, thus al10wing large volume changes with only small changes in 
pressure. This indicates that perfluorocarbons with the lowest surface tension should lead to the 
highest TLC35• In the present study however, APF 175A, which has almost the highest surface 
tension of all tested pertluorocarbons, was the only perfluorocarbon with an increase in TLC35 
compared to the ventilated control group (Fig. 2). 
The presence of non-compress able perfluorocarbons in the alveoli prevents them from 
end-expiratory collapse. There is evidence that repeated alveolar collapse leads to the OCCllrrence 
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of shear forces, which have been shown to damage the alveolar-capillary membrane and lead to 
alveolar protein influx [15, 16]. In the APF 140 and 175A treated animals, in which 
perfluorocarbons prevented alveolar collapse during a large part of the ventilation period as 
indicated by the sustained improvement in PaOb alveolar protein influx was not increased 
compared to healthy controls (Fig. 3). In the APF 215 and Fe 3280 treated groups, as well as 
in the ventilated control group, repeated alveolar collapse is likely to have occurred given the 
lack of improvement in PaOl, which is in accordance with the increase in alveolar protein influx 
(Fig. 3). 
In a previous study, it was found that 3 h of partial liquid ventilation increased the loss 
of radioactive labeled phospholipids from the lungs of healthy rabbits [17]. In another study, it 
was found that PLY for 5.5 h in healthy rabbits enhanced surfactant phospholipid production 
[18]. However, in the present study no significant differences were observed between the 
ventilated groups in total phosphorus or SMA ratio (Table 3). We therefore conclude that 4 
h of PLY with all tested perfluorocarbons in this model of surfactant deficiency had no effect 
on the pulmonary surfactant system, compared with conventional ventilation, but the exact 
effects of partial liquid ventilation on the pulmonary surfactant system remain to be elucidated. 
In conclusion, it proves difficult to predict the efficacy of perfluorocarbons for use in 
partial liquid ventilation based on their physico-chemical properties. PLY with APF 175A 
resulted in a sustained improvement in gas exchange, an increase in TLC35 and a decrease in 
alveolar protein influx, suggesting it might be useful for clinical purposes. However, future 
studies remain necessary to elucidate the exact mechanisms involved. 
Speculation 
Most published experimental and clinical data on partial liquid ventilation were obtained with 
Perflubron. Although Pertlubron was not tested in the present study, our group earlier 
investigated Perflubron in lung-Iavaged adult rabbits. The results that we obtained on PaO, with 
APF 175A are comparable with the results that were obtained with Perflubron. In the laller 
study, TUtUncU et al. administered Perflubron in a dose of 12 mlIkg to lung-Iavaged rabbits, who 
were subsequently ventilated with a PEEP of 6 cm1l,O (Fig. 4) [2]. In the Perflubron treated 
animals a decrease in Pa02 was observed 4 h after lavage, which was attributed to evaporational 
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loss of Pertlubron, since no substitution doses were administered in that study. The data from 
the present study show that for improving oxygenation, APF 175a could be a useful alternative 
for Perflubron. 
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Figure 4. PaQz values (nmlHg. mean ± SD) from APF 175A treated animals from the present study, and 
Pcrflubron treated animals. Striped bm=lung lavaged rabbits treated with Perflubron (12 mllkg); hatched 
bar~lung lavaged rats treated with APF 175 A ((15 mllkg) (from reference [3]). 
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SUI111nal'Y and conclusions 
The central role of the pulmonary suti~1ctant system in the development and progression 
of the acute respiratory distress syndrome (ARDS) is outlined in Chapter 1. In ARDS, a lack of 
active surfactant leads to an increase in retractive forces in the lung resulting in alveolar 
collapse. 
Mechanical ventilation is mandatory in this situation; however, if alveoli are not stabilized 
during expiration repeated alveolar collapse will occur, and open lung units will be 
overdistended when large tidal volumes are used in partially collapsed lungs. The pulmonary 
surfactant system is vulnerable to damage by mechanical ventilation, especially in conditions 
where its function is already compromised, such as in ARDS. An additional decrease in 
surfactant function caused by mechanical ventilation can lead to progression of the syndrome; 
that is why ARDS might be, in part, a product of our therapy - rather than the progression of the 
underl)ing disease. A physiologic rationale for ventilation strategies that aim to prevent loss of 
surfactant function is discussed, as well as the possibilities for substitution of the lost active 
surfactant. 
Chapter 2 presents a study which investigated whether prevention of end-expiratory 
alveolar collapse by applying a high enough positive end-expiratory pressure (PEEP) during 
initiation of ARDS could attenuate the decrease in pulmonary function. During surfactant 
depletion by repeated lung lavage in rats, end-expiratory alveolar collapse was prevented in one 
group by mechanical ventilation with a PEEP of 15 cmH,O (open lung group), and compared 
with a group ventilated with a PEEP of 8 cmH,O which did not prevent alveolar collapse 
(ventilated control group). After surfactant depletion, ventilation was continued for 4 hours. It 
was shown that application of the high PEEP prevents a decrease in gas exchange, attenuates the 
deterioration in lung mechanics, and attenuates an increase in protein leakage, compared with 
the ventilated control group. TIle attenuation of the decrease in lung mechanics in the open lung 
group was attributed to the reduction in inhibition of the remaining pulmonary surfactant by 
plasma proteins. 
Mechanical ventilation with high PEEP, partial liquid ventilation and exogenous 
surfactant therapy have been shown to improve oxygenation in animal models of acute lung 
injury, and are therefore currently under investigation in clinical studies. In Chapter 3, these new 
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treatment strategies were compared for their effect on gas exchange, lung mechanics, lung 
injury, protein leakage, and the surfactant system. Following induction of acute respiratory 
failure by repeated lung lavage during ventilation with a PEEP of 6 cmH20, the rats were either 
ventilated with a high PEEP that kept the lungs open, or received exogenous slllfactant (120 
mg/kg) followed by ventilation with nnchanged ventilator settings, or received perfluorocarbon 
(15 mllkg) followed by ventilation with unchanged ventilator settings (plli1ialliquid ventilation). 
These three groups were compared with a control group that was ventilated with a low PEEP. 
Although all three strategies improved oxygenation, only ventilation with high PEEP and 
exogenous surfactant therapy prevented transfer of proteins into the alveoli, whereas partial 
liquid ventilation did not. The conversion of active into non-active surfactant aggregates was 
increased in the partial liquid ventilation group and the group ventilated with high PEEP, but 
obviously not in the surfactant-treated group. Lung injury score was reduced in the partial liquid 
ventilation group and the surfactllilt group compared with the groups that were ventilated only. 
It was concluded that although all three strategies improved oxygenation to pre-lavage values, 
their impact on pulmonary function differed markedly. Only exogenous surfactant therapy led 
to an improvement in all measured parameters. 
Using the same model as in Chapter 3, the difference in protein leakage into the alveoli 
between the animals that were ventilated only with high or low PEEP in Chapter 3 was further 
evaluated in Chapter 4. Because surfactant function is known to be inhibited by plasma proteins, 
it was investigated whether the efficacy of exogenous surfactant in improving pulmonary 
function, when administered after 4 hours of mechanical ventilation, could be enhanced by 
application of high PEEP compared to a ventilated control group. Two groups of rats underwent 
whole lung lavages to induce acute respiratory failure, followed by mechanical ventilation with 
either a high or low PEEP for 4 hours. Then, both groups received an equal dose of exogenous 
surfactant (120 mglkg), after which ventilation with unchanged settings was continued for only 
15 min in order to study the acute effects of surfactant administration. In the group that was 
ventilated with high PEEP prior to surfactant administration, protein leakage was lower and lung 
mechanics were better after surfactant adnlinistration than in the group that was ventilated with 
conventional ventilator settings. These results indicate that in the clinical setting, where patients 
with ARDS are usually ventilated before exogenous surfactant therapy, it is important to apply 
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a ventilation strategy that does not increase protein leakage. 
High frequency oscillatory ventilation (HFOV) applies a high mean airway pressure and 
small pressure amplitude, and has previously been propagated as a safe ventilation technique to 
recruit and stabilize collapsed alveoli when used as a "high lung volume strategy". Chapter 5 
presents a study in which exogenous surfactant therapy, which allows alveolar recruitment and 
stabilization at lower airway pressures, was combined with either HFOV or conventional 
mechanical ventilation (CMV), iu lung-Iavaged rabbits. Two additional groups were studied that 
received HFOV or CMV only. Oxygenation increased in both HFOV groups and also in the 
CMV Isurfactant group, but when mean airway pressures were decreased after 4 hours of 
ventilation PaO, decreased to post-lavage values in the HFOV group that did not receive 
surfactant, but not in either of the surfactant-treated groups. In the sUlt~1ctant-treated animals less 
lung injury was found than in the animals that were ventilated only. It is concluded that HFOV 
recruits and stabilizes alveoli with a high mean airway pressure, whereas exogenous surfactant 
therapy allows reduction in mean airway pressure without the occurance of alveolar collapse and 
aggravation of lung injury. 
Apart from enhancing gas exhange in ARDS by improving ventilation, there are 
indications that it might be beneficial to alter pulmonary perfusion by nitric oxide (NO) 
inhalation. NO is a gas that can be administred during mechanical ventilation and results in a 
selective pulmonary vasodilatation (Le. only in aerated lung areas), thus reducing intrapulmonary 
shunt. In clinical trials a considerable percentage of patients fails to respond to NO inhalation, 
and it has been suggested that alveolar recruitment and stabilization prior to NO inhalation might 
be beneficial. Three strategies that prevent end-expiratory alveolar collapse are exogenous 
surfactant therapy, ventilation with an increased PEEP, and partial liquid ventilation. In the 
study described in Chapter 6, NO inhalation was started in lung-Iavaged rabbits after initiation 
of either ventilation with a PEEP of 10 cmH,O or administration of exogenous surfactant (25 
mglkg), After the initial improvement in oxygenation that was obtained by exogenous surfactant 
or ventilation with a PEEP of 10 cmH,O alone, an additional increase in PaO, during NO 
inhalation was seen only in the surfactant-treated group. In the control group that was ventilated 
only with a PEEP of 6 cmH,O, NO inhalation did not improve oxygenation. 
In Chapter 7 the combination of NO inhalation and alveolar recruitment and 
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stabilization by perfluorocarbon instillation is described. Lung lavaged pigs were submitted to 
partial liquid ventilation by administration of four incremental doses of 5 mIIkg of 
perfluorocarbon per dose. After each dose of perfluorocarbon, NO inhalation was started and 
the effect 011 oxygenation was recorded. After each dose of perfluorocarbon there was an 
increase in oxygenation, as well as an additional increase of PaOz by NO inhalation. Also, at 
each dose of perfluorocarbon, the maximal increase in oxygenation that was obtained with NO 
inhalation was similar to the increase obtained with administration of the subsequent dose of 
perfluorocarbon. It is concluded that alveolar recruitment and prevention of end-expiratory 
alveolar collapse prior to NO inhalation improves effective delivery of NO and thereby enhances 
its efficacy improve oxygenation. The lack of response to inhaled NO in the high PEEP group 
was attributed to mechanical compression of the pulmonary vessels, which did not allow 
pulmonary vasodilatation. 
In Chapter 8, the mechanisms involved in the improvement in pulmonary function by 
partial liquid ventilation are investigated. Four perfluorocarbons with different physico~chemical 
profiles were compared in lung-lavaged rats to study their efficacy in improving gas exchange 
and lung mechanics, and their effect on protein leakage and the surfactant system. Although the 
different preparations showed a range of responses, it was not possible to predict the efficacy 
of a pert1uorocarbon to improve pulmonary function during partial liquid ventilation based on 
the physico~chemical properties alone. 
In conclusion, the studies described in this thesis contribute to the general knowledge 
on strategies that are currently under investigation for use in patients with acute lung 
injury! ARDS. It is shown that recruitment of collapsed alveoli and prevention of repeated end-
expiratory alveolar collapse is beneficial in improving pulmonary function, whereas the strategy 
used to achieve this is of secondary importance. The best results are obtained with exogenous 
surfactant therapy, which allows ventilation with lower airway pressures. \Vithout surt'actant, 
an open lung strategy with higher airway pressures can be applied that prevents further 
deterioration of pulmonary function, especially when instituted in an early phase of respiratory 
fallure. Furthermore, prior recruitment and stabilization of collapsed lung units can improve the 
efficacy of subsequent treatment with exogenous surfactant or inhaled nitric oxide. Future 
studies are necessary to determine the exact role of these different treatment strategies in clinical 
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use for patients with ARDS. 
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Samenvatting en conclusies 
In Hoofdstuk 1 wordt de centrale rol van het pulmonale surfactant systeem bij het ontstaan en 
beloop van het acnte respiratory distress syndrome CARDS) beschreven. Bij ARDS leidt een 
tekort aan actief slufactant tot een toename van de retractive krachten in de long, hetgeen 
resulteert in het collaberen van alveoli. In deze situatie is kunstmatige beademing absollilit 
noodzakelijk. Eehter, indien de alveoli in de uitademingsfase niet gestabiliseerd worden, zullen 
ze iedere keer collaberen. Daarbij kllnnen de geopende iongdelen overrekt worden indien grote 
slagvolnmes worden toegepast op de gedeeltelijk gccollabeerde longen. Het is bekend dat het 
pulmonale surfactant systeem bvetsbaar is voor schade die kan ontstaan tijdens kunstmatige 
beademing, vooral in situaties waar de surfactant functie al is aangedaan, zoals bij ARDS. Een 
verdere verslechtering van de surfactant functie kan dan de progressie vall dit syndroom 
versnellen. Om die reden is het waarschijnlijk dat ARDS, in ieder geval gedeeltelijk, een gevolg 
is van onze behandeling, in plaats van aileen een voortschrijdillg van het onderliggende 
ziekteproces. De fysiologische achtergronden van beademingsstrategieen die als doel hebben 
dit verdere verlies van surfactant-functie te voorkomen en mogelijkheden am verloren surfactant 
te vervangen, worden in dit hoofdstuk besproken. 
In Hoofdslllk 2 wordt een shldie beschreven waarin werd onderzocht of preventie van 
eind-expiratoire alveolaire collaps tijdens inductie van ARDS door toepassing van een 
voldoende hoge positievc eind-expiratoire druk (PEEP) de verslechtcnng van de longfunctie kan 
verminderen. In deze studie ondergingen ratten herhaalde long lavages am een surfactant 
deficientie te induceren en daarmee een acute respiratoire insufficientie. In deze studie werd 
eind-expiratoire alveolaire collaps tijdens kUllstmatige beademing in een groep voork6men door 
toepassing van een PEEP van 15 cmH20 (open long groep). De resuItaten werden vergeleken 
met die van een groep die werd beademd met een PEEP van 8 cmH20, hetgeen niet voldoende 
is am alveolaire collaps te voorkomen Cbeademde controle groep). Na surfactant deplctie werd 
beademing gecontinueerd gedurende vier uur. Toepassing van een hoge PEEP voorkwam 
verslechtering van de gasllitwisseling, verminderde de achteruitgang van longmechanica en 
verminderde de toename van eiwitlekkage, in vergelijking met de beademde controlegroep. De 
verminderde achteruitgang van longmechanica in de open long groep was te wijten aan de 
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afgenomen inactivatie van het resterende longsurfactant door plasma eiwitten. 
Kunstmatige beademing met hoge PEEP, parti~le vloeistof beademing en exogene 
surfactant therapie, verbeteren aile de oxygenatie in diermodellen lIlet acuut longfalen en worden 
momenteel geevalueerd in klinische studies. In Hoofdstuk 3 worden deze nieuwe 
behandelingsstrategie~n met elkaar vergeleken v~~r wat betref! het effect op gasuitwisseling, 
iongmechanica, longschade, eiwitlekkage en surfactant systeem. In deze studie werd bij ratten 
acuut longfalen gei"nduceerd door herhaalde long lavages tijdens beademing met een PEEP van 
6 cmH,O. Hierna werden de dieren 6f beademd met een hoge PEEP die de longen open hield, 
6f werden ze behandeld met exogeen sllIt:,ctant (120 mglkg), 6f met perfluorocarbon (15 rnllkg) 
(parti~le vloeistof beademing). Deze drie groepen werden vergeleken met een controlegroep die 
werd beademd met een lage PEEP. Hoewel bij aile drie de strategie~n de oxygenatie verbeterde, 
werd eiwitlekkage in de alveoli aileen voorkomen door beademing met een hoge PEEP en 
exogene surfactant therapie. Partiele vloeistof beademing deed dit niet. De conversie van actieve 
in niet-actieve surfactant aggregaten bleek verhoogd te zijn in de partiele vloeistof 
beademingsgroep en in de groep die werd beademd met een hoge PEEP, Illaar niet in de groep 
die met exogeen surfactant IVas behandeld. In de partWle vloeistof beademingsgroep en in de 
surfactant groep werd minder longschade gevonden, vergeleken met de groepen die aileen 
werden beademd. Wij conciudeerden dat door de drie strategie~n de oxygenatie verbeterde, maar 
dat de invloed op de longfunctie nogal verschillend was. Aileen behandeling met exogeen 
surfactant resulteerde in een verbetering van aIle gemeten parameters. 
Het verschil in eiwitlekkage naar de alveoli tussell de groepen die aileen werden 
beademd met een hoge dan weI een lage PEEP, dat werd gevonden in de voorgaande studie, 
werd verder onderzocht in Hoo/tls/llk 4. Het is bekend dat slllfactant functie wordt geremd door 
plasma eiwitten. Daarom werd onderzocht of de effectiviteit waarmee exogeen surfactant de 
longfunctie verbetert. kan worden vergroot door het surfactant toe te dienen na een periode van 
kunstmatige beademing Illet een hoge PEEP. In twee groepen ratten werd actlut respiratoir falen 
ge'induceerd door long lavages. waama een groep werd beademd met een hoge PEEP en een 
tweede groep met een lage PEEP. Na vier uur werden beide groepen behandeld met een gelijke 
dosis exogeen surfactant (120 mglkg), waarna de beademing werd voortgezet gedurende 15 
minuten om de acute effecten van surfactant toediening te onderzoeken. In de groep die v66r de 
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surfactant toediening werd beademd met een hoge PEEP, werd na surfactant toediening minder 
eiwitlekkage en betere longmechanica gevonden dan in de groep die met een lage PEEP werd 
beademd. Deze resuItaten impHceren dat in de klinische situatie, waarin ARDS~patienten 
meestal voorafgaand aan exogene surfactant toediening worden beademd, het van belang is dat 
een beademingsstrategie wordt gebruikt die niet leidt tot een toename van eiwitlekkage. 
Tijdens high frequency oscillatory ventilation (HFOV) wordt een hoge gemiddelde 
beademingsdruk en een kleine drukamplitude gebruikt. Deze strategie is in het veri eden 
aangeprezen ais een veilige beademingstechniek am gecoUabeerde alveoli te rekruteren en te 
stabiliseren indien HFOV wordt gebruM als "haag long volume strategie". In HoD/tis/uk 5 wordt 
een studie beschreven waarin bij gelaveerde konijnen HFOV of conventionele mechanische 
ventilatie (CMV) werd gecombineerd met toediening van exogeen surfactant. Hierdoor is 
rekrutering en stabilisatie van alveoli met lagere beademingsdrukken mogelijk. Twee extra 
groepen werden aileen beademd met HFOV of CMV. De oxygenatie verbeterde in beide HFOV 
groepen en in de CMV/surfactant groep. Zodra na vier uur beademing de gemiddelde 
beademingsdruk werd verlaagd, daalde de PaO, naar dezelfde waarde als die van direct post-
lavage in de groep die aileen met HFOV werd beademd. Dit gebeurde niet in beide surfactant 
groepen. In de groepen die met surfactant werden behandeld, werd minder longschade gevonden 
dan bij de dieren die aileen beademd werden. Wij concludeerden dat HFOV alveoli rekruteert 
en stabiliseert door toepassing van een hoge gemiddelde beademingsdruk, terwijl exogene 
surfactant toediening een verlaging van de gemiddelde beademingsdruk toelaat, zonder dat de 
alveoli opnieuw collaberen en longschade verergerd wordt. 
Naast het verbeteren van de gasuitwisseling tijdens ARDS door het optimaliseren van 
de ventilatie, zijn er aanwijzingen dat het gunstig kan zijn am de pulmonale perfusie te 
veranderen met stikstof monoxide (NO) inhalatie. NO is een gas dat toegediend kan worden 
tijdens kunstmatige beademing, hetgeen resulteert in een selectieve pulmonale vasodilatatie (Le. 
aileen in de geventileerde longdelen) en daardoor een afname van de intrapulmonale shunt. In 
klinische studies wordt vaak waargenomen dat een aanzienlijk percentage pati~nten niet reageert 
op NO inhalatie. Hierbij wordt gesuggereerd dat rekrutering en stabilisatie van alveoli 
voorafgaand aan NO inhalatie gunstig zou zijn. Drie strategieen die eind-expiratoire alveolaire 
collaps voork6men, zijn exogene surfactant therapie, beademing met een hoge PEEP en partiele 
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vloeistof beademing. In de studie beschreven in Hoofdslilk 6 werd gestart met NO inhalatie in 
een groep gelaveerde kanijnen beademd met een PEEP van 10 cmHzO en in een groep waaraan 
exogeen surfactant werd toegediend (25 mglkg). Dit resulteerde in beide groepen in enige 
alvealaire rekrutering, zander dat de longen voUedig werden geopend. Na de initiele toename 
van de oxygenatie die werd verkregen door exogeen sUlfactant of beademing met een PEEP van 
10 cmH,O, werd aileen in de groep die met surfactant werd behandeld een additionele toename 
van de PaO, door NO inhalatie gezien. In de controlegroep, die aileen werd beademd met een 
PEEP van 6 cmH,O, verbeterde NO de oxygenatie niet. In Hoofdslilk 7 wordt de combinatie van 
NO inhalatie met alveolaire rekrutering en stabilisatie door toediening van pertluorocarbonen 
beschreven. Bij varkens werd na long lavage begonnen met partieie vloeistof beademing door 
toediening van vier opeenvolgende doses perfluorocarbon van 5 ml/kg per dosis. Na iedere dosis 
perfluorocarbon werd gestart met NO inhalatie, waarna het effect op de oxygenatie werd 
geregistreerd. De oxygenatie verbeterde na iedere dosis perfluorocarbon en ua NO illhalatie. De 
maximale toename van de oxygenatie door NO inhalatie was gelijk aan de toename in 
oxygenatie door toediening van de volgende dosis perfluorocarbon. Rekrutering van 
gecollabeerde alveoli en preventie van eind·expiratoire collaps lijken de effectieve afgifte van 
gelnhaleerd NO te verbeteren, waardoor het effect op de oxygenatie groter is. In de met een hoge 
PEEP beademde groep werd geen effect gezien van ge'lnhaleerd NO. Dit wordt geweten aan 
mechauische cornpressie van de pulmonale vaten, waardoor vasodilatatie niet meer ll10gelijk is. 
In Hoofdslilk 8 werden tens lotte vier perfluorocarbonen met verschillende fysisch· 
chemische eigenschappen vergeleken in een diermodel wat betreft effectiviteit in het verbeteren 
van gasuitwisseling en longmechanica en het effect op eiwitlekkage en surfactant systeem. 
Hoewelmeerdere verschillen tussen de preparaten werden gevonden, bleek het niet mogelijk om 
op basis van fysisch·chemische eigenschappen aileen de effectiviteit te voorspellen waarmee 
pertluorocarbonen de longfunctie verbeteren tijdens partieie vloeistof beademing. 
De studies beschreven in dit proefschrift dragen bij aan de aigemene kennis omtrent 
beademingsstrategieen die momenteel worden geevalueerd voor klinische toepassing bij 
patienten met acuut longfalenl ARDS. Aangetoond werd dat rekrutering van gecollabeerde 
alveoli en het voorkomen van herhaaldelijk collaberen aan het eind van de expiratiefase gunstig 
is voor de longfunctie, terwijl de strategie die hiervoor wordt gebruikt van ondergeschikt belang 
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is. De beste resultaten worden behaald met exogelle surfactant therapie. waarbij lagere 
beademingsdrukken gebruikt kunnen worden. Zander surfactant kan een open long 
beademingsstrategie worden toegepast die een verdere achteruitgang van de longfunctie 
voorkomt. met name indien wordt begonnen in een vroege fase van longfalen. Tevens kan het 
rekruleren en slabiliseren van gecollabeerde longdelen voorafgaand aan verdere behandeling mel 
exogeen smfactant en stikstof monoxide inhalatie de effectiviteit van deze toepassingen 
verbeteren. Toekomstige studies zijn nodig am de exacte plaats van deze strategieen in de 
behandeling van ARDS pati~nlen Ie bepalen. 
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